Eurentina 2014 - London - Final programme

11-14 September 2014LONDON14th EURETINA Congress

Programme

NICE15th EURETINA Congress

17 – 20 September 2015

LONDON14th EURETINA Congress

1CONTENTS

Board&Officers 2

LetterfromthePresident 3

ProgrammeOverview 4

SurgicalSkillsTrainingCourses 8

ScientificProgramme–Thursday 9

ScientificProgramme–Friday 25

ScientificProgramme–Saturday 43

ScientificProgramme–Sunday 61

E-PosterPresentations 71

VideoCompetition 94

GeneralInformation 98

Sponsors 100

PlanofCongressCentre 102

PlanofExhibition 104

ListofExhibitors&BoothNumbers 107

EuroTimesSatelliteEducationProgramme 115

Index 119

Online Regististration - Social Networking - Mobile Solutions - Event Analytics

Event Management Software


2

PresidentFrancesco Bandello ITALY

Vice-PresidentUrsula Schmidt-Erfurth AUSTRIA

General SecretarySebastian Wolf SWITZERLAND

Immediate Past PresidentGisbert Richard GERMANY

Vice-President ElectJan van Meurs THE NETHERLANDS

Board MembersJose García Arumí SPAIN

Frank Holz GERMANY

Alistair Laidlaw UK

Anat Loewenstein ISRAEL

Stefan Seregard SWEDEN

Ramin Tadayoni FRANCE

Co-Opted Board MembersBorja Corcóstegui SPAIN

Morten la Cour DENMARK

David Pelayes ARGENTINA

Programme CommitteeFrancesco Bandello ITALY (CHAIRMAN)

Alistair Laidlaw UK

Gisbert Richard GERMANY

Ursula Schmidt-Erfurth AUSTRIA

Jan van Meurs THE NETHERLANDS

Sebastian Wolf SWITZERLAND

Past PresidentsBill Aylward UK

José Cunha-Vaz PORTUGAL

Borja Corcóstegui SPAIN

Rosario Brancato ITALY

August Deutman THE NETHERLANDS

BOARD & OFFICERS


3PRESIDENT’S LETTER

EURETINATempleHouseTempleRoad

BlackrockCo.Dublin

IrelandTel:+35312100092Fax:+35312091112

Email:[email protected]:www.euretina.org

DearColleagues,

OnbehalfoftheBoardandOfficersoftheEuropeanSocietyofRetinaSpecialists,itismypleasuretowelcomeyoutoLondonforthe14thEURETINACongress.

WearedelightedtoonceagainpartnerourannualcongresswiththatofESCRSandEuCornea.Ibelievethatthecombinationofthreesuperiorscientificprogrammesprovidesauniqueforumforglobalnetworkingandwillmakethe ExCeLLondonastimulatinghubofresearchandknowledgeexchangeinworldwideophthalmology.

TheProgrammeCommitteehasbuiltontheenormoussuccessofthe13thCongressinHamburg,compilinganexcitingscientificprogrammeforLondon.ThemeetingwillonceagainhostmanyofthepopulartraditionalfeaturesoftheEURETINAprogramme,whilenewinfluenceshavebeenintroducedtokeepituptodateandcuttingedge.

IthasbeenmostrewardingtoseetheEURETINACongressgrowfromstrengthtostrengthoverthelastnumberofyearswithattendancenumberssteadilyincreasingeachyear.Thisisthankstotheparticipationofhighlyregardedspeakersandthewillingnessofsomanydelegatestotraveltoheartheircontributions.EURETINAismostgratefulasalwaystotheIndustryfortheircontinuedsupportthroughparticipationintheexhibitionandsatellitesymposia,aswellasthroughsponsorshipofvariousaspectsofthemeeting.

IwishyouawonderfulcongressandhopethatyouenjoyyourstayinLondon.

Yourssincerely,

Francesco Bandello

President of EURETINA & Chairman of the Programme Committee


4 PROGRAMME OVERVIEW

TH

UR

SDA

Y 1

1 SE

PT

EM

BE

R

08.00

09.00

10.00

11.00

12.00

13.00

14.00

15.00

16.00

17.00

18.00

19.00

FREE

PAP

ER 1

Vitre

oret

inal

Sur

gery

I

MAI

N SE

SSIO

N 1

Dry

AMD

MAI

N SE

SSIO

N 2

Diab

etic

Ret

inop

athy

OPEN

ING

CERE

MON

Y

WEL

COM

E RE

CEPT

ION

FREE

PAP

ER 2

Vasc

ular

Dis

ease

s &

Diab

etic

Ret

inop

athy

I

GERM

AN

RETI

NA S

OCIE

TYTr

eatm

ent o

f Ret

inal

Di

seas

e

BEAV

RS S

YMPO

SIUM

Retin

al D

etac

hmen

t Ou

tcom

es

INDU

STRY

SPO

NSOR

EDSA

TELL

ITE

MEE

TING

QUIC

K FI

RE F

REE

PAPE

R 1

QUIC

K FI

RE F

REE

PAPE

R 3

QUIC

K FI

RE F

REE

PAPE

RS 2

RETI

NAL

DETA

CHM

ENT

COUR

SE

COUR

SE 1

Curre

nt M

anag

emen

t of

Uve

al M

elan

oma

COUR

SE 3

Curre

nt M

anag

emen

t of

Paed

iatri

c VR

Dis

ease

s

COUR

SE 5

Fluo

rosc

ein

& IC

G-An

giog

raph

y

INDU

STRY

SPO

NSOR

EDSA

TELL

ITE

MEE

TING

INDU

STRY

SPO

NSOR

EDSA

TELL

ITE

MEE

TING

COUR

SE 2

The

Role

of

the

Vitre

ous

COUR

SE 4

3D V

ideo

Cou

rse:

25 –

27G

Sur

gery

COUR

SE 6

Min

imal

Inva

sive

Vi

trect

omy

SURG

ICAL

SKI

LLS

COUR

SES

AUDI

TORI

UMLE

VEL

0BO

ULEV

ARD

CLE

VEL

1BO

ULEV

ARD

DLE

VEL

1BO

ULEV

ARD

ELE

VEL

1BO

ULEV

ARD

HLE

VEL

1BO

ULEV

ARD

GLE

VEL

1BO

ULEV

ARD

ILE

VEL

1W

ETLA

B RO

OMS

LEVE

L 1

UVEI

TIS

COUR

SE

P.12

P.17

P.20

P.23

P.21

P.22

P.20

P.21

P.13

P.17

P.14

P.18

P.10

P.16

P.15

P.16

P.19

P.8

P.19


5PROGRAMME OVERVIEW

FR

IDA

Y 1

2 SE

PT

EM

BE

R

08.00

09.00

10.00

11.00

12.00

13.00

14.00

15.00

16.00

17.00

18.00

19.00

MAI

N SE

SSIO

N 3

Rege

nera

tive

Med

icin

e &

Gene

The

rapy

KREI

SSIG

LEC

TURE

AMST

ERDA

M

RETI

NA D

EBAT

E

MAI

N SE

SSIO

N 4

The

Eye

& Br

ain

MAI

N SE

SSIO

N 5

Neov

ascu

lar A

MD

FREE

PAP

ER 3

AMD

I FR

EE P

APER

4AM

D II

AFIV

FRE

NCH

ISRA

ELI S

OCIE

TY

COUR

SE 7

Au

toflu

ores

cenc

e Im

agin

g: S

tate

-of-

the-

Art

COUR

SE 8

Elec

troph

ysio

logy

COUR

SE 9

Ne

w S

trate

gies

in

Ocu

lar T

raum

a

FREE

PAP

ER 5

Vasc

ular

Dis

ease

s &

Diab

etic

Ret

inop

athy

II

FREE

PAP

ER 6

Imag

ing

I

COU

RSE

10

Stat

e-of

-the

-Art

in

Anti-

VegF

The

rapy

COU

RSE

11

Lase

r The

rapy

in R

etin

al

Dise

ase

COUR

SE 1

2Im

agin

g of

Pos

terio

r Fu

ndus

COU

RSE

13

Mac

ular

Dys

troph

ies

SURG

ICAL

SK

ILLS

CO

URSE

S

INDU

STRY

SPO

NSOR

EDSA

TELL

ITE

MEE

TING

INDU

STRY

SPO

NSOR

EDSA

TELL

ITE

MEE

TING

INDU

STRY

SPO

NSOR

EDSA

TELL

ITE

MEE

TING

FREE

PAP

ERS

7 Vi

treor

etin

al S

urge

ry II

EVIC

R.NE

TCl

inic

al T

rial R

esea

rch

BIO-

ENGI

NEER

ING

SOCI

ETY

Futu

re o

f VR

Surg

ery

COUR

SE 1

4

Pr

olife

rativ

e Di

abet

ic

Retin

opat

hy

COUR

SE 1

5

SD-O

CT In

terp

reta

tion

C

OURS

E 16

Uvei

tis: D

iagn

osis

&

Ther

apy

in 2

014

FREE

PAP

ERS

8 Im

agin

g II

FREE

PAP

ERS

9 Va

scul

ar D

isea

ses

&

Di

abet

ic R

etin

opat

hy II

I

ASRS

Retin

a in

the

Futu

re:

Whe

re A

re W

e He

aded

?

COUR

SE 1

7 Up

date

in O

cula

r On

colo

gy 2

014

COUR

SE 1

8 Su

bthr

esho

ld L

aser

Su

rger

y

Cour

se 1

9Up

date

in O

CT Im

agin

g

INDU

STRY

SPO

NSOR

EDSA

TELL

ITE

MEE

TING

INDU

STRY

SPO

NSOR

EDSA

TELL

ITE

MEE

TING

INDU

STRY

SPO

NSOR

EDSA

TELL

ITE

MEE

TING

INDU

STRY

SPO

NSOR

EDSA

TELL

ITE

MEE

TING

INDU

STRY

SPO

NSOR

EDSA

TELL

ITE

MEE

TING

INDU

STRY

SPO

NSOR

EDSA

TELL

ITE

MEE

TING

AUDI

TORI

UMLE

VEL

0BO

ULEV

ARD

CLE

VEL

1BO

ULEV

ARD

DLE

VEL

1BO

ULEV

ARD

ELE

VEL

1BO

ULEV

ARD

HLE

VEL

1BO

ULEV

ARD

GLE

VEL

1BO

ULEV

ARD

ILE

VEL

1W

ETLA

B RO

OMS

LEVE

L 1

GENE

RAL

ASSE

MBL

Y (M

embe

rs o

nly)

P.26

P.30

P.31

P.35

P.38

P.31

P.35

P.39

P.32

P.36

P.39

P.32

P.36

P.40

P.33

P.37

P.40

P.33

P.8

P.37

P.41

P.34

P.34

P.38

P.26

P.27

P.28

P.29

P.29

P.30


6 PROGRAMME OVERVIEW

SAT

UR

DA

Y 1

3 SE

PT

EM

BE

R

08.00

09.00

10.00

11.00

12.00

13.00

14.00

15.00

16.00

17.00

18.00

19.00

MAI

N SE

SSIO

N 6

Uv

eal M

elan

oma

EURE

TINA

Sc

ienc

e &

Med

icin

e In

nova

tion

Awar

d 20

14

ESCR

S/ E

URET

INA

VR C

ompl

icat

ions

of

Ant

erio

r Seg

men

t Su

rger

y

CLUB

JUL

ES G

ONIN

Min

imal

& M

axim

al

Surg

ery

ASIA

/PAC

IFIC

VRS

Mac

ulop

athy

in th

e As

ian

Popu

latio

n

FREE

PAP

ERS

10

Vitre

oret

inal

Sur

gery

III

YOUN

G EU

ROPE

AN

RETI

NAL

SPEC

IALI

STS

(YOU

RETI

NA)

COUR

SE 2

0

Intra

ocul

ar M

irror

Te

lesc

ope

COUR

SE 2

1

Subm

acul

ar

Haem

orrh

ages

AM

D

FREE

PAP

ERS

12

New

Dru

g Tr

eatm

ent

EVER

Imag

ing

of O

cula

r Fu

ndus

FAN

CLU

B F

REE

PAPE

RS 1

1 M

isce

llane

ous

COU

RSE

22M

anag

ing

DME:

Pe

arls

& P

itfal

ls

COU

RSE

23Vi

treor

etin

al In

terfa

ce

COU

RSE

24

Ster

oids

in R

etin

al

Ther

apy

INDU

STRY

SPO

NSOR

EDSA

TELL

ITE

MEE

TING

INDU

STRY

SPO

NSOR

EDSA

TELL

ITE

MEE

TING

INDU

STRY

SPO

NSOR

EDSA

TELL

ITE

MEE

TING

FREE

PAP

ERS

14

Vasc

ular

Dis

ease

s &

Diab

etic

Ret

inop

athy

IV

FREE

PAP

ERS

13

Imag

ing

III

RETI

NAW

SM

isad

vent

ures

in th

e Op

erat

ing

Room

COUR

SE 2

5

Ey

e &

Brai

n: R

NFL

Anal

ysis

COUR

SE 2

6

Ch

rom

ovitr

ecto

my:

Nove

l Vita

l Dye

s

COUR

SE 2

7

In

traoc

ular

& P

seud

o Tu

mou

rs

COUR

SE 2

8

Path

olog

y

MAI

N SE

SSIO

N 7

Imag

ing

EURO

LAM

Unus

ual C

ase

Stud

ies

COUR

SE 2

9 M

acul

ar E

dem

a

COUR

SE 3

0

Retin

al T

reat

men

t M

odal

ities

COUR

SE 3

1

Surg

ical

App

roac

h of

VR

Inte

rface

Cour

se 3

2VR

Com

plic

atio

ns o

f Ca

tara

ct S

urge

ry

INDU

STRY

SPO

NSOR

EDSA

TELL

ITE

MEE

TING

INDU

STRY

SPO

NSOR

EDSA

TELL

ITE

MEE

TING

INDU

STRY

SPO

NSOR

EDSA

TELL

ITE

MEE

TING

INDU

STRY

SPO

NSOR

EDSA

TELL

ITE

MEE

TING

INDU

STRY

SPO

NSOR

EDSA

TELL

ITE

MEE

TING

AUDI

TORI

UMLE

VEL

0BO

ULEV

ARD

FLE

VEL

1BO

ULEV

ARD

CLE

VEL

1BO

ULEV

ARD

DLE

VEL

1BO

ULEV

ARD

ELE

VEL

1BO

ULEV

ARD

HLE

VEL

1BO

ULEV

ARD

GLE

VEL

1BO

ULEV

ARD

ILE

VEL

1

P.47

P.44

P.48

P.53

P.56

P.45

P.49

P.50

P.51

P.51

P.54

P.54

P.55

P.55

P.56

P.52

P.57

P.58

P.58

P.59

P.59

P.57

P.45

P.49

P.46

P.47

P.44

P.48

P.52


7PROGRAMME OVERVIEW

SUN

DA

Y 1

4 SE

PT

EM

BE

R

08.00

09.00

10.00

11.00

12.00

13.00

14.00

15.00

16.00

17.00

18.00

19.00

MAI

N SE

SSIO

N 8

PV

R &

Inno

vatio

n in

Ret

inal

De

tach

men

t Sur

gery

FREE

PAP

ERS

15Va

scul

ar D

isae

ases

&

Diab

etic

Ret

inop

athy

V

QUIC

K FI

RE

FREE

PAP

ERS

4

ESAS

O

New

Con

cept

s in

VR

Surg

ery

COUR

SE 3

4AB

C in

Oph

thal

mic

Pu

blis

hing

COUR

SE 3

5 PV

R M

anag

emen

t Up

date

MAI

N SE

SSIO

N 9

Ve

in O

cclu

sion

SPA

NISH

VR

SOCI

ETY

Path

olog

ic M

yopi

a

COUR

SE 3

6M

anag

ing

Com

plic

atio

ns

in V

R Su

rger

y

COU

RSE

33M

anag

emen

t of R

etin

al

Vasc

ular

Occ

lusi

on

COU

RSE

37Op

timis

ing

Inje

ctio

n Cl

inic

s

COUR

SE 3

8

Di

abet

ic E

ye S

cree

ning

FREE

PAP

ERS

16Vi

treor

etin

al S

urge

ry IV

QUIC

K FI

RE

FREE

PAP

ERS

5

BOUL

EVAR

D C

LEVE

L 1

BOUL

EVAR

D D

LEVE

L 1

BOUL

EVAR

D B

LEVE

L 1

BOUL

EVAR

D E

LEVE

L 1

BOUL

EVAR

D H

LEVE

L 1

BOUL

EVAR

D G

LEVE

L 1

BOUL

EVAR

D I

LEVE

L 1

P.62

P.62

P.63

P.64

P.67

P.67

P.68

P.69

P.70

P.70

P.65

P.65

P.66

P.66


8 SURGICAL SKILLS TRAINING COURSES

Surgical Skills Training Courses

Chairperson: S. Binder AUSTRIA

Instructors: I. Krebs AUSTRIA K. Krepler AUSTRIA U. Stolba AUSTRIA

Thursday 11 September

Course No. Course Name Course Time Room

01 FirstStepsinVitreoretinalSurgery 09.00–12.00 WetlabRoom1(Level1)

02 FirstStepsinVitreoretinalSurgery 09.00–12.00 WetlabRoom2(Level1)

03 CombinedAnterior&PosteriorSegmentSurgery 13.00–16.00 WetlabRoom1(Level1)

Friday 12 September

Course No. Course Name Course Time Room

04 IntraocularTamponades 09.00–12.00 WetlabRoom1(Level1)

05 IntravitrealInjection 12.00–13.00 WetlabRoom2(Level1)

First Steps in Vitreoretinal Surgery (Course 1 & 2)Firststepswith20gor23gtechniquesexplainedstepbystepandpracticedonpigs’eyes.

Participantsshouldhavesomeexperienceinanteriorsegmentmicrosurgery.

Combined Anterior and Posterior Segment Surgery (Course 3)Thecombinedprocedureincludingcataractsurgery,IOLimplantationand23gvitrectomyaredemonstratedandpracticedonpigs’eyes.

ParticipantsshouldhaveskillsinanteriorsegmentsurgeryorshouldhaveparticipatedinCourses1or2.

Intraocular Tamponades (Course 4)Variousvitreoustamponades,theirpropertiesandindicationsaredemonstrated.Theexchangetechniquesareexplainedandpracticed onpigs’eyes.

ParticipantsshouldbeskilledinanteriorsegmentsurgeryorshouldhaveparticipatedinCourses1or2.

Intravitreal Injection (Course 5)Thistechniqueisdemonstratedandpracticedonpigs’eyes.

Participantsdonotneedmicrosurgicalexperience.

THURSDAY11 September

LONDON

9

14th EURETINA Congress


THURSDAY 11 SEPTEMBER10

08.00 – 16.00

104TH RETINAL DETACHMENT COURSE

Diagnostics, Options for Repair: The Diabetic EyeBoulevard H (Level 1)

Cost: €120

08.00 Welcome I. Kreissig GERMANY

1. Diagnostics: Rhegmatogenous Primary Retinal Detachment

Moderators: I. Kreissig GERMANY F. LaFranco USA

1.1 The4rulestofindtheprimarybreak I. Kreissig GERMANY

1.2 Adetachmentwithoutabreak:whattotryfirst? U. Mester GERMANY

2. Cerclage with Drainage

2.1 Alookatcerclageafter50years:indications,complications,long-termresults

I. Kreissig GERMANY

3. Minimal Segmental Buckling with Sponge (s) Without Drainage

3.1 Indications,optimaltamponadeofbreak(s),videoofsurgery,complications,long-termresults

F. LaFranco USA

3.2 Complicationsandlong-termanatomicaland functionalresults

S. Mennel AUSTRIA

3.3 Differentialdiagnosisofresidualfluid J. Jonas GERMANY

4. Minimal Segmental Buckling with Temp. Buckle Without Drainage

Moderators: S. Yamamoto JAPAN G. Richard GERMANY

4.1 Application,indications,videoofsurgery,complications,long-termresults

I. Kreissig GERMANY

5. Gas Operations

5.1 Perfluorocarbongases:Physicalproperties;intraandpostoperativecomplications

V. Ferrara ITALY

5.2 Pneumaticretinopexyforuncomplicateddetachments T. Boeker GERMANY

10.30 Coffee Break

10.55

6. Primary Vitrectomy

Moderators: B. Aylward UK U. Mester GERMANY

6.1 Rationale,indications,complications,long-termresults S. Mennel AUSTRIA

7. Minimal Segmental Buckling for Complicated Detachments

7.1 Reoperation:The4rulestofindtheundetectedbreak I. Kreissig GERMANY

7.2 HowtominimizeriskofPVR N. Sivkova BULGARIA

7.3 PVRC1/C2detachments.Trybucklingfirst:Long-termvisualresults

P. Stanga UK

8. Fellow Eye of Retinal Detachment

Moderators: T. Boeker GERMANY S. Mennel AUSTRIA

8.1 Latticedegenerationandbreaksinfelloweye:Whattodoornotdo?

B. Aylward UK

9. Vitrectomy for Vitreoretinal Problems

9.1 Macularhole:Whenandhowtotreat?Complications,long-termresults

S. Yamamoto JAPAN

9.2 Comparisonof20,23,25gaugevitrectomy:Indications,complications,results

J. Schmidt GERMANY

12.40 Group Photo

13.00 Lunch Break


THURSDAY 11 SEPTEMBER 11

14.00

10. The Diabetic Eye

Moderators: F. LaFranco USA J. Schmidt GERMANY

10.1 Classificationofdiabeticretinopathy B. Stoffelns GERMANY

10.2 Lasercoagulation:Whentodo? U. Vossmerbaeumer GERMANY

10.3 Intravitrealpharmacotherapy:Whentodo? F. LaFranco USA

10.4 Vitrectomyinthediabeticeye:Indications,complications,long-termresults

G. Richard GERMANY

11. Comparison of Present Techniques for Repair of Primary Retinal Detachment

11.1 Temporaryballoonbucklevs.pneumaticretinopexyvs.segmentalbucklingvs.primaryppv

T. Boeker GERMANY

12. Various

12.1 Misdiagnosisofretinaschisis I. Kreissig GERMANY

12.2 Ambulatorydoublepatching B. Stoffelns GERMANY

13. Case Presentations

Moderator: I. Kreissig GERMANY

Organiser: T. Boeker GERMANY

Panel:

B. Aylward UK

V. Ferrara ITALY

S. Mennel AUSTRIA

U. Mester GERMANY

G. Richard GERMANY

J. Schmidt GERMANY

N. Sivkova BULGARIA

P. Stanga UK

U. Vossmerbaeumer GERMANY

S. Wolf SWITZERLAND

S. Yamamoto JAPAN

14. Distribution of Diplomas

16.00 End of Course



08.00 – 10.00

FREE PAPER SESSION 1

Vitreoretinal Surgery IVenue: Auditorium (Level 0)

Chairpersons: M. De Smet GERMANY S. Rizzo SPAIN

08.00 E. Zrenner, K. Bartz-Schmidt, F. Gekeler, T. Jackson, R. MacLaren, S. Katarina GERMANY Visualoutcomein29blindretinitispigmentosapatientswithelectronicsubretinalimplantAlpha-IMS

08.08 J. Pournaras, T. Wolfensberger, C. Salvisberg, C. Fouda, A. Hainard, N. Turck SWITZERLAND Vitreousproteomicanalysis-newmarkersforvitreoretinaldiseases?

08.16 E. Van Zeeburg, H. de Jong, M. Cereda, M. Van Velthoven, K. Vermeer, J. van Meurs THE NETHERLANDS Arandomizedcontrolledtrialcomparingintravitrealversussubretinalinjectionofrecombinanttissueplasminogenactivatorfordisplacementofanacutesubmacularhaemorrhageinage-relatedmaculardegeneration

08.24 P. Banerjee, W. Xing, C. Bunce, A. Chandra, D. Charteris UK Apilotstudyofintraocularuseofintensiveanti-inflammatory-triamcinoloneacetonidetopreventproliferativevitreoretinopathyineyesundergoingvitreoretinalsurgeryforopenglobetrauma-theadjunctsinoculartrauma(AOT)trial

08.32 L. Lytvynchuk, A. Sergiienko, I. Savytska, G. Petrovski UKRAINE Cytologicalstudyofneedletipaspiratesafterintravitrealinjectioninrats

08.40 M. Dogramaci, T. Williamson, M. Bayazit, A. Cunningham UK Understandingunintentionalretinalshiftafterparsplanavitrectomy(PPV)forretinaldetachment(RRD)throughsurgicalreverseengineering(SRE)technology.Phase3results(dataprocessing)

08.48 W. Lam, L. Zhao, E. Mandelcorn, P. Kertes, R. Devenyi, M. Mandelcorn CANADA Aprospectiverandomizedclinicalstudycomparingtopicalnepafenacsodium0.1%versusintra-operativeintravitrealtriamcinoloneacetateversusplaceboinvitrectomysurgeryformacularedema

08.56 P. Tranos, S. Asteriades, T. Vakalis, S. Koukoula, G. Perganda GREECE Theroleofinternallimitingmembranepeelinginepiretinalmembranesurgery.Arandomizedcontrolledtrial

09.04 P. Stalmans, J. Van Calster BELGIUM Ocriplasminintheclinicalsetting-anoverviewofpost-approvalsafetyoutcomes

09.12 A. Chandra, J. Smith, J. Kam, B. Wang, E. Kurniawan, S. Sandhu, P. Allen AUSTRALIA Endophthalmitisafterparsplanavitrectomy-a15yearprospectivestudy

09.20 S. Ganesan, T. Sharma INDIA Endophthalmitisinfulltermneonatespresentingasthediagnosticfeatureofsepticemia

09.28 Y. Luo, Z. Mclelland, L. da Cruz UK Positivecentralscotomasobservedafterroutinemacula-onretinaldetachmentsurgery

09.36 A. Gomaa, Y. Hegazy EGYPT Roleofintra-vitrealbevacizumabinpreventionofpost-operativevitreoushemorrhagefollowingparsplanavitrectomyforcomplicationsofproliferativediabeticretinopathy

09.44 C. Geenen, M. Dogramaci, T. Williamson UK Theriskfactorsandtheoutcomeofiatrogenicretinalbreaksduringparsplanavitrectomyforrhegmatogenousretinaldetachment

09.52 J. Bouchepillon, P. Koehrer, C. Binquet, C. Tzourio, A. Bron, C. Creuzot-Garcher FRANCE AnalysisofthevitreomacularinterfaceinaFrenchpopulation-basedstudy(TheMontrachetstudy-maculopathy,opticnerve,nutrition,neurovascularandheartdiseases)

10.00 Endofsession



08.00 – 10.00


Vascular Diseases & Diabetic Retinopathy IVenue: Boulevard C (Level 1)

Chairpersons: B. Corcóstegui ITALY S. Wolf SWITZERLAND

08.00 F. Bandello, A. Augustin, D. Boyer, R. Belfort, Y. Yoon, R. Maturi, S. Whitcup ITALY 3-year,randomized,sham-controlledtrialofdexamethasoneintravitrealimplantinpatientswithdiabeticmacularedema(MEADstudy)

08.08 U. Chakravarthy UK Long-termvisualoutcomesbasedonbaselinevisioninpatientswithchronicdiabeticmacularedema(DME)treatedwithfluocinoloneacetonide(FAc)

08.16 B. Kuppermann, B. Ding, I. Stoilov USA Anti-VEGFtreatmentsfordiabeticmacularedema-comparisonofphaseIIIrandomizedcontrolledclinicalstudies

08.24 R. Leite, N. Gomes, L. Mendonça, K. Sousa, G. Santos, R. Gentil, F. Vaz PORTUGAL Choroidalthicknessinpatientswithdiabeticretinopathy

08.32 C. Lobo, S. Nunes, M. Costa, M. Simões, C. Egas, C. Faro, J. Cunha-Vaz PORTUGAL Differentphenotypesonnon-proliferativediabeticretinopathyassociatedwithdifferentgeneticpolymorphisms

08.40 E. Midena, J-F. Korobelnik ITALY Impactofbaselinevisualacuityonvisualandanatomicaloutcomesinpatientswithdiabeticmacularedema(DME)treatedwithintravitrealaflibercept(IVT-AFL)-datafromtheVIVID/VISTA-DMEstudies

08.48 E. Midena, J-F. Korobelnik ITALY Intravitrealafliberceptfordiabeticmaculeredema(DME)–100-WeekresultsfromtheVIVID-DMEandVISTA-DMEstudies

08.56 J-F. Korobelnik, L. Kodjikian, C. Delcourt, V. Gualino, R. Leaback, M. Velard FRANCE MulticentrelongitudinalstudyoftheuseofdexamethasoneintravitrealimplantfortreatmentofmacularedemaduetoretinalveinocclusionintheFrenchclinicalsetting-aninterimanalysis

09.04 I. Kozak, J. Arevalo, V. Gupta, J. Chhablani, J. Kim SAUDI ARABIA Targetedretinalphotocoagulation(TRP)usingnavigation-newtechnique

09.12 D. Alonistiotis, A. Takis, E. Kontou, D. Panagiotidis, N. Ioannou, D. Papaconstaninou, P. Theodossiadis GREECE ComparisonandfollowupoftheretinalnervefiberlayerofdiabeticpatientstypeII,withnormalsubjectsofthesameageandgender

09.20 R. Belfort, The Ozurdex MEAD Study Group BRAZIL Intraocularpressureinpatientswithdiabeticmacularedematreatedwithdexamethasoneintravitrealimplant-MEADstudyfindings

09.28 M. Gillies, S Fraser-Bell, L. Lim, A. Campain, W. Salem, C. Aroney, I. McAllister AUSTRALIA Randomisedclinicaltrialofintravitrealbevacizumabversusintravitrealdexamethasonefordiabeticmacularedema.TheBEVORDEXstudy

09.36 B. Burton UK BaselinecharacteristicsofpatientswithretinalveinocclusionenrolledwithintheLUMINOUSstudy

09.44 S. Vujosevic, M. Berton, S. Bini, E. Convento, F. Martini, E. Midena ITALY Choroidalandretinalmodificationsafteranti-VEGFtreatmentincenterinvolvingdiabeticmacularedema

09.52 L. Pierro, C. La Spina, C. Del Turco, M. Gagliardi, G. Casalino, M. Battaglia Parodi, F. Bandello ITALY Innerretinallayerschangesindiabeticretinopathy(DR)-aspectraldomainOCT(SDOCT)study

10.00 Endofsession



08.00 – 10.00

FREE PAPER SESSION

Quick Fire Free Paper Session 1Venue: Boulevard D (Level 1)

Chairpersons: J. García Arumí SPAIN A. Sharma INDIA

08.00 J. Gonzalez-Lopez, B. Arya, P. Addison UK Earliestreal-lifeexperienceusinglucentisformacularedemasecondarytobranchretinalveinocclusioninthenationalhealthservice(NHS)-bravo?

08.05 D. Chakraborty, T. Sinha, A. Das, S. Boral, B. Dutta-Choudhury INDIA Managinganti-VEGFresistanceindiabetic macularedema

08.10 A. Korol, O. Zadorozhnyy, T. Kustryn, I. Nasinnyk UKRAINE Newindicationsforafliberceptinpatientswithneovascularisation

08.15 K. Nabawi, A. Sharaf, H. Sowelam EGYPT Short-termresultsofintravitrealranibizumabinjectionineyeswithdiabeticmacularedema

08.20 R. Narayanan, J. Chhablani, I. Kozak, G. Jonnadula, A. Venkata, R. Pappuru, P. Rao INDIA Choroidalthicknessinmaculartelangiectasiatype2

08.25 H. Al-Nashar EGYPT Evaluationoftopicalalpha-2agonistinthetreatmentofmixeddiabeticmaculopathy

08.30 R. Hillier, E. Ojaimi, D. Wong, A. Berger, S. Boyd, R. Kohly, R. Muni UK Aqueouscytokinelevelsasindicatorsofdiseaseseverityandpredictorsoftreatmentresponsetoranibizumabindiabeticmacularedema

08.35 L. Hattenbach, N. Eter, H. Hans, N. Feltgen, L. Gabriele, G. Lambrou, T. Knorr GERMANY Efficacyandsafetyof0.5mgranibizumabcomparedwithintravitrealimplantcontaining0.7mgdexamethasoneinpatientswithbranchretinalveinocclusionover6months

08.40 S. Theodoropoulou, O. Bartfai, R. Johnston, A. Sallam UK Dexamethasoneimplantinretinalveinocclusion-efficacyandsafetyusingrepeatinjectionsasneeded

08.45 K. Xue, E. Yang, V. Chong UK Ultra-widefieldfundusfluoresceinangiographyrevealsdistinctmechanismsofdiabeticmacularedemaandhelpstopredictresponsetoranibizumabtreatment

08.50 G. Bikbova, T. Oshitari, S. Yamamoto JAPAN RegenerativeeffectofrangeneurotrophicfactorsinhighdoseAGEsexposedisolatedratretinas

08.55 M. Kernt GERMANY Combinationofnavigatedlaserphotocoagulationandintravitrealranibizumabinthetreatmentofdiabeticmacularedema-2yearresults

09.00 J. Garweg, M. Halberstadt SWITZERLAND Outcomeofvitrectomyforsuprachoroidealhemorrhage

09.05 V. Agrawal, K. Khilnani, R. Saini, A. Singh INDIA Retinaldetachmentassociatedwithcolobomaofchoroid-managementstrategiesandoutcome

09.10 L. Akhundova, M. Karimov AZERBAIJAN Supplementalscleralbucklingforrhegmatogenousretinaldetachmentwithahighriskproliferativevitreoretinopathy

09.15 N. Acar TURKEY Anewforeignbodyforcepsdesignedfortheremovalofmosttypesofintraocularforeignbodies

09.20 R. Troyanovsky, B. Monakhov, A. Baranov, S. Solonina, O. Sinyavskiy, A. Golovin, N. Malinovskaya RUSSIA Perforatingopenglobeinjuries-epidemiology,diagnosisandmanagement

09.25 J. Nobre-Cardoso, A. Cardoso, N. Marques, A.Miranda,B.Beltrán,J.Silva,N.CamposPortugal Vitreoretinalinterfacefeaturesonspectraldomainopticalcoherencetomographyoffelloweyesofpatientswithidiopathicmacularholes

09.30 J. Figueira, I. Laíns, D. Sousa Martins, J. Lencart, R. Belfort, M. Maia PORTUGAL Efficacyandsafetyanalysisofintraocularlutein-baseddyesforvitreoretinalsurgeryinpreclinicaland clinicalmodels

09.35 F. Rodrigues, R. Almeida, F. Trindade, R. Pereira, S. Moniz PORTUGAL RetinaldetachmentepidemiologyinMadeiraIsland

09.40 C. Sinapis, R. Newsom, S. Lash, D. Hornan, A. Warwick, P. Alexander UK Vitrectomyindiabeticpatients-thefelloweye

09.45 C. de Giacinto, R. Piermarocchi, D. Minutola, D. Tognetto ITALY Thespontaneousclosure,reopeningandthefurtherspontaneousclosureofastageIVfull-thicknessidiopathicmacularhole-acasereport

10.00 Endofsession



08.45 – 18.30

INSTRUCTIONAL COURSE

Update on Posterior UveitisBoulevard E (Level 1)

Course Organisers: C.P. Herbort SWITZERLAND C. Pavesio UK

Cost: €120

I. Diagnosis, Work-up & Investigational Procedures

08.45 P. Murray UK Introduction:Clinicalassessmentofposterioruveitis

09.10 A. Denniston UK Investigationalwork-upofposterioruveitis

09.30 C.P. Herbort SWITZERLAND Angiographicwork-upforposterioruveitis

09.55 P. Neri ITALY OCTinposterioruveitis

10.10 A. Mantovani ITALY Autofluorescenceandinfraredimaginginuveitis

10.30 Discussion

10.40 Coffee Break

II. Main Entities

IIa. Infectious

11.00 C. Pavesio UK Toxoplasmosis

11.18 M. Westcott UK Viralretinitis

11.36 M. Stanford UK Tuberculosis

11.54 P. Kestelyn BELGIUM Syphilis

12.12 Discussion

IIb1. Non-infectious

12.15 M. Stanford UK Behçet

12.35 C.P. Herbort SWITZERLAND Choriocapillaritis–MEWDS APMPPE Multifocalchoroiditis

13.00 Discussion

13.10 Lunch Break

IIb2. Non-infectious

14.10 M. Westcott UK Serpiginouschoroidopathy

14.25 P. Kestelyn BELGIUM StromalchoroiditisI:VKH&SO

14.40 P. LeHoang FRANCE StromalchoroiditisII:Birdshot

14.55 N. Jones UK Sarcoidosis

15.10 P. LeHoang FRANCE Masquerades

15.40 Discussion

15.50 Coffee Break

III. Treatment, Complications & Surgery

16.10 C. Pavesio UK Localtherapiesinposterioruveitis

16.26 P. Murray UK Steroidsandimmunosuppressives

16.42 A. Denniston UK Biologics

16.58 Discussion

IV. Complications & Surgery

17.00 P. Neri ITALY CMO

17.15 N. Jones UK Cataract

17.35 P. LeHoang FRANCE Glaucoma

17.55 L. da Cruz UK VitreoretinalSurgery

18.10 Discussion

18.30 EndofSession



08.30 – 10.00

INSTRUCTIONAL COURSE 1

Current Management of Uveal Melanoma Boulevard G (Level 1)

Course Organiser: D.E. Pelayes ARGENTINA

Cost:€25

08.30 D.E. Pelayes ARGENTINA FNABandbiopsy

08.39 N. Bechrakis AUSTRIA Clinicalpresentationanddifferentialdiagnosis

ofpseudeomelanomas

08.48 S. Seregard SWEDEN Brachytherapy

08.57 L. Zografos SWITZERLAND ProtonBeamradiotherapyofuvealmelanomas

09.06 M. Foerster GERMANY Irismelanomas

09.15 L. Desjardins FRANCE Epidemiology

09.24 N. Bornfeld GERMANY Endoresection

09.33 E. Midena ITALY Metastaticuvealmelanoma

09.42 S. Coupland UK Pathology

09.51 Discussion

10.00 Endofcourse

08.30 – 10.00


The Role of the Vitreous in Retinal DiseaseBoulevard I (Level 1)

Course Organiser: E. Stefánsson ICELAND

Cost:€25

08.30 J. Sebag USA Vitreousstructureandtheinfluenceofanomalousposteriorvitreousdetachmentonretinaldisease

08.45 E. Stefánsson ICELAND Vitreousphysiologyandretinaldisease

09.00 E. Stefánsson ICELAND Cataractformationandvitreous

09.15 M. Trese USA Vitreolysis

09.30 A. Augustin GERMANY Clinicaltreatmentofvitrealdisease

09.45 Discussion

10.00 Endofcourse



11.00 – 13.00

MAIN SESSION 1

Dry AMDAuditorium (Level 0)

Chairpersons: J. García Arumí SPAIN U. Schmidt-Erfurth AUSTRIA

11.00 C. Chan USA Aging,degeneration,inflammation,apoptosis:mechanismsofAMD

11.20 E. Souied FRANCE Drusen,pseudodrusen,ghostdrusen:origins andoutcomes

11.40 U. Schmidt-Erfurth AUSTRIA ImagingandquantificationofRPEand photoreceptordisease

12.00 C. Toth USA (FOR THE AREDS 2 OCT GROUP) Dryage-relatedmaculardegeneration:mechanisms,

therapeutictargets,andimaging

12.20 Z. Yehoshua USA ComplementinhibitioninthetreatmentofAMD

12.40 R. MacLaren UK Currenthorizonoftransplantation,stemcell andgenetherapy

13.00 Endofsession

11.00 – 12.30

GERMAN RETINA SOCIETY SYMPOSIUM

Common Misconceptions & Mistakes in the Treatment of Retinal DiseasesBoulevard C (Level 1)

Chairpersons: H. Heimann GERMANY D. Pauleikhoff GERMANY

11.00 S. Schmitz-Valckenberg GERMANY The5mostcommonmistakesinOCTinterpretation

11.15 D. Pauleikhoff GERMANY The5mostcommonmistakesinprntreatmentof

exudativeagerelatedmaculardegeneration

11.30 H. Helbig GERMANY The5mostcommonmistakesinthetreatmentof

diabeticretinopathy

11.45 N. Bornfeld GERMANY The5mostcommonmistakesinocularoncology

12.00 H. Heimann GERMANY The5mostcommonmistakesinthetreatmentof

retinalbreaksandretinaldetachment

12.15 C. Eckardt GERMANY The5mostcommonmistakesinvitreoretinalsurgery

12.30 Endofsymposium



11.00 – 12.30

FREE PAPER SESSION


Chairpersons: P. LeHaong FRANCE E. Stefánsson ICELAND

11.00 A. Caramoy, K. Droege, B. Kirchhof, S. Fauser GERMANY Retinallayersmeasurementsinhealthyeyesandineyesreceivingsiliconeoil-basedendotamponade

11.05 M. Bhende, M. K P INDIA Effectofocularmagnificationonmeasurementsmadeonspectraldomainopticalcoherencetomography

11.10 A. Mathai, M. Nicholson, R. Reddy Pappuru INDIA FundusautofluorescenceabnormalitiesinacutecentralserouschorioretinopathyanditsdiagnosticaccuracytodetecttheareaofRPEleak

11.15 G. Satirtav, G. Kaya, M. Donbaloglu, H. Kerimoglu, R. Oltulu TURKEY Evaluationofchoidalthicknessinrelationtogender, age,axiallengthandrefractiveerrorinyoung Turkishpopulation

11.20 E. Merce, M. Fortane FRANCE Bilateralchorioretinalfoldsassociatedwithafourth-ventricularependymoma

11.25 C. Ferreira, J. Beato, M. Falcão, E. Brandão, Â. Carneiro, F. Falcão-Reis PORTUGAL Choroidalthicknessinmultisystemicautoimmunediseasesunderhydroxychloroquinetreatmentwithoutophthalmologicmanifestations

11.30 R. Rothwell, D. Meira, M. Oliveira, L. Ribeiro, S. Fonseca PORTUGAL Evaluationofchoroidalthicknessduringpregnancyusingenhanceddepthimagingopticalcoherencetomography

11.35 I. Panova, M. Prokopieva, N. Varnavskaya RUSSIA OCT-monitoringofvariousethiologychorioretinitis

11.40 I. Panova, O. Avdeeva, N. Varnavskaya RUSSIA OCT-verificationofactivitythevariousethiologychorioretinitis

11.45 A. El Habbak, M. Nagy EGYPT Siliconeoil1000Csand2000Cstamponadeisnearlyaseffectiveassilicone5000Csinparsplanavitrectomywithlesscomplications

11.50 S. Jordan, O. Garcia-Garcia, O. Subirà, H. Brosa, S. Jordán SPAIN Vogt-Koyanagi-Haradasyndrome-areviewof32casesdiagnosedinourarea

11.55 M. Tikhonovich, S. Gavrilova RUSSIA Aratmodelofproliferativevitreoretinopathyinduced bydispase

12.00 S. Soedarman, A. Djatikusumo, S. Widyawati, A. Setiawati INDONESIA Theeffectofprophylacticnepafenac0,1%eyedropsonmacularchangesafterphacoemulsificationfornon-proliferativediabeticretinopathypatientsinIndonesia-apreliminaryreport

12.05 S. Zanak INDIA Correlationofopticalcoherencetomographymeasuredretinalnervefiberlayerthicknesswithrefractivestatusoftheeye

12.10 A. Sharma, J. Sheth, M. RJ, V. N, S. SK, J. Patil INDIA Characteristicsofcentralserousretinopathy(CSR)withpigmentepithelialdetachment(PED)andwithoutPEDinAsianIndians

12.15 K. Ghasemi Falavarjani, M. Modarres, M. Parvaresh, M. Hashemi, M. Naseripour, A. Hadavand Khani IRAN Intra-siliconeoilinjectionofmethotrexateattheendofretinalreattachmentsurgeryforsevereproliferativevitreoretinopathy

12.30 Endofsession



11.00 – 13.00


Current Management of Paediatric Vitreoretinal DiseasesBoulevard G (Level 1)

Course Organisers: A. Kychenthal CHILE G. Caputo FRANCE

Cost:€25

11.00 M. Trese USA CurrentmanagementofROP

11.15 C. Wong UK Familialexudativevitreoretinopathyandretinoschisis

11.30 P. Dorta CHILE Paediatricretinalimaging

11.45 K. Tawansy USA Type1ROP:currentmanagement(laser-antiVEGF)

12.00 A. Kychenthal CHILE ROPretinaldetachment

12.15 G. Caputo FRANCE Coatsdisease&persistentfetalvasculature syndrome(PFV)

12.30 M. Shapiro USA Paediatricrhegmatogenousretinaldetachment

12.45 Discussion

13.00 Endofcourse

11.00 – 13.00


The First 3D Video Course on Current Wide Angle 25-27G SurgeryIncluding Guidelines for 3D Teaching Videos in Vitreoretinal Surgery

Boulevard I (Level 1)

Course Organisers: A. Nikolakopoulos GREECE T. Aaberg USA C. Riemann USA

Cost:€25

11.00 M. Mura THE NETHERLANDS

11.09 V. Ferrara ITALY

11.18 S. Kaynak TURKEY

11.27 F. Balta ROMANIA

11.36 C. Forlini ITALY

11.45 K. Kandonosono JAPAN

11.54 F. Boscia ITALY

12.03 S. Gotzarides GREECE

12.12 S. Rizzo ITALY

12.21 C. Claes BELGIUM

12.30 F. Fayyad JORDAN

13.00 Endofcourse



14.00 – 16.00

MAIN SESSION 2

Diabetic Retinopathy Auditorium (Level 0)

Chairpersons: F. Bandello ITALY J. Cunha-Vaz PORTUGAL

14.00 M. Porta ITALY Frombenchtoslitlamp

14.20 E. Stefánsson ICELAND The EURETINAprojectfordiabeticretinopathyscreening

14.40 J. Cunha-Vaz PORTUGAL Genotypeandphenotypeassociationsindiabeticretinopathy

15.00 R. Simo SPAIN TheEUROCONDORproject

15.20 M. Battaglia Parodi ITALY Noveltiesinthefieldofdiabeticmacularedema

15.40 S. Sivaprasad UK Recentperspectivesfortreatmentofproliferativediabeticretinopathy

16.00 Endofsession

14.00 – 15.30


Fluorescein and ICG-Angiography in Macular Diseases: Interpretation and Comparison with Other Imaging ModalitiesBoulevard G (Level 1)

Course Organisers: D. Pauleikhoff GERMANY G. Staurenghi ITALY

Cost:€25

14.00 D. Pauleikhoff GERMANY IsfluoresceinandICGangiographyinmaculardiseasesstillimportant?Astatementtowardsmultimodalimaging

14.13 S. Wolf SWITZERLAND Imagingtoolsforangiography–prosandcons

14.26 G. Staurenghi ITALY ICGangiography–indicationsandinterpretation

14.39 F. Sallo UK Correlationofangiography,autofluorescence,OCT Anexample:MultimodalimaginginMacTeltype2

14.52 A. Tufail UK Angiographicassessmentvs.OCTduring anti-VEGF-therapy

15.05 P. Charbel Issa GERMANY Imagingmaculardystrophies–novelapproaches andthevalueofangiography

15.18 Discussion

15.30 Endofcourse



14.30 – 16.00

BRITISH & EIRE ASSOCIATION OF VITREORETINAL SURGEONS SYMPOSIUM (BEAVRS)

The How & Why of Measuring Retinal Detachment Outcome:Introducing the EURETINA Members Retina Detachment Outcome Project

Boulevard C (Level 1)

Chairpersons: B. Aylward UK (PRESIDENT, BEAVRS) D. Steel UK

14.30 B. Aylward UK Background/Introduction:whyshouldwemeasurecomplexityadjustedoutcome?

14.43 T. Williamson UK DevelopingtheRDstandardiseddataset

14.56 S. Winder UK TheEURETINAonlinedatacollectiontool: demoandsignup

15.09 D. Yorston UK BEAVRSresults:thefirst2000cases-complexityadjustedresults

15.22 D. Steel UK Researchpotentialandpublicationplans

15.35 H. Heimann GERMANY Hasn’ttheEVRSdonethis?

15.48 B. Aylward UK Summaryandsignup

16.00 Endofsymposium

14.00 – 15.30


Minimal Invasive VitrectomyBoulevard I (Level 1)

Course Organiser: C. Prünte SWITZERLAND

Cost:€25

14.00 C. Prünte SWITZERLAND Basictechnicalaspectsofminimalinvasivevitrectomy

14.18 J. García Arumí SPAIN Safetyaspectsofminimalinvasivevitrectomy

14.36 J-F. Korobelnik FRANCE Managingdiabeticretinopathyandother proliferativediseases

14.54 A. Augustin GERMANY Managingretinaldetachment

15.12 Discussion

15.30 Endofcourse



14.30 – 16.00

FREE PAPER SESSION


Chairpersons: C. Creuzot-Garcher FRANCE G. Querques ITALY

14.30 S. Yu, H. Kwak SOUTH KOREA Analysisofdrusenvolumeandareachanges

14.35 I. Laíns, J. Marques, M. Costa, I. Pires, M. Cachulo, J. Figueira, R. Silva PORTUGAL Retinalangiomatousproliferation-incidenceandphenotypeofneovascularizationinthefellow-eye

14.40 J. Pinheiro-Costa, J. Costa, J. Beato, P. Freitasda-Costa, M. Falcão, F. Falcão-Reis, A. Carneiro PORTUGAL Analysisoftheeffectsofafliberceptinchronicneovascularage-relatedmaculardegenerationpreviouslytreatedwithbevacizumaborranibizumab

14.45 N. Yadav, T. Sharma, A. Banker, A. Naik, S. Sarkar INDIA Characteristicsofpatientswithneovascularage-relatedmaculardegenerationinIndia-datafromUNVEILstudy

14.50 J. Quadrado Gil, J. Marques, I. Lains, M. Costa, S. Nunes, M. Cachulo, R. Silva PORTUGAL Reticularpseudodrusenandthe5yearriskofprogressionforlateAMD-amultimodalimagingapproach

14.55 R. Agrawal, P. Addison, G. Fernandez-Sanz, S. Bala UK DesegmentationofOzurdeximplantinvitreouscavity–reportoftwocases

15.00 R. Hua, R. Gangwani, L. Chen CHINA TocompareBruchmembraneopeningandneuralcanalinpreperimetricglaucomatouseyeswithabnormalposteriorpoleasymmetryanalysis

15.05 L. Gopal, A. Wagle, B. Maheshwar SINGAPORE ICGfindingsinthefelloweyeofpatientswithpolypoidalchoroidalvasculopathy

15.10 P. Guzman-Salas, E. Guinto-Arcos, M. Pedroza-Seres MEXICO EpidemiologiccharacteristicsofpatientswithsympatheticophthalmiainMexico

15.15 C. Claes BELGIUM Ultrahighspeed27Gvitrectomy

15.20 M. El Rashedy EGYPT Asymmetricdiabeticretinopathyandcarotidinsufficiency-acorrelativestudy

15.25 A. Sharma, J. Sheth, RJ. Nadhisuden, N. Vidhya, SK. Sundaramoorthy, J. Patil INDIA Prevalenceofpigmentepithelialdetachment(PED)incasesofcentralserousretinopathy(CSR)inAsianIndians

15.30 M. Kim, D. Lee, Y. Cho SOUTH KOREA Surgicaloutcomeofsimultaneousintraocularlens(IOL)rescueandsuturelessintrascleraltunnelfixationofdislocatedIOLs

15.35 A. Hegazy, S. Esmat, T. Macky, R. Zedan EGYPT Retinalganglioncellcomplexchangesusingspectraldomainopticalcoherencetomographyindiabeticpatientswithoutretinopathy

15.40 W. Gan, N. Jones UK Serpiginous-likechoroiditis-asamarkerfortuberculosisinanon-endemicarea

15.45 Z. Elhousseini, A. Laidlaw, E. Lee UK Effectofexpansilegasbubblefollowingparsplanavitrectomyonretinaldisplacement

15.50 A. El-Sawy Habib, H. Makled EGYPT AprospectiverandomizedstudyontheroleofviscoadaptiveOVDHealon5versuscombiningviscodispersive-viscocohesiveOVDs(soft-shelltechnique)inprotectingthecornealendotheliumduringphacoemulsificationofhardcataract

15.55 S. Mahapatra, G. Kanungo INDIA Retinalangiomas-acaseseries

16.00 Endofsession


14th EURETINA CongressLONDON

16.00 – 17.00

Opening Ceremony & EURETINA Lecture

Auditorium (Level 0)

Chairperson: F. Bandello ITALY

16.00 Welcome from the President F. Bandello ITALY (PRESIDENT, EURETINA)

16.10 The EURETINA Lecture 2014 DonatedbytheClaereJungFoundation,Hamburg

Gene Therapy for Retinal Disease – What Lies Ahead R. MacLaren UK

PresentationofCertificate S. Wolf SWITZERLAND (GENERAL SECRETARY, EURETINA)

16.40 EURETINA Video Competition Awards F. Bandello ITALY (PRESIDENT, EURETINA)

16.50 Closing Remarks U. Schmidt-Erfurth AUSTRIA (VICE-PRESIDENT, EURETINA)

17.00 End of Ceremony

EURETINADISCOVER

Visit the Resource Centre to discover the rewards

Sign up for Membership

EURETINA InSight (online interactive courses)

EURETINA On Demand (online library of presentations from EURETINA Congresses)

Find us in the exhibition hallBOOTH B01

FRIDAY12 September

25



FRIDAY 12 SEPTEMBER26

08.00 – 10.00

MAIN SESSION 3

Regenerative Medicine with Presentations on Gene TherapyAuditorium (Level 0)

Chairpersons: J. Sahel FRANCE E. Banin ISRAEL

08.00 R. Ali UK Introductory overview

08.13 L. da Cruz UK Cell therapy

08.26 D. Dalkara FRANCE Vectors

08.39 Y. Arsenevic SWITZERLAND Lentiviruses

08.52 E. Banin ISRAEL Gene therapy for acromatopsia caused by mutations in the CNGA3 gene: from a large animal model to the clinic

09.05 R. MacLaren UK Photoreceptor transplantation

09.18 J. Bainbridge UK New perspectives (substrates for RPE transplantation)

09.31 J. Sahel FRANCE Gene-independent strategies to extend cone photoreceptors functional life

09.44 Discussion

10.00 End of session

08.00 – 09.45


AMD IVenue: Boulevard C (Level 1)

Chairpersons: A. Loewenstein ISRAEL L. Mastropasqua ITALY M. Nehemy BRAZIL

08.00 M. Buckle, A. Lee, I. Stratton, R. Healey, A. Tufail, R. Johnston UK Prevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the UK

08.08 H. Elbaz, T. Peto, R. Höhn, G. Zur Hausen, P. Wild, A. Mirshahi, N. Pfeiffer UK Epidemiology of ophthalmic conditions and their association with ocular and systemic diseases in Germany. An interdisciplinary work within the Gutenberg health study

08.16 C. Schütze, M. Wedl, B. Baumann, M. Pircher, C. Hitzenberger, U. Schmidt-Erfurth AUSTRIA Response of the retinal pigment epithelium (RPE) to antiangiogenic therapy in neovascular age-related macular degeneration (AMD)

08.24 R. Mahdy, M. Brinkmann, Y. Miura, M. Rudolf, S. Grisanti GERMANY Evaluating pharmacologic effects of different drugs in an in-vitro model of the outer blood-retinal barrier using different microscopic techniques

08.32 H. Sharma, P. Mathewson, M. Lane, P. Shah, H. Palmer, A. Denniston, M. Tsaloumas UK The role of social deprivation in severe neovascular age related macular degeneration

08.40 A. Rosenblatt, G. Lavi, G. Rabina, R. Kehat, O. Rubalsky, A. Loewenstein, M. Goldstein ISRAEL Long term follow up of patients treated with bevacizumab for neovascular age-related macular degeneration

08.48 I. Mantel, C. Gianniou, A. Dirani, L. Jang, A. Ambresin SWITZERLAND Functional outcome of neovascular AMD with intra- or subretinal fluid refractory to monthly anti-VEGF treatment

08.56 S. Tavassoli, M. Buckle, A. Sallam, R. Johnston UK First signs of neovascular age-related macular degeneration requiring anti-VEGF treatment in second eyes under monthly surveillance after treatment in the first eye

09.04 I. Westborg, S. Albrecht, E. Granstam, G. Bjärnhall, N. Karlsson SWEDEN Endophthalmitis and safety in intravitreal treatments in Sweden - the Swedish macula register – operative routines in intravitreal treatments in Sweden 2013

09.12 J. Mones SPAIN What does early neovascular AMD look like?


FRIDAY 12 SEPTEMBER 27

09.20 A. Augustin GERMANY AMD management – analysis of effectiveness in the detection of CNV following the integration of the foreseehome tele-monitoring system in the management of intermediate AMD patients

09.28 U. Chakravarthy UK The home monitoring of the eye (HOME) study

09.36 A. Loewenstein (HOME Study Research Group) ISRAEL The HOME study- lesion characteristics of early CNV


08.00 – 09.45


AMD IIVenue: Boulevard D (Level 1)

Chairpersons: M. Larsen DENMARK J.C. Pastor SPAIN

08.00 M. Cachulo, I. Laíns, C. Lobo, J. Figueira, M. Costa, S. Nunes, R. Silva PORTUGAL Prevalence of age-related macular degeneration in Portugal- the Coimbra eye study

08.08 T. Jackson, A. Muldrew, T. Peto, S. Harding, J. Sahni, U. Chakravarthy UK External beam X-ray therapy for the treatment of neovascular age-related macular degeneration- 3 year safety outcomes of the INTREPID trial

08.16 C. Klaver, G. Buitendijk, N. Amin, A. Hofman, C. van Duijn, J. Vingerling THE NETHERLANDS Direct-to-consumer personal genome testing for age-related macular degeneration

08.24 H. Gerding SWITZERLAND How many injections of ranibizumab are necessary in the first year of wet AMD treatment? A meta-analysis

08.32 M. Rudolf, A. Mohi, S. Grisanti, Y. Miura GERMANY ApoA-I mimetic peptide L-4F reduces significantly lipid deposits in Bruch’s membrane and complement activation in geriatric monkeys with age-related maculopathy

08.40 E. Pras, N. Shoshany, I. Vulih, D. Volodarsky, O. Isakov, D. Kristal ISRAEL Whole exome sequencing (WES) in age-related macular degeneration (AMD) patients uncovers novel mutations in macular degeneration genes

08.48 L. Lytvynchuk, A. Sergiienko, G. Lavrenchuk, G. Petrovski UKRAINE Antiproliferative and apoptotic action of aflibercept on fibroblast-like cell strain in vitro

08.56 M. Gillies, D. Barthelmes AUSTRALIA Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors- observational study data

09.04 S. de Massougnes, A. Ambresin, W. Ferrini, I. Mantel SWITZERLAND Pigment epithelial detachment response to aflibercept in neovascular age-related macular degeneration previously refractory to ranibizumab

09.12 H. Kwak, S. Yu SOUTH KOREA Five year results of combined treatment for polypoidal choroidal vasculopathy- verteporfin PDT and intravitreal anti-VEGF

09.20 S. Yu, H. Kwak SOUTH KOREA Reliability of smartphone-based electronic visual acuity testing - (applications in remote monitoring and clinical research of macular pathology)



08.00 – 09.30

AFIV-RETINA SYMPOSIUM (ASSOCIATION FRANCO ISRAELI FOR VISION – RETINA)Boulevard E (Level 1)

Part 1: Updates in Retina Moderators: A. Loewenstein ISRAEL I. Chowers ISRAEL E. Souied FRANCE

08.00 G. Querques ITALY Black is black, grey is grey

08.06 R. Hashmonay USA Novel treatments in retinal disease

08.12 A. Loewenstein ISRAEL Early detection of AMD

08.18 L. Kodjikian FRANCE Update on H2H studies

08.24 I. Chowers ISRAEL Pharmacogenetics in AMD

08.30 E. Souied FRANCE Ghost Drusen

08.36 M. Goldstein ISRAEL Somatotype in patients with CSR

08.42 S. Razavi FRANCE Swept source and choroid

08.48 D. Weinberger ISRAEL AntiVEGF – do we inject too much?

08.54 G. Coscas FRANCE En face OCT

Part 2: Pearls in Retina: Clinical Cases Moderators: M. Goldstein ISRAEL G. Querques ITALY G. Coscas FRANCE

09.00 S-Y. Cohen FRANCE Mystery case 1

09.06 M. Regenbogen ISRAEL Mystery case 2

09.12 E. Averbukh ISRAEL Mystery case 3

09.18 M. Goldstein ISRAEL Mystery case 4

09.24 Closing comments

09.30 End of symposium

09.28 J. Marques, I. Laíns, J. Figueira, C. Farinha, M. Cachulo, M. Costa, R. Silva PORTUGAL Polypoidal choroidal vasculopathy- can SD-OCT overtake indocyanine-green angiography?

09.36 A. Tufail, L. Aaron, U. Chakravarthy, P. Keane, R. Johnston, C. Egan, D. Sim UK UK neovascular AMD database study- time to reactivate after a pause in treatment - outcomes from over 92,000 intravitreal ranibizumab injections




08.00 – 09.30


Autofluorescence Imaging: State-of-the-ArtBoulevard H (Level 1)

Course Organiser: F. Holz GERMANY

Cost: €25

08.00 S. Schmitz-Valckenberg GERMANY How to optimize autofluorescence image acquisition

08.15 F. Holz GERMANY Interpreting AF images: a practical approach

08.30 A. Tufail UK Autofluorescence imaging in inflammatory diseases

08.45 M. Fleckenstein GERMANY The role of autofluorescence in AMD

09.00 T. Theelen THE NETHERLANDS Making the correct diagnosis: macular and retinal dystrophies

09.15 Discussion

09.30 End of course

08.00 – 10.00


Electrophysiology: Principles & PracticeBoulevard G (Level 1)

Course Organiser: G. Holder UK

Cost: €25

08.00 G. Holder UK An introduction to the tests

08.25 B. Leroy BELGIUM Electrophysiology and inherited disease

08.50 D. Thompson UK Paediatric electrophysiology

09.15 G. Holder UK Electrophysiology in acquired and inflammatory disease

09.40 Discussion

10.00 End of course



11.00 – 12.00

Kreissig LectureAuditorium (Level 0)

Chairperson: I. Kreissig GERMANY

Introduction

F. Bandello ITALY (PRESIDENT, EURETINA)

Keynote Lecture

J. Seddon USA

Understanding the mechanisms and etiology of macular degeneration-genetics and modifiable factors

Presentation of Award

I. Kreissig GERMANY

08.00 – 10.00


New Strategies in Ocular TraumaBoulevard I (Level 1)

Course Organisers: C. Forlini ITALY A. Nikolakopoulos GREECE

Cost: €25

08.00 S. Natarajan INDIA The behaviour in complicated trauma of intrascleral sutureless IOL

08.10 A. Nikolakopoulos GREECE Intrascleral acrysoft in a post traumatic aniridia, dropped nucleus and retinal detachment

08.20 P. Szurman GERMANY Iris reconstruction in traumatic aniridia

08.30 M. Forlini ITALY Case report: iris trauma – the different way of iris reconstruction

08.37 C. Forlini ITALY Artificial iris and IOL implant in pole to pole surgery in severe trauma cases

08.47 P. Sullivan UK How not to do it – mistakes in the management of severe trauma

08.57 F. Fayyad JORDAN Traumatic giant retinal tears: case reports

09.07 K. Sabti KUWAIT The use of microendoscopy in selected cases of severe posterior segment trauma

09.17 M. Nagpall INDIA IOFB removal: an assortment of cases

09.27 H. Mortada EGYPT Combined chorioretinectomy and ILM peeling for prophylaxis of recurrent proliferation in open globe injuries

09.37 W. Schrader GERMANY Case report: severe rupture caused by the fork of a fork lift truck - whether and when to give up reconstruction

09.44 T. Imshanetskaya BELARUS Case report: combined Ahmed valve implantation and removal of dislocated lens for treatment of traumatic glaucoma after ocular contusion

09.51 C. Forlini ITALY, A. Nikolakopoulos GREECE Discussion conclusion

10.00 End of course



11.00 – 12.30


Vascular Diseases and Diabetic Retinopathy IIVenue: Boulevard C (Level 1)

Chairpersons: T. Avitabile ITALY R. Tadayoni FRANCE

11.00 K. Sousa, C. Ferreira, L. Mendonça, R. Gentil, R. Leite, F. Vaz, N. Gomes PORTUGAL Efficacy of micropulse 532 NM green laser in diabetic macular edema

11.08 V. Yarmak, T. Imshenetskaya, G. Vashkevich, I. Malinovskaya BELARUS Clinical characteristics of endophthalmitis after intravitreal injection of antivascular endothelial growth factor agent

11.16 T. Sujirakul, D. Rojanaporn, P. Preechawat, P. Hanutsaha, C. Chen, A. Orlin, L. Yannuzzi USA Retrograde ocular arterial occlusions after subcutaneous filler injections

11.24 M. Abdul Karim, R. Singh, P. Ashwin UK Sustained topical anaesthesia for intravitreal implantation surgery

11.32 P. Volodin, I. Iablokova, A. Borisova RUSSIA Optimized technique of pattern laser photocoagulation for active retinopathy of prematurity

11.40 V. Dzinic, M. Dzinic, A. Oros SERBIA Central macular thickness (CMT) changes after phacoemulsification in patients with previously treated diabetic retinopathy (DR) and diabetic macular edema (DME)

11.48 J. Kirk, R. Healy, P. Scanlon, R. Johnston, Q. Mohamed UK Change in glycosylated haemoglobin in patients with centre involving diabetic macular edema treated with intravitreal ranibizumab

11.56 F. Manurung, G. Adriono INDONESIA Intravitreal bevacizumab therapy for treatment of retinopathy of prematurity- experience in Jakarta eye center, Indonesia

12.04 R. Narayanan, B. Panchal, J. Chhablani, T. Das, S. Jalali, R. Pappuru INDIA A randomized, double masked, controlled study of the efficacy and safety of intravitreal ranibizumab versus bevacizumab in subjects with macular edema secondary to branch retinal vein occlusion

12.12 T. Papathomas, L. Makris, A. Kamal UK 1 year follow-up of dexamethasone intravitreal implant (Ozurdex®) in macular edema due to retinal vein occlusions

12.20 P. Prakash, D. Hanumunthadu, S. Arghandawi UK Efficacy of intravitreal dexamethasone implants for macular edema secondary to retinal vein occlusion - in day to day NHS practice


11.00 – 12.30


Imaging IVenue: Boulevard D (Level 1)

Chairpersons: G. Coscas FRANCE C.H. Meyer GERMANY

11.00 T. Alabduljalil, C. Toth, A. Reginald, C. Westall, S. Farsiu, A. Arshavsky, W. Lam CANADA Demonstration of anatomical development of the human macula within the first five years of life using bioptigen optical coherence tomography (OCT)

11.08 K. Eibenberger, B. Gerendas, P. Roberts, W. Bühl, M. Kundi, U. Schmidt-Erfurth, S. Sacu AUSTRIA Prediction of recurrent central serous chorioretinopathy at initial examination

11.16 J. Ruiz-Medrano, I. Flores-Moreno, P. Peña-García, J. Montero, J. Duker SPAIN Macular choroidal thickness profile in a healthy population measured by swept-source optical coherence tomography

11.24 A. Arora, E. Pavlidou, K. Kopsidas, V. Papastefanou, V. Cohen, M. Sagoo UK Variability of choroidal thickness measurements in choroidal nevi using enhanced depth optical coherence tomography

11.32 U. Schraermeyer GERMANY Foveolar cones and müller cells of monkeys and humans have a unique, still unknown morphology with impact for understanding the Stiles-Crawford effect

11.40 A. Ferrero, A. Bonnabel, L. Gascard, A. Bron, C. Creuzot-Garcher FRANCE 1 year results of the follow-up of patients with asymptomatic idiopathic epiretinal membrane

11.48 M. Abouhussein, A. Gomaa EGYPT OCT findings in high myopia

11.56 T. Burke, T. Duncker, R. Woods, R. Smith, R. Allikmets, J. Sparrow, F. Delori USA Quantitative fundus autofluorescence in recessive Stargardt disease

12.04 T. Duncker, S. Tsang, W. Lee, J. Zernant, R. Allikmets, F. Delori, J. Sparrow USA Quantitative fundus autofluorescence and optical coherence tomography in bull’s-eye maculopathy

12.12 D. Odrobina, P. Gozdek, M. Maroszyński, I. Laudańska-Olszewska POLAND Subfoveal choroidal thickness after scleral buckling surgery with and without encircling band for macula-off rhegmatogenous retinal detachment in long-term observations

12.24 K. Spiteri Cornish, J. Ho, S. Downes, N. Lois UK The epidemiology of Stargardt disease




11.00 – 12.30


Laser Therapy in Retinal Disease: Indications & ProceduresBoulevard H (Level 1)

Course Organisers: T. Lai HONG KONG A. Loewenstein ISRAEL E. Midena ITALY

Cost: €25

11.00 F. Bandello ITALY PRP for PDR

11.12 C. Pournaras SWITZERLAND Mechanisms of laser treatment and its influence on blood retina barrier

11.24 T. Lai HONG KONG PDT: is it still relevant?

11.36 A. Augustin GERMANY Laser for vein occlusion

11.48 E. Midena ITALY Laser for DME, including subthreshold

12.00 R. Siegel ISRAEL Laser for ROP

12.12 M. Goldstein ISRAEL Case studies and discussion

12.24 Discussion

12.30 End of course

11.00 – 12.30


State-of-the-Art in Anti-VEGF TherapyBoulevard E (Level 1)

Course Organiser: U. Schmidt-Erfurth AUSTRIA

Cost: €25

11.00 U. Schraermeyer GERMANY What are the differences between anti-VEGF substances?

11.13 U. Schmidt-Erfurth AUSTRIA What works best in neovascular AMD?

11.26 A. Loewenstein ISRAEL When and why to switch from one substance to another?

11.39 M. Larsen DENMARK How much anti-VEGF is needed in DME?

11.52 F. Bandello ITALY Is anti-VEGF the only option in RVO?

12.05 A. Klettner GERMANY Is the discussion about safety over?

12.18 Discussion

12.30 End of course



11.00 – 12.30


Pearls & Pitfalls in the Imaging of the Posterior FundusBoulevard G (Level 1)

Course Organiser: U. Chakravarthy UK

Cost: €25

11.00 R. Danis USA Interpreting multicolor imaging

11.15 G. Staurenghi ITALY Misuse and misinterpretation of indocyanine green angiography

11.30 G. Soubrane FRANCE Misuse and misinterpretation of optical coherence tomography

11.45 P. Praveen UK Automated segmentation misuse and misinterpretation in OCT

12.00 S. Sadda USA Misuse and misinterpretation of autofluorescence

12.15 Discussion

12.30 End of course

11.00 – 12.30


Macular DystrophiesBoulevard I (Level 1)

Course Organisers: G. Querques ITALY E. Souied FRANCE

Cost: €25

11.00 G. Querques ITALY Best disease

11.15 C. Boon THE NETHERLANDS Pattern dystrophies

11.30 E. Souied FRANCE Stargardt disease and FFM

11.45 C. Hoyng THE NETHERLANDS Macular dystrophies mimicking AMD

12.00 B. Leroy BELGIUM Cone dysfunction syndromes

12.15 I. Audo FRANCE X-linked retinoschisis

12.30 End of course



14.00 – 16.00

MAIN SESSION 4

The Eye & The BrainAuditorium (Level 0)

Chairpersons: D. Palanker USA G. Richard GERMANY

14.00 S. Schippling SWITZERLAND OCT in demyelinating disease of the CNS – is the retina a ‘mini brain’?

14.18 B. Stemplewitz GERMANY Neuroimaging in Parkinson`s disease – does OCT help us?

14.36 A. Augustin GERMANY SD-OCT imaging of nerve fiber layer

14.54 S. Rizzo ITALY Update on the Argus II Retinal Prosthesis System

15.12 D. Palanker USA Restoration of sight with high resolution photovoltaic subretinal prosthesis

15.30 G. Richard GERMANY Limitations of retinal prosthesis

15.48 Discussion


12.00 – 13.00

Amsterdam Retina DebateAuditorium (Level 0)

Chairperson: S. Lesnik-Oberstein THE NETHERLANDS

Debate 1: Surgery Still Has a Role in AMD

For: M. Mura THE NETHERLANDS

Against: F. Holz GERMANY

Debate 2: Floaterectomy is Justified

For: C. Toth USA

Against: A. Laidlaw UK



14.30 – 16.00

EVICR.net Session - Clinical Trial ResearchBoulevard D (Level 1)

Chairperson: J. Cunha-Vaz PORTUGAL

14.30 J. Cunha-Vaz PORTUGAL EVICR.net status. Ongoing network research in retinal diseases

14.40 A. Tufail UK Need for validation of endpoints for retinal diseases

14.50 L. Ribeiro PORTUGAL Identifying NPDR progressors - RET-02 clinical trial

15.00 S. Harding UK EUROCONDOR clinical trial – neuroprotection for non-proliferative diabetic retinopathy

15.10 J. Figueira PORTUGAL PROTEUS clinical trial – anti-VEGF role in proliferative diabetic retinopathy

15.20 F. Holz GERMANY Emerging innovative treatments for dry AMD

15.30 Round-Table: EVICR.net role in investigator-driven clinical research and collaborations with industry

- F. Bandello ITALY - J. Cunha-Vaz PORTUGAL - F. Holz GERMANY - A. Tufail UK - S. Harding UK - I. Kulyk SWITZERLAND - G. Norrgren SWEDEN


14.30 – 16.00


Vitreoretinal Surgery IIVenue: Boulevard C (Level 1)

Chairpersons: S. Schmitz-Valckenberg GERMANY T. Wolfensberger SWITZERLAND

14.30 S. Dsouza, N. Kumar, R. Battu, A. Braganza, D. Das, V. Kharbanda, R. Shetty INDIA The efficacy of 0.75% levobupivacaine versus 0.75% ropivacaine with fentanyl for peribulbar anesthesia in vitreoretinal surgery

14.38 S. Batta Arora, S. Batta, N. Goel, G. Bhushan, S. Thirumalai, A. Seth, M. Thakar INDIA Comparative evaluation of brilliant blue staining using whole blood versus conventional brilliant blue staining for internal limiting membrane peeling in macular hole surgery

14.46 L. Scheerlinck, P. Schellekens, D. Steijns, A. Liem, R. van Leeuwen THE NETHERLANDS Unexplained visual acuity after intraocular silicone oil

14.54 N. Gomes, K. Sousa, S. Guimarães, L. Mendonça, R. Gentil, R. Leite, J. Mendes PORTUGAL Internal limiting membrane peeling in macula-off retinal detachment

15.02 A. Ramezani, H. Ahmadieh, A. Rozegar, M. Soheilian, M. Entezari, S. Moradian, H. Nikkhah IRAN Predictors and outcomes of vitrectomy plus silicone oil injection in eyes with complex diabetic retinopathy

15.10 N. Kannan, K. Arumugam, K. Ramasamy INDIA 2cc 100% SF6 as tamponading agent in macular hole surgery

15.18 T. Papathomas, S. Murjaneh UK Dilated pupil after vitrectomy and argon laser treatment

15.26 M. Elmalt EGYPT Fashioned retinotomy for management of recurrent lower retinal detachment with inferior proliferative vitreo-retinopathy

15.34 P. Susvar, C. Rao, A. Maheshwari INDIA Vitreoretinal perspective of scleral fixated intraocular lens – a case series

15.42 H. Yetik, S. Sirop, C. Dogan, M. Gunay TURKEY Post-vitrectomy macular holes-results of re-operation vitrectomy

15.50 K. Ghasemi Falavarjani, M. Modarres, M. Hashemi, M. Parvaresh, M. Naseripour, A. Karimi Moghaddam, A. Hadavand Khani IRAN Intra-silicone oil injection of methotrexate at the end of vitrectomy for retinal detachment associated with advanced proliferative diabetic retinopathy




14.30 – 16.00


Management of Proliferative Diabetic Retinopathy Boulevard H (Level 1)

Course Organisers: A. Laidlaw UK M. Mohamed UK

Cost: €25

14.30 A. Laidlaw UK Welcome and introduction

14.40 L. Downey UK Pathophysiology of PDR

14.50 S. Mann UK Epidemiology, classification and screening for PDR

15.00 M. Mohamed UK PRP, when to start, where to do it, how much to do, when to stop

15.10 S. Mann UK Addressing general medical risk factors

15.20 R. Wong UK Role of anti-VEGF drugs: current and future, anterior hyaloid proliferation and rubeosis

15.30 T. Williamson UK Diabetic vitreous haemorrhage: aetiology and management

15.40 D. Steel UK Retinal traction from PDR: aetiology and management

15.50 Discussion

16.00 End of course

14.30 – 16.00

BIO-ENGINEERING SOCIETY SYMPOSIUM

RETINATECH: Envisioning the Future of Vitreoretinal SurgeryBoulevard E (Level 1)

Chairpersons: Y. Oshima JAPAN T. Rossi ITALY D. Wong HONG KONG

14.30 T. Rossi ITALY Introduction

14.33 D. Wong HONG KONG Finite element analysis and surgery for high myopia

14.41 C.H. Meyer SWITZERLAND Geometry, penetration forces and cutting profile of different 23G trochar systems

14.49 S. Rizzo ITALY New technologies in vitreous cutter

14.57 C. Eckardt GERMANY The TDC-Cutter – high speed cutting in the fast lane

15.05 T. Rossi ITALY Constant flow vitrectomy/ The fluidics of infusion during pars plana vitrectomy

15.13 T. Hassan USA The continuing evolution of portable vitrectomy

15.21 T. Rossi ITALY Real time pressure monitoring during pars plana vitrectomy

15.29 M. Romano ITALY Temperature control: a new surgical tool

15.37 D. Chow CANADA Advances in endoillumination

15.45 K. Kojima, Y. Oshima JAPAN Supra-choroidal approach for retinal surgery: results from basic experiments

15.53 Conclusion




14.30 – 16.00


Key Issues for SD-OCT InterpretationBoulevard G (Level 1)

Course Organisers: A. Gaudric FRANCE G. Staurenghi ITALY A. Tufail UK

Cost: €25

14.30 A. Gianni ITALY, G. Staurenghi ITALY Basics of OCT interpretation, new nomenclature: Choroid in various diseases Retinal angiomatous proliferation

15.00 P. Keane UK, A. Tufail UK Age macular degeneration

15.30 A. Gaudric FRANCE, S. Mrejen USA Vitreo-macular diseases, macular edema

16.00 End of course

14.30 – 16.00


Uveitis – Diagnosis & Therapy in 2014Boulevard I (Level 1)

Course Organisers: M. Funk AUSTRIA H. Kaplan USA

Cost: €25

14.30 H. Kaplan USA New advances in diagnosis

14.48 M. Funk AUSTRIA New advances in imaging

15.06 U. Pleyer GERMANY Update on therapy

15.24 J. de Boer THE NETHERLANDS Update on pediatric uveitis

15.42 Discussion

16.00 End of course



16.00 – 18.00

MAIN SESSION 5

Neovascular AMDAuditorium (Level 0)

Chairpersons: M. la Cour DENMARK S. Wolf SWITZERLAND

16.00 T.L. Sørensen DENMARK Systemic immunological changes in AMD. Are they relevant?

16.18 F. Holz GERMANY Long term results after anti-VEGF therapy in exudative AMD

16.36 K. Berg NORWAY LUCAS-Study

16.54 M. Zinkernagel SWITZERLAND Is zero tolerance necessary?

17.12 G. Staurenghi ITALY Eye drops for the treatment of neovascular age-related macular degeneration

17.30 S. Harding UK Treatment of exudative AMD: Mechanism beyond VEGF

17.48 R. Johnston UK Neovascular age-related macular degeneration (nAMD): visual outcomes of treatment naïve eyes with baseline visual acuity better than 70 ETDRS letters



16.30 – 18.00


Imaging IIVenue: Boulevard C (Level 1)

Chairpersons: A. Gaudric FRANCE G. Soubrane FRANCE

16.30 C. Kucukerdonmez, M. Zengin, S. Yılmaz, E. Cinar TURKEY Choroidal thickness changes during growth- a cross-sectional study in participants aged between 4-23 years

16.38 P. Aristodemou, N. Kumar, S. Murjaneh, M. Brelen, M. Majid, R. Haynes, A. Dick CYPRUS The reliability of OCT in detecting attached posterior vitreous before surgery for macular holes and epiretinal membranes

16.46 D. Mitry, T. Peto, J. Morgan, P. Foster UK Crowdsourcing as a novel technique for retinal fundus photography classification

16.54 L. Berger, C. Dysly, J. Kowal, S. Wolf, M. Zinkernagel SWITZERLAND Fluorescence lifetime characteristics in central serous chorioretinopathy

17.02 S. Pastor-Idoate, M. Gil-Martinez, S. Charles, S. Biswas, D. Henson, D. McLeod, P. Stanga UK Swept-source optical coherence tomography assessment of the cortical vitreous and choroidal thickness in different macular disorders

17.10 O. Fleck, P. Koehrer, S. Vinault, C. Tzourio, A. Bron, C. Binquet, C. Creuzot-Garcher FRANCE Macular thickness in a French population over 75 years old (Montrachet’s study- maculopathy, optic nerve, nutrition, neurovascular and heart diseases)

17.18 C. Mitsch, R. Leitgeb, U. Schmidt-Erfurth AUSTRIA Non-invasive retinal and choroidal microangiography using 1060nm dual-beam doppler optical coherence tomography in patients with choroidal neovascularization, proliferative diabetic retinopathy and branch retinal vein occlusion

17.26 S. Patwary, S. Winder UK Virtual clinics using ultra-widefield retinal photography in patients with posterior vitreous detachment

17.34 U. Kayabasi, R. Sergott TURKEY Retina examination with examination with curcumin for the diagnosis of Alzheimer’s disease

17.42 A. Abdullatif, H. Mortada, M. Abdelhakim, H. El Said EGYPT Structure-function relationship following primary vitrectomy for rhegmatogenous retinal detachment of intermediate severity




16.30 – 18.00

ASRS SYMPOSIUM

Retina in the Future: Where Are We Headed?Boulevard E (Level 1)

Chairpersons: T. Hassan USA P. Kaiser USA

16.30 T. Hassan USA The state-of-the-art in vitreous cutters – now and in the future

16.41 D. Chow CANADA Intraoperative light: the continued evolution

16.52 P. Ferrone USA Surgical visualization: what can we see now and what will we see in the future?

17.03 S. Schwartz USA Stem cell therapy for retinal disease

17.14 S. Rizzo ITALY Artificial vision: what will the future hold?

17.25 P. Kaiser USA The future of AMD therapy

17.36 P. Dugel USA Neuroprotection of the retina: now and in the future

17.47 C. Gonzales USA A novel therapy targeting tissue factor for the treatment of neovascular AMD


16.30 – 18.00


Vascular Diseases and Diabetic Retinopathy IIIVenue: Boulevard D (Level 1)

Chairpersons: B. Leroy FRANCE J. van Meurs THE NETHERLANDS

16.30 A. Loewenstein, E. Moisseiev ISRAEL A collaborative retrospective trial on the efficacy and safety of intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema (ARTES study)

16.38 R. Eltanamly, R. Abdelfattah, M. Nabih, M. Kamal EGYPT Association of VEGF gene polymorphism rs699947 and rs10434 with diabetic retinopathy in Egyptian patients

16.46 Y. Dong, M. Elgohary, M. Syrimi, V. Sivagnanavel UK Intravitreal dexamethasone implant in retinal vein occlusion - clinical outcome using as-required repeat injection regimen

16.54 A. Awadein, M. El-Shazly EGYPT Diabetic neurosensory serous detachment of the fovea- patient characteristics and response to intravitreal ranibizumab

17.02 S. Malhotra, D. Agarwal, S. Chatterjee, A. Sahu, I. Nanda INDIA Visual outcome and central macular thickness after phacoemulsification with intravitreal bevacizumab in patients with diabetic macular edema and cataract

17.10 S. Sizmaz, E. Esen, A. Sariyeva, N. Demircan TURKEY Laser photocoagulation in retinopathy of prematurity and prognostic factors

17.18 S. Nicoara, C. Nascutzy, C. Cristian, I. Irimescu, A. Stefanut, G. Zaharie ROMANIA Avastin monotherapy in severe retinopathy of prematurity - outcomes and prognostic factors

17.26 T. Pilkevich, N. Pasyechnikova, V. Naumenko, V. Vit, E. Ivanitskaya UKRAINE Peculiarities of structural changes of the retina in streptozotocin-induced diabetic rats in different terms (2 weeks and 1 month)

17.34 Y. Cho, M. Kim, H. Koh SOUTH KOREA Changes in visual acuity, central foveal thickness and choroidal thickness in refractory diabetic macular edema after intravitreal dexamethasone implant

17.42 M. Kaya, S. Kaynak, D. Er, T. Ozturk, N. Kocak TURKEY Evaluation on intraretinal hyperreflective foci density with SD-OCT after Ozurdex application in patients with diabetic macular edema

17.50 N. Feltgen GERMANY Impact of baseline perfusion status on visual outcomes in patients with macular edema secondary to central retinal vein occlusion (CRVO) treated with intravitreal aflibercept (IVT-AFL)- data from the COPERNICUS and GALILEO studies




16.30 – 18.00


Update in Ocular Oncology 2014Boulevard H (Level 1)

Course Organiser: A. Joussen GERMANY

Cost: €25

16.30 A. Riechardt GERMANY Are OCT, FAG and autofluorecense sufficient for differential diagnosis of small choroidal lesions?

16.42 H. Heimann GERMANY Cyberknife, binuclid radioactive plaques or proton beam?

16.54 M. Rehak GERMANY Should every lesion be biopsied?

17.06 N. Bechrakis AUSTRIA Surgery after irradiation of large ocular tumours – a necessity or possible alternatives?

17.18 S. Leyvraz SWITZERLAND Help in sight for metastatic choroidal melanoma?

17.30 I. Seibel GERMANY, S. Erzkuraj GERMANY Choroidal metastesis – sight of the clinician and the pathologist

17.42 A. Joussen GERMANY Vascular tumours and vascular abnormalities – treatment challenges

17.54 Discussion

18.00 End of course

16.30 – 18.00


Subthreshold Laser SurgeryBoulevard G (Level 1)

Course Organisers: C. Boon THE NETHERLANDS V. Chong UK J. Keunen THE NETHERLANDS E. Midena ITALY

Cost: €25

16.30 J. Keunen THE NETHERLANDS Recent developments in subthreshold laser surgery

16.45 V. Chong UK Basic principles of micropulse laser and differences to other subthreshold laser techniques

17.00 E. Midena ITALY Subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation in DME

17.15 J. Luttrull USA Safety of transfoveal subthreshold diode micropulse laser for DME in eyes with good visual acuity

17.30 C. Boon THE NETHERLANDS The PLACE trial: subthreshold micropulse laser treatment versus PDT in chronic central serous chorioretinopathy

17.45 Discusssion

18.00 End of course



16.30 – 18.00


Update in OCT Imaging: Indications, Features, ConsequencesBoulevard I (Level 1)

Course Organiser: U. Schmidt-Erfurth AUSTRIA

Cost: €25

16.30 C. Simader AUSTRIA A long list of OCT deficiencies

16.43 U. Schmidt-Erfurth AUSTRIA Novel OCT concepts in early and late AMD

16.56 G. Staurenghi ITALY An updated role of OCT in DME

17.09 A. Lotery UK OCT features in retinal dystrophies

17.22 C. Toth USA Hallmarks of progression from early to intermediate to advanced AMD by OCT

17.35 M. Pircher AUSTRIA Advances in adaptive optics (AO) imaging

17.48 Discussion

18.00 End of course

EURETINA Winter MeetingSaturday 24 January 2015

5th

University of Oxford, UKwww.euretina.org

SATURDAY13 September


43


SATURDAY 13 SEPTEMBER44

08.00 – 10.00

MAIN SESSION 6

Uveal Melanoma: Current Conflicts & ControversiesAuditorium (Level 0)

Chairpersons: D.E. Pelayes ARGENTINA S. Seregard SWEDEN

08.00 M. Jager THE NETHERLANDS What makes uveal melanoma special

08.15 J. García Arumí SPAIN Why primary endoresection is harmless

08.30 N. Bornfeld GERMANY Why primary endoresection is harmful

08.45 L. Zografos SWITZERLAND Tumours are best treated with protons

09.00 S. Seregard SWEDEN Tumours are best treated with plaques

09.15 T. Kivelä FINLAND Screening for metastases is useful

09.30 D. Gombos USA Screening for metastases is useless

09.45 Discussion

10.00 End of Session

08.00 – 09.30

THE CLUB JULES GONIN SYMPOSIUM

Minimal and Maximal Surgery: What is Sufficient, What is Necessary? Boulevard C (Level 1)

Chairpersons: B. Aylward UK F. Bandello ITALY Y. Le Mer FRANCE

08.00 J. van Meurs THE NETHERLANDS RPE-choroid transplantation: an alternative when there is nothing left to do

08.10 C. Claes BELGIUM 27G vitrectomy: gadget or future of surgery?

08.20 P. Szurman GERMANY Corneal keratoprosthesis and vitrectomy in severely traumatised eyes

08.30 T. Wolfensberger SWITZERLAND Some euros to save the cornea

08.40 D. Charteris UK Retinal detachment complicated with severe PVR: when to stop?

08.50 A. Laidlaw UK Do we still need positioning after MH surgery?

09.00 F. Bandello ITALY, R. Tadayoni FRANCE Submacular hemorrhages in AMD: we don't need vitrectomy/we need vitrectomy to save vision

09.20 Discussion



SATURDAY 13 SEPTEMBER 45

08.00 – 09.30

ASIA PACIFIC VITREORETINAL SOCIETY SYMPOSIUM (APVRS)

Maculopathy in the Asian PopulationBoulevard D (Level 1)

Chairpersons: A. Chang AUSTRALIA T. Lai HONG KONG M. Ohji JAPAN

08.00 T. Iida JAPAN Imaging techniques of polypoidal vasculopathy

08.11 X. Li CHINA Two approaches to treat polypoidal vasculopathy

08.22 G. Kokame HAWAII, USA The role of anti-VEGF in treatment of polypoidal vasculopathy

08.33 G. Cheung SINGAPORE Epidemiology of myopia in Asia

08.44 T. Lai HONG KONG Management options in myopic choroidal neovascularisation

08.55 Y. Ikuno JAPAN Pathogenesis of myopic foveoschisis

09.06 M. Ohji JAPAN Surgical treatments for foveoschisis and macular hole retinal detachment

09.17 A. Chang AUSTRALIA Complications and pitfalls in the surgery of myopic maculopathy

09.28 Discussion


08.00 – 10.00


Vitreoretinal Surgery IIIVenue: Boulevard E (Level 1)

Chairpersons: F. Arevalo SAUDI ARABIA S. Binder AUSTRIA

08.00 P. Stavrakas, A. Vakalis, S. Asteriadis, E. Lokovitis, P. Tranos GREECE Persistent subretinal fluid after successful full thickness macular hole surgery - prognostic factors, morphological features and implications on functional recovery

08.08 R. Singh, R. Samanta, M. Dogra, A. Gupta INDIA 23-gauge transconjunctival sutureless vitrectomy versus 20-gauge vitrectomy with scleral buckling in pseudophakic rhegmatogenous retinal detachment

08.16 C. Gupta, C. Shroff, P. Gupta, D. Shroff, N. Atri INDIA Comparison of three different formulations of brilliant blue G dye with indocyanine green dye and trypan blue dye for ILM staining in macular hole surgery

08.24 M. Elgohary, P. Pongsachareonnont, R. Muni, W. Lam, P. Kertes, A. Ali UK Outcome of surgical excision and histopathologcial features of cyclitc membranes in children

08.32 N. Ferreira, C. Vale, T. Coelho PORTUGAL Late onset familial amyloid polyneuropathy (FAP) ocular manifestations in Portuguese patients

08.40 A. Kaintatzis, R. Johnston, N. Kirkpatrick, A. Sallam UK Risk of retinal detachment following complicated and uncomplicated cataract surgery- a review of 30,188 consecutive cataract operations

08.48 M. El-Ashry, H. Rehman, H. Goh, N. Gunn, A. Babar, M. Costen, N. UK Vitrectomy for floaters in the national health service (NHS)- fiction or fact

08.56 T. Rossi, G. Querzoli, C. Malvasi, A. Rossi, G. Angelini ITALY Continuous real-time pressure monitoring during pars plana vitrectomy

09.04 J. Park, B. Ramasamy, S. Shaw, S. Prasad, R. Ling UK A prospective and nationwide study investigating endophthalmitis following pars plana vitrectomy

09.12 S. Saw SINGAPORE Myopia-related fundus changes in Singaporean adults with high myopia

09.20 S. Sheta EGYPT Vitrectomy for the management of diabetic vitreo macular traction with impending macular hole

09.28 I. Dooley, H. Laviers, H. Zambarakji UK Is cystoid macular edema more frequent in vitrectomised internal limiting membrane-peeled eyes undergoing phacoemulsification?



08.00 – 09.30

YOUNG EUROPEAN RETINA SPECIALISTS SYMPOSIUM (YOURETINA)

Frontiers in Retinal Therapy: Revelations and Revolutions Boulevard H (Level 1)

Chairpersons: C. Boon THE NETHERLANDS M. Fleckenstein GERMANY G. Querques FRANCE

08.00 D. Fischer UK Gene therapy – coming to your clinic soon?

08.15 R. Gallego-Pinazo SPAIN Age-related macular degeneration – time for personalized medicine?

08.30 S. Mrejen USA Impact of different AMD phenotypes on cone density

08.45 M. Rehak GERMANY Do we really need modern retinal imaging in patients with retinal vein occlusion?

09.00 J. Dolar-Szczasny POLAND Ultra-widefield imaging – clinical revolution?

09.15 M. Romano ITALY Surgical treatment of non-tractional diabetic macular edema: does it make sense?


09.36 T. Sinha, S. Boral INDIA Sub silicon oil triamcinolone(TA) drop - a new simple approach to prevent post operative proliferative vitreoretinopathy (PVR)

09.44 A. Papayannis, D. Bonsanto, P. Iacono, M. Battaglia Parodi, F. Foltran, G. Prosdocimo, F. Bandello ITALY Multimodal imaging of sticky oil phenomenon in eyes with rhegmatogenous retinal detachment treated with vitrectomy and gas or silicone oil tamponade




08.00 – 09.30


The Intraocular Mirror Telescope: An Additive Treatment for AMD EyesA Practical Course on Patient Selection, Surgical Technique & Clinical Results

Boulevard G (Level 1)

Course Organisers: I. Lipshitz ISRAEL A. Loewenstein ISRAEL

Cost: €25

08.00 I. Lipshitz ISRAEL Introduction; advantages of implanted telescopes

08.10 A. Loewenstein ISRAEL Review of available intraocular telescopes for AMD

08.20 I. Lipshitz ISRAEL Concept and design: description, specification, performance

08.30 A. Loewenstein ISRAEL Patient selection, education and examination

08.40 I. Lipshitz ISRAEL OptoLight Vision Testing program (OVT)

08.50 A. Agarwal INDIA Clinical and surgical experience

09.00 A. Loewenstein ISRAEL Clinical experience

09.10 I. Lipshitz ISRAEL Future of mirror implanted products

09.20 Discussion

09.30 End of course

08.00 – 09.30


Submacular Haemorrhages in AMD: A Practical Course on Optimum ManagementBoulevard I (Level 1)

Course Organiser: D. Steel UK

Cost: €25

08.00 D. Steel UK Introduction

08.12 Speaker TBC Epidemiology, mechanisms of visual loss, risk factors and classfn

08.24 Z. Koshy UK Clinical assessment: How to decide what to do – observation, anti VEGFs alone or surgery?

08.36 J. van Meurs THE NETHERLANDS Pneumatic displacement – how to do it

08.48 J. Hillenkamp GERMANY Vitrectomy and subretinal TPA/anti VEGF – how to do it

09.00 D. Yorston UK Results, complications and limitations – how do the two techniques compare?

09.12 D. Steel UK Too big to displace? What else can be tried

09.24 Discussion

09.30 End of course



11.00 – 13.00

EURETINA Science & Medicine Innovation Award 2014Auditorium (Level 0)

Chairpersons: E. Stefánsson ICELAND S. Wolf SWITZERLAND

The EURETINA Science & Medicine Innovation Award is an initiative founded in 2011 with the purpose of supporting and encouraging innovation in the field of retinal science and medicine. All applications received have been reviewed by a panel of experts, from which six applicants are shortlisted to present their work at the 2014 Innovation Award Session. First and second place trophies are awarded at the end of the session.

11.00 – 12.30

EVER

Functional and Morphological Imaging of the Ocular FundusBoulevard C (Level 1)

Chairpersons: G. Holder UK C. Pournaras SWITZERLAND

11.00 L. Zografos SWITZERLAND Wide view 150° ICG and FA in ocular oncology

11.11 V. Vaclavik SWITZERLAND Wide view auto-fluorescence in retinal dystrophies

11.22 C. Pournaras SWITZERLAND OCT imaging of the vitreoretinal interface

11.33 L. El Matri TUNISIA Evaluation of choroidal thickness in macular pathologies

11.44 L. Schmetterer AUSTRIA Functional OCT

11.55 G. Holder UK Electrophysiological evaluation in the investigation of inherited retinal disease

12.06 E. Stefánsson ICELAND Retinal oximetry on the evaluation of retinal metabolism

12.17 Discussion




11.00 – 12.30

FAN CLUB

Retinal Imaging Cases for Discussion with a PanelBoulevard D (Level 1)

Chairpersons: V. Chong UK A. Leys BELGIUM M. van Schooneveld THE NETHERLANDS

Each case presentation lasts for ten minutes with five minutes for discussion. This symposium is open to all to attend.

11.00 – 13.00


MiscellaneousVenue: Boulevard E (Level 1)

Chairpersons: G. Richard GERMANY T. Rossi ITALY

11.00 N. Vilà, P. Zoroquiain, V. Bravo-Filho, P. Logan, M. Burnier CANADA Primary intraocular and central nervous system lymphomas- are they the same?

11.08 A. Filloy Rius, S. Jordan, J. Caminal SPAIN Swept-source optical coherence tomography imaging of choroidal tumors

11.16 P. Kaiser, Y. Ito, S. Srivistava, J. Ehlers USA Clinical experience with ocriplasmin for the treatment of vitreomacular traction and macular hole - a single-centre case series

11.24 P. Lanzetta ITALY The time-course and resolution of key adverse events in the ocriplasmin clinical trial programme

11.32 L. Arias, M. López-Gálvez, M. Roura, M. Balaña SPAIN A phase II clinical trial to compare the efficacy and safety of ranibizumab versus laser photocoagulation in patients with visual impairment due to diabetic macular edema- the RE-DES study

11.40 E. Krüger, F. Holz, T. Heeren, T. Clemons, H. Scholl, A. Bird, P. Charbel Issa GERMANY Progression of functional loss in macular telangiectasia type 2

11.48 P. Jain, M. Thakar, U. Kaul Raina, B. Ghosh, G. Bhushan INDIA Comparative evaluation of conventional (pars plana vitrectomy) versus intravitreal bevacizumab assisted treatment for non-resolving vitreous hemorrhage (NRVH) in Eales’ disease

11.56 S. Das, R. Roy, S. Pal INDIA Microbiological trends and drug sensitivity patterns in endophthalmitis in Eastern India

12.04 M. Hosny, N. Khalil, R. Abdel Salam EGYPT Changes in retinal nerve fiber layer thickness following mechanical microkeratome-assisted versus femtosecond-assisted LASIK

12.12 S. Parikh, R. Jain, S. Malli INDIA Comparison of conventional scleral fixation versus modified trans scleral fixation of intra ocular lens during combined vitreoretinal surgery

12.20 M. Barman, H. Bhattacharjee, S. Deka, D. Das INDIA Intraocular helminthic infestation-presentation and management

12.28 S. Binder, C. Falkner-Radler, F. Zeiler, C. Ginzel, C. Glittenberg AUSTRIA Intraoperative continuous OCT- the rescan 700



11.00 – 12.30


Managing Diabetic Macular Edema: Pearls and PitfallsBoulevard H (Level 1)

Course Organisers: A. Joussen GERMANY E. Midena ITALY

Cost: €25

11.00 A. Joussen GERMANY Diabetic macular edema (DME): a multifactorial entity

11.15 T. Peto UK Detecting DME: the screening approach

11.30 S. Vujosevic ITALY DME multimodal imaging: diagnostic and prognostic implications

11.45 E. Midena ITALY DME treatment: a tailored approach

12.00 M. Bolz AUSTRIA Vitreoretinal surgery in DME: early approach vs last chance

12.15 Discussion

12.30 End of course

12.36 T. Painhas, M. Ruão, R. Soares, C. Manso, A. Gomes da Rocha, J. Chibante-Pedro PORTUGAL Pneumatic retinopexy in the treatment of rhegmatogenous retinal detachment- our experience

12.44 G. Pardianto INDONESIA Impact of intraocular pressure fluctuation in cataract surgery to specific area and volume of the macula

12.52 Q. Nguyen, L. Wilson, J. Naor, W. Liu, M. Valentine, N. Shams USA Baseline characteristics of SAKURA- a phase III, multicenter, randomized, double-masked study of intravitreal injections of DE-109 for the treatment of active, non-infectious uveitis of the posterior segment




11.00 – 12.30


Steroids in Retinal TherapyBoulevard I (Level 1)

Course Organiser: A. Augustin GERMANY

Cost: €25

11.00 B. Kuppermann USA Steroids for the treatment of retinal diseases: basic research and devices

11.15 F. Boscia ITALY Steroids for the treatment of DME

11.30 A. Loewenstein ISRAEL Steroids for the treatment of uveitis and other vascular diseases

11.45 S. Rizzo ITALY Steroid as an important adjunct before, during and after vitreoretinal surgery

12.00 A. Augustin GERMANY Combination of steroids with drugs and/or laser for the treatment of macular edema

12.15 Discussion

12.30 End of course

11.00 – 12.30


Vitreoretinal InterfaceBoulevard G (Level 1)

Course Organiser: D.E. Pelayes ARGENTINA

Cost: €25

11.00 D.E. Pelayes ARGENTINA New OCT technology in VRIF. Retinal digital biopsy

11.09 A. Nikolakopoulos GREECE Current pucker and traction macular surgery in VR interface. New techniques using wide angle observation systems

11.18 A. Gaudric FRANCE Early vitreo-macular traction: Do we know the natural history?

11.27 T. Wolfensberger SWITZERLAND Pharmacological and surgical combination in vitreoretinal interface

11.36 R. Cano MEXICO Predictors of visual outcome in vitreo macular surgery

11.45 F. Graue MEXICO The importance of internal limiting membrane and external limiting membrane

11.54 M. Nehemy BRAZIL Surgical techniques for special cases of macular disease

12.03 B. Corcóstegui SPAIN Myopic hole interface

12.12 Y. Le Mer FRANCE Small macular holes: do we still need surgery?

12.21 D.E. Pelayes ARGENTINA Discussion

12.30 End of course



14.00 – 16.00

ESCRS/EURETINA JOINT SYMPOSIUM

Vitreoretinal Complications of Anterior Segment SurgeryAuditorium (Level 0)

Chairpersons: F. Bandello ITALY R. Bellucci ITALY

14.00 O. Findl AUSTRIA The broken capsule and the vitreous

14.15 M. la Cour DENMARK Pseudophakia and retinal detachment

14.30 Discussion

14.40 R. Nuijts THE NETHERLANDS Cystoid macular edema

14.55 G. Richard GERMANY Choroidal detachment after anterior segment surgery

15.10 Discussion

15.20 S. Wolf SWITZERLAND How to handle a dropped nucleus

15.35 U. Schmidt-Erfurth AUSTRIA The retina after anti-VEGF injections at the time of cataract surgery

15.50 Discussion


14.30 – 16.30


New Drug Treatment Venue: Boulevard F (Level 1)

Chairpersons: B. Kuppermann USA Y. Le Mer FRANCE

14.30 J-F. Korobelnik FRANCE The MYRROR study - detailed evaluation of visual outcomes following intravitreal aflibercept injection in patients with choroidal neovascularisation secondary to pathological myopia

14.38 L. Ceklic, U. Wolf-Schnurrbusch, S. Wolf SWITZERLAND Visual acuity outcomes of ranibizumab vs verteporfirin photodynamic therapy (vPDT) treatment response in highly myopic eyes with dome shaped macular feature and choroidal neovascularisation

14.46 T. Wong SINGAPORE Prognostic factors associated with visual outcomes in patients receiving intravitreal aflibercept for choroidal neovascularisation secondary to pathological myopia- post hoc analyses from the MYRROR study

14.54 G. Cosendai, L. da Cruz, J. Sahel, P. Stanga, F. Hafezi, R. Greenberg, AII Study Group Switzerland Latest results from the Argus II retinal prosthesis system clinical trial

15.02 M. Arsiero, S. Rizzo, P. Walter, B. Kirchhof, A. Augustin, S. Grisanti, G. Richard SWITZERLAND European post-market surveillance study results for the Argus II retinal prosthesis system

15.10 C. Quijano, M. Gil-Martinez, S. Pastor-Idoate, S. Biswas, P. Stanga UK Anatomical and functional outcomes in x-linked retinoschisis treated with topical carbonic anhydrase inhibitor – dorzolamide

15.18 S. Hassan, M. Aboul Naga, M. Dithmer, M.M. Soliman, T.A. Macky, J. Roider, A. Klettner EGYPT Time-dependent intracellular pattern of bevacizumab uptake in RPE cells

15.26 A. Miranda, N. Marques, J. Cardoso, A. Cardoso, S. Barros, P. Telles, N. Campos PORTUGAL Evaluation of macular pigment optical density in patients treated with hydroxychloroquine

15.34 A. Machalińska, B. Machaliński, A. Józkowicz, J. Dulak POLAND Long-term neuroprotective effects of NT-4-engineered mesenchymal stem cells injected intravitreally in a mouse model of acute retinal injury

15.42 A. Aramburu del Boz, F. Díaz Corrales, B. de la Cerda Haynes, L. Valdés Sánchez, D. Rodriguez Martínez, S. Bhattacharya SPAIN Spatial vision and c-wave are affected in mouse models of human autosomal dominant retinitis pigmentosa caused by PRPF31 mutations



15.50 M. Gil, S. Pastor-Idoate, Y. D’Souza, S. Mahmood, C. Stephen, D. Henson, P. Stanga SPAIN Safe and effective barely visible and subthreshold endpoint treatment parameters for 577NM (yellow) Pascal® laser with and without endpoint management® in proliferative diabetic retinopathy and diabetic macular edema

15.58 T. Park, S. Lee, H. Kim, R. Brinkmann SOUTH KOREA Cellular response to selective retina therapy by microsecond-pulsed laser equipped with automated real-time reflectometry

16.06 A. Rajendran, T.P. Vignesh, K. Ramasamy INDIA A comparative analysis of the efficacy of subthreshold micropulse 577-nm yellow laser versus 577 nm green laser for central serous chorioretinopathy

16.14 A. Grzybowski, J. Pieczynski POLAND The role of antibiotics in the prevention of post-intravitreal anti-VEGF endophthalmitis - primum non nocere!


14.30 – 16.00


Imaging IIIVenue: Boulevard C (Level 1)

Chairpersons: S. Sadda INDIA S. Seregard SWEDEN

14.30 R. Hua, L. Chen CHINA The progression rate of retinal pigment epithelium atrophy in punctate inner choroidopathy

14.38 P. Theodossiadis, G. Theodossiadis, V. Grigoropoulos, S. Theodoropoulou, I. Datseris GREECE Spontaneous resolution of vitreomacular traction demonstrated by spectral-domain optical coherence tomography

14.46 A. Sharma, J. Sheth, RJ. Madhusudan, N. Vidhya, SK. Sundonamorthy, J. Patil INDIA Relationship of choroid and retinal thickness in high myopes using enhanced depth imaging optical coherence tomography

14.54 K. Gocho, S. Kameya, S. Kikuchi, K. Shinoda, A. Mizota, K. Yamaki, H. Takahashi JAPAN High-resolution adaptive optics images of microcystic macular edema in patients with autosomal dominant optic atrophy

15.02 S. Schmitz-Valckenberg, S. Liakopoulos, G. Spital, F. Ziemssen, A. Wiedon, F. Holz GERMANY ORCA – comparison of SD-OCT image analysis in real life compared to standardized reading center analysis

15.10 G. Yilmaz, N. Yesilirmak, S. Gur Gungor, E. Yaman Pinarci, I. Akkoyun TURKEY Enhanced depth imaging optical coherence tomography in patients with different phases of Behcet’s panuveitis

15.18 M. Gil, S. Pastor-Idoate, A. Jalil, J. Garcia-Vallejo, T. Ivannova, S. Charles, P. Stanga SPAIN Wide-field fundus autofluorescence and swept-source-optical coherence tomography imaging findings as predictor of visual outcome after successful retinal detachment surgery

15.26 I. Pires PORTUGAL Identifying progression of retinal disease in eyes with mild NPDR in diabetes type 2 using non-invasive procedures

15.34 A. Mohi, M. Ranjbar, H. Frenzel, S. Grisanti, M. Rudolf GERMANY First description of a melanoma-associated paraneoplastic syndrome with retinopathy and cochleopathy

15.42 V. Capuano, G. Querques, E. Cavallero, P. Frascio, E. Souied FRANCE Analysis of choroidal maps in non-exudative age-related macular degeneration using swept source optical coherence tomography

15.50 H. Almuhtaseb, J. Badal, M. Biarnés, J. Monés SPAIN Performance characteristics of multicolour versus blue light and infrared imaging in the identification of reticular pseudodrusen




14.30 – 16.00


Eye & Brain: Retinal Nerve Fiber Layer (RNFL) Analysis in the Evaluation of Neurodegenerative Disorders Boulevard E (Level 1)

Course Organisers: P. Barboni ITALY A. Grzybowski POLAND

Cost: €25

14.30 A. Grzybowski POLAND Eye and brain – introduction

14.43 P. Barboni ITALY RGCs in neurodegenerative diseases

14.56 F. Cordeiro UK Retinal imaging animal models of neurodegenerative diseases

15.09 P. Yu Wai Man UK OCT and inherited optic neuropathies

15.22 J. Ascaso SPAIN OCT in schizophrenia

15.35 I. Bodis-Wallner USA OCT in Parkinson disease

15.48 Discussion

16.00 End of course

14.30 – 16.00

RETINAWS SYMPOSIUM

Misadventures in the Operating RoomBoulevard D (Level 1)

Chairperson: K. Rezaei USA

Panel: C. Claes BELGIUM J. García Arumí SPAIN H. Heimann GERMAY K. Kadonosono JAPAN G. Pertille ITALY S. Rizzo ITALY R. Tadayoni FRANCE J. van Meurs THE NETHERLANDS

Programme Topics:

• Intra-operative OCT

• Vascular occlusion during vitrectomy

• Melanoma and retinal detachment

• Coloboma

• Trauma related retinal detachment

• 27G vitrectomy

• Tough PVD

• Macular hole and retinal detachment in high myopia

• Severe trauma

• Capillary hemangioma in Von Hippel Lindau disease

• Anterior melanoma

• Massive choroidal hemorrhage

• ERM Peeling



14.30 – 16.00


Chromovitrectomy: Novel Vital Dyes & Illumination Systems for Vitreoretinal SurgeryBoulevard H ( Level 1)

Chairpersons: C.H. Meyer SWITZERLAND E.B. Rodrigues BRAZIL

14.30 B.V. Stanzel GERMANY From cell culture to surgery: impact of experimental studies for the development on novel dyes

14.45 P.B. Henrich SWITZERLAND Illumination and contrast: impact of light the light source on the contrast of vital dyes

15.00 R. Tadayoni FRANCE Benefit of chromovitrectomy visualization in tractional maculopathies

15.15 S. Rizzo ITALY Ala Purple: a novel dye in chromovitrectomy

15.30 E.B. Rodrigues BRAZIL Future perspective in chromovitrectomy

15.45 Discussion

16.00 End of course

14.30 – 16.00


Differential Diagnosis of Intraocular Tumours and Pseudo-tumoursBoulevard G (Level 1)

Course Organiser: L. Zografos SWITZERLAND

Cost: €25

14.30 N. Bechrakis AUSTRIA Differential diagnosis of small pigmented choroidal tumours

14.43 L. Desjardins FRANCE Differential diagnosis of un-pigmented choroidal tumours

14.56 T. Kivelä FINLAND Differential diagnosis of choroidal tumours in opaque media

15.09 F. Munier SWITZERLAND Differential diagnosis of intraocular tumours in pediatric population

15.22 L. Zografos SWITZERLAND Differential diagnosis of peripheral chorioretinal tumours and pseudo-tumours

15.35 E. Midena ITALY Differential diagnosis of tumours and pseudo-tumours of the optic disk

15.48 Discussion

16.00 End of course



16.00 – 18.00

MAIN SESSION 7

IMAGINGBoulevard C (Level 1)

Chairpersons: F. Holz GERMANY R. Tadayoni FRANCE

16.00 F. Delori USA Quantitative autofluorescence imaging

16.15 R. Tadayoni FRANCE Imaging for recent onset neovascular AMD

16.30 P. Stalmans BELGIUM Imaging and disease classification of the vitreomacular interface

16.45 F. Holz GERMANY Imaging intrinsic signals in dry AMD

17.00 W. Drexler AUSTRIA Choroidal OCT imaging

17.15 G. Staurenghi ITALY When should I use widefield imaging?

17.30 S. Wolf SWITZERLAND Fluorescence lifetime imaging

17.45 Discussion


14.30 – 16.00


Pathology Could be the Key in Complicated Intraocular Inflammatory DiagnosisBoulevard I (Level 1)

Course Organiser: J.C. Pastor SPAIN

Cost: €25

14.30 J.C. Pastor SPAIN Indications and techniques for intraocular biopsies

14.48 J.C. López SPAIN Samples management. Samples processing. Molecular biology techniques.

15.06 A. Sala, E. Carreño, S. Pastor-Idoate SPAIN Case presentations and discussion

15.24 J.C. Pastor SPAIN Final remarks

15.42 Discussion

16.00 End of course



16.30 – 18.00

EUROLAM SYMPOSIUM

Clinical & Surgical Cases of Unusual Presentation & Complex ResolutionBoulevard D (Level 1)

Synopsis: Using intraoperative videotapes and case presentations, a panel of internationally recognized experts will demonstrate their approach to various types of vitreoretinal diseases. Clinical evolution and diagnosis options will also be analyzed along with a review of the different management options employed by the panelists.

Chairpersons: D.E. Pelayes ARGENTINA G. Richard GERMANY

16.30 M. Battaglia Parodi ITALY Autofluorescence changes after intravitreal ranibizumab for myopic choroidal neovascularization

16.39 R. Cano MEXICO EPR transplantation in AMD

16.48 B. Corcóstegui SPAIN Combined surgery vitrectomy and cataract with femtolaser

16.57 C. Abdala COLOMBIA Central retinal artery occlusion after embolisation of facial arterious malformation, case report

17.06 U. Schmidt-Erfurth AUSTRIA Efficacy of aflibercept in neovascular AMD

17.15 F. Graue MEXICO SD OCT prognosis factor in macular pucker and macular hole

17.24 M. Nehemy BRAZIL Fungal endophthalmitis

17.33 G. Gabela ECUADOR AMD: when to change the anti VEGF and what to expect with the switch

17.42 S. Binder AUSTRIA Surgery for central artery occlusion (2 cases)

17.51 Discussion


16.30 – 18.00


Vascular Diseases and Diabetic Retinopathy IVVenue: Boulevard F (Level 1)

Chairperson: A. Deutman THE NETHERLANDS

16.30 A. Maa, E. Pillow, W. Feuer, Q. Davis, R. Caywood, T. Brown, S. Fransen USA Comparing technical failure rates in diabetic retinopathy screening between RETeval, a 30 Hz flicker electroretinogram device, and mydriatic, 7-field, stereo fundus photography

16.38 R. Leite, N. Gomes, L. Mendonça, K. Sousa, R. Gentil, G. Santos, F. Vaz PORTUGAL The effect of intravitreal injection of bevacizumab on subfoveal choroidal thickness in patients with diabetic macular edema

16.46 D. Chakraborty, T. Sinha, A. Das, S. Boral, B. Dutta-Choudhury INDIA Spectraldomain OCT evaluation of vitreomacular interface in retinal vein occlusions

16.54 U. Schraermeyer GERMANY Pathological fenestration is not the morphological base for leakage in choroidal neovascular vessels

17.02 P. Schlottmann, L. Tuomi, K. Basu, J. Ehrlich ARGENTINA 0.5 mg ranibizumab PRN for diabetic macular edema- long-term open-label extension of the phase III RIDE and RISE trials

17.10 A. Ahmed, R. Staff, A. Fleming, J. Olson, G. Prescott, P. Sharp, S. Philip UK The automated detection of longitudinal change in diabetic retinal screening images

17.18 N. Saxena, V. Garg, A. Supriya, A. Seth, M. Thakkar INDIA Low fluence indocyanine green mediated photothrombosis(IMP) in the treatment of chronic central serous chorioretinopathy(CCSC)

17.26 E. Cetin, S. Acer, N. Cesur, R. Yağcı TURKEY Ocular pulse amplitude in retinal vein occlusion

17.34 P. Monaco, L. Tollot, M. Del Borrello, A. Frattolillo, F. Sperti, M. Cigada ITALY Intravitreal ranibizumab versus subthreshold micropulse diode laser in clinically significant diabetic macular edema

17.42 A. Oros, B. Dedovic, Z. Grgic, M. Kostic SERBIA Do we need to give the anti-VEGF inhibitor in AP-ROP?

17.50 O. Dorokhova, E. Maltsev, O. Zborovska UKRAINE Comparative changes of the retinal pigment epithelium in different models of diabetes mellitus




16.30 – 18.00


Understanding Fundamentals of Cutting-Edge Retinal Treatment ModalitiesBoulevard H (Level 1)

Course Organiser: A. Pollreisz AUSTRIA

Cost: €25

16.30 K. Balaggan UK Anti-angiogenic gene therapies for the treatment of AMD – from mouse to man

16.48 A. Pollreisz AUSTRIA Antibody-based treatment options in AMD – from bench to bedside

17.06 M. Singh UK Stem cell treatments for restoring sight to the blind retina – understanding fundamentals and clinical application

17.24 L. da Cruz UK Artificial retina – development, advances and challenges

17.42 Discussion

18.00 End of course

16.30 – 18.00


Macular EdemaBoulevard E (Level 1)

Course Organiser: P. Tranos GREECE

Cost: €25

16.30 R. Hamilton UK Pathophysiology of macular edema

16.40 P. Hykin UK Diabetic macular edema

16.50 A. Tufail UK Retinal vein occlusion

17.00 P. Tranos GREECE Macular edema and ocular inflammatory diseases

17.10 S. Asteriades GREECE Postoperative macular edema

17.20 M. Sagoo UK Ocular oncology and macular edema

17.30 T. Moore UK Macular edema and inherited dystrophies

17.40 J. van Meurs THE NETHERLANDS Macular edema and tractional disorders

17.50 Discussion

18.00 End of course



16.30 – 18.00


Surgical Approach to the Vitreoretinal InterfaceBoulevard G (Level 1)

Course Organiser: P. Brazitikos GREECE

Cost: €25

16.30 P. Brazitikos GREECE Vitreomacular traction: Lamellar macular holes

16.42 F. Devin FRANCE Myopic foveoschisis

16.54 A. Gaudric FRANCE Macular hole surgery: new trends

17.06 S. Rizzo ITALY Macular pucker

17.18 A. Augustin GERMANY Diabetic macular edema

17.30 S. Androudi GREECE Functional and anatomic outcomes of ILM peeling

17.42 Discussion

18.00 End of course

16.30 – 18.00


Vitreoretinal Complications of Cataract SurgeryBoulevard I (Level 1)

Course Organiser: B. Little UK

Cost: €25

16.30 B. Little UK Vitreous loss: prevention

16.45 A. Laidlaw UK Dropped nucleus & fragments and dropped IOLs

17.00 L. Benjamin UK Anterior segment causes of RD and vitreous wick

17.15 B. Little UK Suprachoroidal haemorrhage

17.30 A. Laidlaw UK Pseudophakic RD

17.45 L. Benjamin UK Anterior vitrectomy/triamcinolone

18.00 End of course

Saving sight, transforming lives orbis.org.uk

WITHOUT SURGERY

SUNDAY14 September


61


SUNDAY 14 SEPTEMBER62

08.00 – 10.00

MAIN SESSION 8

PVR and Innovation in Retinal Detachment SurgeryBoulevard C (Level 1)

Chairpersons: A. Laidlaw UK J. van Meurs THE NETHERLANDS

08.00 D. Charteris UK PVR prophylaxis - Existing and future therapy

08.14 J.C. Pastor SPAIN Genetics of retinal detachment, bench to bedside, causative genes, associated genes, PVR genes inform future therapies

08.28 R. Hoerster GERMANY PVR: from flare to fibrosis

08.42 B. Aylward UK How do tamponade agents work, partial, heavy or light?

08.56 V. Martinez-Castillo SPAIN, W. Heriot AUSTRALIA No tamponade surgery and thermofusion

09.16 S. Tan THE NETHERLANDS OCT Changes after RD surgery' IS/OS, microfolds, macrofolds

09.30 E. Lee UK AF changes after RD surgery, posture and tamponade

09.44 M. Veckeneer THE NETHERLANDS Sub macular blebs: aetiology, natural history, treatment



08.00 – 10.00


Vascular Diseases and Diabetic Retinopathy VVenue: Boulevard D (Level 1)

Chairpersons: A. Joussen GERMANY S. Natarajan INDIA

08.00 J. Ruiz-Moreno, J. Araiz, L. Arias, J. Montero, A. García-Layana, M. Figueroa, R. Silva SPAIN Intravitreal anti-VEGF therapy for choroidal neovascularization secondary to pathologic myopia- 6 year outcome

08.08 C. Bailey, V. Bezlyak, A. Cole, C. Thorburn, P. Margaron, R. Hashmonay, P. Watson UK Ranibizumab in diabetic macular edema- review of cardiovascular and cerebrovascular safety events from cumulative controlled clinical trial experience

08.16 F. Ziemssen, S. Liakopoulos, S. Schmitz-Valckenberg, G. Spital, A. Wiedon, F. Holz GERMANY OCEAN study – German non-interventional trial to observe anti-VEGF treatment patterns with ranibizumab in all approved indications under real-life conditions

08.24 M. Larsen, F. Boscia, H. Gerding, J. Mones, I. Pearce, S. Priglinger, R. Tadayoni, M. Gekkieva, A. Lotery, G. Lambuou DENMARK Individually dosed ranibizumab, alone or combined with laser, versus laser alone in branch retinal vein occlusion patients with visual impairment due to macular edema- 6 month results of the BRIGHTER study

08.32 P. Hykin, H. Gerding, F. Boscia, R. Tadayoni, S. Priglinger, I. Pearce, J. Mones, W. Stubbings, M. Gekkieva, A. Cole UK Efficacy and safety of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to central retinal vein occlusion- design and baseline characteristics of the CRYSTAL study

08.40 K. Lorenz GERMANY Intravitreal aflibercept (IVT-AFL) improved vision-related function in patients with macular edema secondary to central retinal vein occlusion (CRVO)- 24-week and 52-week results from the COPERNICUS and GALILEO studies

08.48 S. Taylor, R. Tadayoni, I. Pearce, J. Warburton, P. Margaron, J. Wright, G. Lambrou UK Visual acuity outcomes in patients with retinal vein occlusion treated with ranibizumab according to baseline ischaemic status- an analysis of BRIGHTER and CRUISE

08.56 C. Boon, E. de Jong, M. Breukink, R. Schellevis, J. Keunen, C. Hoyng, A. den Hollander THE NETHERLANDS Chronic central serous chorioretinopathy- genetic associations and genotype-phenotype correlations


SUNDAY 14 SEPTEMBER 63

09.04 S. Sadda, R. Danis, X. Li, H. Cui, Y. Hashad, S. Whitcup USA Morphological effects of long-term treatment with dexamethasone intravitreal implant in diabetic macular edema- a pooled analysis of findings from 2 randomised multicentre phase 3 trials

09.12 P. Cardoso, I. Laíns, I. Sobral, C. Farinha, S. Leal, M. Cachulo, R. Silva PORTUGAL Intravitreal ranibizumab for myopic choroidal neovascularization – 5 year results and main predictors

09.20 D. Sun CHINA A novel molecular imaging for early diagnosis of diabetic retinopathy

09.28 A. Sallam, I. Stratton, R. Johnston, U. Dexamethasone, Implant for Retinal Vein Occlusion Study Group UK UK national database of intravitreal dexamethasone implant (Ozurdex®) for retinal vein occlusion related macular edema. A descriptive study of patients’ pre-treatment characteristics and treatment procedure

09.36 H. Cilliers, U. Thakur UK Intra-vitreal dexamethasone / ozurdex implant in retinal vein occlusions, review of efficacy and safety in clinical practice 1 and 2 year results

09.44 A. Shafi, S. MacKenzie UK Real world experience with dexamethasone 700 mcg intravitreal implant (ozurdex) for the treatment of retinal vein occlusions


08.00 – 10.00

FREE PAPER SESSION

Quick Fire Free Paper Session 4Venue: Boulevard B (Level 1)

Chairpersons: C.H. Meyer SWITZERLAND D.E. Pelayes ARGENTINA

08.00 G. Buitendijk, J. Vingerling, A. Hofman, A. Uitterlinden, T. Berendschot, C. Klaver THE NETHERLANDS A new gene associated with macular pigment optical density

08.05 G. Lambrou, G. Liew, P. Keane, D. Sim, C. Egan, J. Warburton, A. Tufail FRANCE Visual benefit vs visual gain - the effect of baseline presenting visual acuity on improvement in vision over 2 years. A pooled analysis of ANCHOR and MARINA

08.10 C. Riemann, M. Wilkes, R. Sisk, D. Miller, R. Foster, R. Hutchins, B. Genereux USA Endophthalmitis is more common after intravitreal injection of ranibizumab and aflibercept than bevacizumab

08.15 C. Meyer, C. Chan, Z. Liu, T. Krohne SWITZERLAND Pharmacokinetic profile of intraocular aflibercept in patients receiving intravitreal aflibercept therapy for neovascular age-related macular degeneration

08.20 R. Hamilton, S. Taylor, B. Burton, R. Johnston, P. Patel, J. Warburton, C. Brand UK Clinical outcomes in the UK for 866 patients with wet age-related macular degeneration (AMD) treated with ranibizumab for 1 year using an individualised patient treatment approach- LUMINOUS UK interim 1 year results

08.25 G. Menon, S. Mahmood, N. Patel, S. Kelly, R. Gale, J. Warburton, C. Brand UK Real world safety outcomes for 866 patients with wet age-related macular degeneration (AMD) treated with ranibizumab for 1 year in the UK national health service- LUMINOUS UK interim 1 year results

08.30 M. Idrees SAUDI ARABIA Laser lysis of weiss ring

08.35 S. Mahmood, B. Arya, M. Westcott, C. Pavesio UK An investigation of the disc hyperfluorescence in Fuchs’ heterochromic uveitis using optical coherence topography imaging

08.40 M. Abrishami, M. Abrishami, S. Ghasemi-Moghaddam IRAN Visual function in diabetes mellitus type 2

08.45 L. Tulasiram, P. Puttaiah, J. Prasanna INDIA Effect of intravitreal ranibizumab in cases of circumscribed choroidal haemangioma - our experience

08.50 M. Abrishami, Y. Panahi, M. Naderi, K. Jadidi IRAN In vivo evaluation of efficacy of systemic administration of oral slow release diclofenac sodium on intravitreal concentration



08.00 – 10.00


Management of Retinal Vascular OcclusionBoulevard H (Level 1)

Course Organisers: N. Feltgen GERMANY G. Lang GERMANY

Cost: €25

08.00 G. Lang GERMANY Diagnosis and classification of retinal vein occlusions (RVO)

08.20 N. Feltgen GERMANY Update on anti-VEGF and steroid treatment in RVO

08.40 G. Lang GERMANY What is the role of laser treatment in RVO?

09.00 H. Heimann GERMANY Is there still a role for surgical treatment in RVO?

09.20 N. Feltgen GERMANY Diagnosis and treatment of retinal artery occlusions (RAO)

09.40 Discussion

10.00 End of course

08.55 M. Mesquida, V. Llorens, J. Fontenla, A. Adán SPAIN Use of ultra-wide-field retinal imaging in the management of active Behçet’s retinal vasculitis

09.00 M. Abouhussein EGYPT Optical coherence tomography evaluation of retinal and optic nerve head neovascularisation in proliferative diabetic retinopathy

09.05 Y. Alahmadawy, M. Nabih, A. Khattab, R. Eltanamly EGYPT Bevacizumab as a monotherapy versus combined bevacizumab and laser photocoagulation in diabetic macular edema

09.10 B. Chanana, V. Kumar INDIA Intravitreal triamcinolone for diabetic macular edema not responding to bevacizumab therapy

09.15 M. Hosny, M. Zayed, A. Shalaby EGYPT Effect of intracameral bevacizumab injection on corneal endothelial cells - in vivo evaluation

09.20 M. Picoto Passarinho, J. Portelinha, A. Marques, A. Rodrigues, F. Vaz PORTUGAL Health and vision related quality of life among patients with age related macular degeneration

09.25 A. Ambresin, A. Dirani, I. Mantel SWITZERLAND Recurrent macular edema in retinal vein occlusion treated with intravitreal ranibizumab using a modified treat and extend regimen

09.30 I. Rospond-Kubiak, J. Kociecki POLAND The analysis of risk factors for the radiation retinopathy following ruthenium brachytherapy of uveal melanoma

09.35 R. Mathew, R. Bafiq, M. Richardson, S. Sivaprasad UNITED ARAB EMIRATES Normative data of retinal and choroidal thickness in various ethnic groups

09.40 T. Leong, C. Kon UK Postoperative macular edema - posterior sub-Tenon’s triamcinolone as first line therapy

09.45 I. Corcostegui, T. Suarez, X. Landaluce SPAIN Development of an innovative single-handed intra-ocular drug injector

09.50 M. Mazen, M. Soliman, T. Macky, G. Ragab EGYPT Intravitreal infliximab for sight-threatening relapsing posterior uveitis in Behçet disease - a safety and efficacy clinical study

09.55 F. Patelli, P. Radice, F. Viola, M. Romano, F. Bottoni ITALY Optic pit maculopathy - surgical technique and long term follow-up




08.30 – 10.00

ESASO FORUM

New Concepts in Vitreoretinal SurgeryBoulevard E (Level 1)

Chairpersons: F. Bandello ITALY B. Corcóstegui SPAIN G. Guarnaccia ITALY

08.30 E. Averbukh ISRAEL Considerations for placement of trocars in vitrectomy

08.40 E. Zinicola UNITED ARAB EMIRATES New surgical instruments in vitreoretinal surgery

08.50 T. Rossi ITALY Constant flow vitrectomy: a fluid dynamics study

09.00 J-F. Korobelnik FRANCE Do we still need perfluorocarbon liquids

09.10 C. Scholda AUSTRIA Vitrectomy for diabetic macular edema: important aspects

09.20 A. Alqahtani SAUDI ARABIA Diagnostic and therapeutic vitrectomy in ocular oncology

09.30 S. Seregard SWEDEN Biopsies for diagnosis of choroidal tumours

09.40 M. Mura THE NETHERLANDS Artificial vision with argus 2 retinal prostheses

09.50 Discussion


08.30 – 10.00


ABC in Effective Ophthalmic PublishingBoulevard G (Level 1)

Course Organiser: A. Grzybowski POLAND

Cost: €25

08.30 E. Stefánsson ICELAND (EDITOR-IN-CHIEF, ACTA OPHTHALMOLOGICA) Essentials of a good article

08.45 F. Bandello ITALY (CO-EDITOR, EUROPEAN JOURNAL OF OPHTHALMOLOGY) Costs of evidence-based-medicine, multicentre trials and independence of research

09.00 A. Loewenstein ISRAEL (EDITOR-IN-CHIEF, CASE REPORTS IN OPHTHALMOLOGY) The challenge of publishing case reports

09.15 J. Cunha-Vaz PORTUGAL (EDITOR-IN-CHIEF, OPHTHALMOLOGICA) What revision means and how should the revision be prepared?

09.30 A. Grzybowski POLAND (ASSOCIATE EDITOR, ACTA OPHTHALMOLOGICA) Ethical aspects of publishing

09.45 Discussion

10.00 End of course



08.30 – 10.00


PVR Management UpdateBoulevard I (Level 1)

Course Organiser: J. García Arumí SPAIN

Cost: €25

08.30 P. Brazitkos GREECE Risk factors

08.45 B. Corcóstegui SPAIN Lensectomy and pseudophakic management

09.00 J. García Arumí SPAIN Membrane peeling: staining and PFCL

09.15 V. Martinez-Castillo SPAIN Relaxing retinotomy

09.30 S. Rizzo ITALY Endotamponades in PVR

09.45 J. García Arumí SPAIN Subretinal membranes in PVR

10.00 End of course

10.30 – 12.30


Managing Complications in Vitreoretinal SurgeryBoulevard H (Level 1)

Course Organiser: P. Sullivan UK

Cost: €25

10.30 P. Sullivan UK Complications of scleral buckling

10.45 A. Laidlaw UK Retinal trauma during vitrectomy

11.00 C. Pavesio UK Inflammation and infection after vitreoretinal surgery

11.15 P. Sullivan UK Post vitrectomy cataract

11.30 K. Barton UK Glaucoma after vitreoretinal surgery

11.45 A. Laidlaw UK Complications of diabetic vitrectomy

12.00 P. Sullivan UK Intraocular haemorrhage during vitrectomy

12.15 Discussion

12.30 End of course



11.00 – 13.00

MAIN SESSION 9

Retinal Vein OcclusionsBoulevard C (Level 1)

Chairpersons: B. Corcóstegui SPAIN A. Loewenstein ISRAEL

11.00 C. Pournaras SWITZERLAND Pathophysiology

11.15 F. Bandello ITALY Anti-VEGF

11.30 B. Kuppermann USA Steroids

11.45 F. Boscia ITALY Vitreoretinal interface in RVO and role of surgery

12.00 I. Mc Allister AUSTRALIA Laser bypass or anastomosis for CRVO

12.15 M. Goldstein ISRAEL Case presentations

12.45 Discussion


11.00 – 13.00


Vitreoretinal Surgery IVVenue: Boulevard D (Level 1)

Chairpersons: M. la Cour DENMARK D. Steel UK

11.00 M. Dogramaci, T. Williamson, M. Bayazit, A. Cunningham, E. Lee UK Understanding unintentional retinal shift after pars plana vitrectomy (PPV) for rheugmatogenous retinal detachment (RRD) through surgical reverse engineering (SRE) technology. Phase 1 (data input) and phase 2 (data acquisition) results

11.08 B. Dupas, P. Rothschild, S. Chahed, P. Massin, R. Tadayoni FRANCE Intra-operative SD-OCT use in surgical management of submacular hemorrhage with subretinal tissue plasminogen activator

11.16 Y. Totan, E. Güler, F. Gürağaç, E. Uzun, E. Doğdu TURKEY Brilliant blue G assisted macular surgery - the effect of longer retinal contact time on ILM staining

11.24 P. Stanga, M. Gil-Martinez, S. Pastor-Idoate, K. Yau, S. Biswas, C. Lloyd UK Swept-source optical coherence tomography assessment and non-drainage pars plana vitrectomy surgery with air tamponade for optic disc pit maculopathy- new imaging findings and surgical approach

11.32 C. Mariotti, M. Reibaldi, M. Nicolai, A. Saitta ITALY Correlation of preoperative retinal pigment epithelium status with foveal microstructure in repaired macular holes

11.40 S. Wong, E. Say, T. Lee UK Outcomes of clear corneal endoscopic vitrectomy for vitreoretinal complications following successful retinoblastoma treatment

11.48 A. Karamitsos, S. Logothetidis, S. Kassavetis, L. Lamprogiannis, V. Karagkiozaki, P. Oikonomidis, P. Brazitikos GREECE Nanomechanical testing of proliferative vitreo-retinal membrane

11.56 D. Steel, K. White UK Does pre-operative ocriplasmin alter the plane of vitreoretinal separation in patients undergoing macular hole surgery?

12.04 D. Steel, K. White, M. Habib UK Does the extent of muller cell debris on excised internal limiting membrane at the time of macular hole surgery correlate with the occurrence and extent of a dissociated optic nerve fibre layer appearance post-operatively?

12.12 J. Tee, A. Laidlaw UK Prevalence and natural history of subfoveal fluid on OCT following surgery for macular off retinal detachments



12.20 K. Krepler, E. Smretschnig, C. Falkner-Radler, S. Binder AUSTRIA Primary vitrectomy for rhegmatogenous retinal detachment – comparison of surgical strategies between 2007 and 2012

12.28 E. Ng, R. Balasubramanian, S. Beatty, S. Welch, P. Hadden, P. Polkinghorne IRELAND Wide-field autofluorescense imaging to differentiate between retinoschisis and retinal detachment

12.36 S. Kusaka, K. Tachibana, Y. Shimomura JAPAN Real-time intraoperative HD-OCT findings during vitrectomy for retinal detachment

12.44 T. Kaga, N. Yoshida, H. Satou, K. Ichikawa JAPAN A new surgical technique without the use of perfluorocarbon liquid to avoid rolled retina or retinal slippage- usefulness of endoscope in fluid–air exchange

12.52 P. Lyskin RUSSIA Intraoperative staining of vitreous body and internal limiting membrane with optimized corticosteroid suspension


11.00 – 13.00

FREE PAPER SESSION

Quick Fire Free Paper Session 5Venue: Boulevard B (Level 1)

Chairpersons: A. Augustin GERMANY T. Rossi ITALY

11.00 A. Subramanyam, V. Dave, S. Sawant INDIA Protocol based screening, treatment and outcomes of retinopathy of prematurity (ROP) and aggressive posterior ROP (APROP) in Western India

11.05 F. Holz, S. Schmitz-Valckenberg, B. Yaspan, Z. Li, E. Henry, E. Strauss GERMANY The MAHALO phase II results - lampalizumab (anti-factor D) in patients with geographic atrophy

11.10 X. Yang, H. Ren CHINA Treatment of hypotony with trabecular meshwork photocoagulation

11.15 S. Batta Arora, S. Batta, N. Goel, A. Seth, G. Bhushan, U. Raina, B. Ghosh INDIA Retinal nerve fibre layer thickness loss after brilliant blue assisted macular hole surgery

11.20 J. Montero-Moreno, A. Merino-Iglesias, J. Ruiz-Moreno, I. Flores-Moreno, J. Ruiz-Medrano SPAIN Management of central serous choroidopathy by half-dose photodynamic therapy with verteporfin

11.25 K. Hatz, C. Prünte SWITZERLAND Treat and extend regimen versus pro re nata regimen in a comparative study of ranibizumab in exudative age-related macular degeneration - 12 month results

11.30 A. Khattab, M. Torkey EGYPT Triple intravitreal bevacizumab, sub-tenon’s triamcinolone, and panretinal photocoagulation in Eales’ disease

11.35 K. Madan, S. Mittal INDIA Intravitreal bevacizumab in the management of chronic central serous chorio-retinopathy

11.40 T. Rossi ITALY What causes damage in blunt trauma - validation of finite element modelling (FEM)

11.45 K. Darrad, H. Malick, P. Stavrou, B. Mushtaq, S. Elsherbiny, A. Mitra, P. Lip UK Treatment of macular edema secondary to central retinal vein occlusions with anti-vascular endothelial growth factor (Bevacizumab) - 1 year results

11.50 A. Dias-Santos, A. Vicente, R. Anjos, A. Cabugueira, J. Ferreira, R. Flores, J. Cunha PORTUGAL Choroidal thickness in nonarteritic anterior ischemic optic neuropathy - a study with optical coherence tomography

11.55 M. Guzey, Y. Isik, O. Yilmaz TURKEY Comparison of mild macular photocoagulation and intravitreal bevacizumab and mild macular photocoagulation and intravitreal ranibizumab combined treatment in patients with diffuse diabetic macular edema



11.00 – 12.30

SPANISH VITREORETINAL SOCIETY SYMPOSIUM

Pathologic MyopiaBoulevard E (Level 1)

Chairpersons: M. Figueroa SPAIN J. García Arumí SPAIN

11.00 I. Jurgens SPAIN Peripapillary findings in high myopia

11.10 A. Garcia Layana SPAIN Genetic studies

11.20 J. Ruiz Moreno SPAIN Choroidal thickness by OCT

11.30 A. Fernandez Vega SPAIN Dome-shaped macula

11.40 J. Monés SPAIN Anti-VEGF therapy for choroidal neovascular membranes

11.50 M. Figueroa SPAIN Myopic traction maculopathy

12.00 L. Arias SPAIN Macular holes

12.10 J. Nadal SPAIN Retinal detachment resulting from a macular hole

12.20 J. García Arumí SPAIN Rhegmatogenous retinal detachment


12.00 F. Ghassemi, C. Shields, A. Khodabandeh IRAN Multi drug intravitreal chemotherapy for viable vitreous seeds in retinoblastoma tumors

12.05 M. Hamed, M. Bahgat, N. Adel, I. Othman EGYPT Effect of micropulse diode laser on contrast sensitivity and macular scar formation in diabetic macular edema

12.10 B. Kapoor, V. Konidaris, F. Mustaq, T. Empeslidis UK Double masked evaluation of the management of neovascular age related macular degeneration by spectral domain OCT images

12.15 M. Agarwal, R. Venkatesh INDIA Role of oral rifampicin in central serous choroidopathy (CSC)

12.20 C. Gonzalez FRANCE Age macular degeneration - drusenoid deposits. Multimodal imaging and its interest for their characterization

12.25 C. Gonzalez FRANCE AMD drusenoid deposits. Characterization with and interest of OCT, OCT en Face

12.30 S. Mishra, A. Gupta, J. Parihar, R. Maggon, S. Kumar, A. Singh INDIA Intravitreal dexamethasone v/s intravitreal triamcinolone in central retinal vein occlusion

12.35 M. Absalijamov, M. Bikbov, N. Shevchuk RUSSIA Immunological profile in patients with neovascular membrane associated with age-related macular degeneration

12.40 T. Sinha INDIA Comparison of results between two groups of patients with open macular hole treated with or without re-ILM peeling and C3F8 gas injection




11.00 – 12.30


Optimizing Injection ClinicsBoulevard G (Level 1)

Course Organiser: M. Zinkernagel SWITZERLAND

Cost: €25

11.00 M. Zinkernagel SWITZERLAND Introduction

11.05 S. Wolf SWITZERLAND The role of retreatment criteria standardization for optimizing injection clinics

11.20 N. Feltgen GERMANY How many stops are bearable?

11.35 P. Lanzetta ITALY Reviewing and improving intravitreal injections

11.50 G. Turner UK Optimizing injection clinics with non-consultant staff

12:05 M. Zinkernagel SWITZERLAND Retreatment criteria for AMD, DME and RVO: different or same?

12.20 Discussion

12.30 End of course

11.00 – 12.30


Advances in Diabetic Retinopathy ScreeningBoulevard I (Level 1)

Course Organisers: P. Scanlon UK E. Stefánsson ICELAND

Cost: €25

11.00 P. Scanlon UK Experience and outcome of the English screening system

11.18 T. Bek DENMARK Focusing on higher risk patients

11.36 E. Stefánsson ICELAND IT and individualized risk assessment to optimize screening

11.54 T. Peto UK Grading and retinopathy detection

12.12 Discussion

12.30 End of course


E-POSTER PRESENTATIONS 71

AMDS. Abou-Ltaif, E. Thompson, N. Karia UK Aflibercept in AMD resistant to intensive ranibizumab treatment

D. Barthelmes, M. Gillies SWITZERLAND Intravitreal therapy for neovascular age-related macular degeneration in patients with bilateral disease- comparision of first and second eye outcomes

C. Brand UK Baseline characteristics of over 10,000 patients enrolled in the LUMINOUS study- ranibizumab in a real world setting

M. Buckle, Q. Mohamed, R. Johnston UK Long-term outcomes of intravitreal ranibizumab treatment for neovascular age-related macular degeneration in a well-defined region of the United Kingdom

V. Castro Navarro, E. Cervera Taulet, J. Montero Hernández, L. Hernández Bel, C. Torralba Rull, C. Navarro Palop, N. Doménech Aracil SPAIN Anatomical and visual outcome after one year of treatment with aflibercept in refractory wet age-related macular degeneration

A. Chang, G. Broadhead, T. Hong, N. Joachim, W. Wijeyakumar, T. Peto, M. Zhu AUSTRALIA Intravitreal aflibercept for treatment resistant neovascular age-related macular degeneration

V. Chaudhary, M. Brent, W. Lam, J. Teichman, F. Farrokhyar, R. Carter, R. Devenyi CANADA Genetic risk evaluation in wet-AMD treatment (G.R.E.A.T) 6 month final study results

K. Chia, A. Laude SINGAPORE The impact of switching anti-vascular endothelial growth factor (anti-VEGF) therapy in the management of exudative age-related macular degeneration (AMD)

S. Ch'ng, S. Deol, P. Tesha UK 'Don’t treat and extend' dosing of intravitreal ranibizumab therapy for neovascular age-related macular degeneration

D. Costin, A. Moraru, D. Branisteanu ROMANIA Risk of age related macular degeneration progression after cataract surgery

A. Cywinski, U. Gajdzik Gajdecka, D. Ferda POLAND Anti-VEGF therapy in the treatment of wet AMD with accompanying subretinal haemorrhage

A. Cywinski, A. Piwońska Lobermajer, U. Gajdzik Gajdecka POLAND Anti-VEGF therapy in the treatment of giant PED. A case report

S. Demirel, F. Calıs, E. Ozmert, F. Batıoğlu TURKEY The effect of lutein supplementation on macular pigment optical density displayed by colour perimetry technique in patients with age-related macular degeneration

A. Dirani, L. Marchionno, D. Decugis, M. Zaugg, I. Mantel SWITZERLAND Comparison of the structural response of pigment epithelium detachments in neovascular age-related macular degeneration, treated with ranibizumab or aflibercept

S. Donati ITALY Treatment of retinal angiomatous proliferation with intravitreal anti-VEGF drugs in real life practice

P. Dugel, S. Kiss, C. Makin, S. Johnston, A. Turpcu USA Treatment patterns of ranibizumab and aflibercept in neovascular age-related macular degeneration- evidence from two large US claims databases

T. Empeslidis, K. Tsaousis, V. Konidaris UK Aflibercept 2mg intraviteal injections in retinal angiomatous proliferation

R. Fayzrakhmanov, M. Bikbov RUSSIA Dynamics of changes in morphometric parameters of foveolar zone in the formation of active fibrovascular membrane associated with the use of anti-VEGF therapy

R. Fayzrakhmanov, M. Bikbov, T. Gilmanshin, A. Yarmukhametova RUSSIA The incidence of epiretinal fibrosis and its impact on the anatomical and functional indices of the central region of the retina

K. Fotis, H. Eleftheriadis UK Treatment outcomes of peripapillary idiopathic polypoidal choroidal vasculopathy with focal laser photocoagulation

K. Gadhvi, E. Mensah, A. Ritchie, A. Khalilli UK The effect of ethnicity on the response to ranibizumab therapy in wet age related macular degeneration (AMD)

T. Georgiou, D. Nicolaou, A. Neokleous, P. Kolovos, S. Michael, C. Ikonomu CYPRUS The importance of arachidonic acid/ eicosapentaenoic acid (AA/EPA) blood ratio in treating dry age-related macular degeneration and macular dystrophies with high doses of omega-3 fatty acids

T. Georgouli, D. Burton, S. Mackenzie, G. Walters UK Converting resistant neovascular age related macular degeneration to aflibercept

M. Gil, M. Santiago, M. Bande, M. Rodriguez Cid, B. Pazos, F. Gomez-Ulla, M. Fernandez SPAIN Outcomes in clinical practice of intravitreous ranibizumab treatment in patients with age-related macular degeneration

A. Giocanti, P. Dourmad, R. Tadayoni, S. Magazzini, S. Cohen FRANCE Predictive value of outer retina enface OCT imaging in geographic atrophy progression

A. Gkountelia, P. Pacheco, A. Ismail, A. Kosmin, M. Karampelas UK Outcomes of aflibercept therapy for neovascular age-related macular degeneration in a clinical setting

O. Ibrahim, S. Oluleye NIGERIA Prevalence and pattern of age related maculopathy in a rural population in Nigeria

U. Inan, M. Karadas, S. Inan, G. Yavas, M. Dogan, T. Kusbeci TURKEY Neuroretinal function improves in the long-term after the ranibizumab treatment of neovascular age-related macular degeneration

U. Inan, B. Kutluksaman, S. Inan, G. Yavas, M. Dogan, O. Polat, T. Kusbeci TURKEY Macular pigment optical density decreases and metamorphopsia increases in patients with early dry-age related macular degeneration

U. Introini, G. Casalino, F. Bandello ITALY Intravitreal ranibizumab for different neovascular AMD subtypes- results from a clinical setting


A. Ivanescu, I. Akram, D. Assheton, A. Tin-u UK Traumatic macular hole immediately after intravitreal injection

R. Johnston, M. Buckle, R. Healy, Q. Mohamed, A. Sallam, E. Fletcher UK Population outcomes of ranibizumab for treatment naïve eyes with neovascular age-related macular degeneration

F. Jonasson, D. Fisher, G. Eiriksdottir, R. Klein, T. Harris, V. Gudnason, M. Cotch ICELAND 5 year incidence and progression of age-related macular degeneration and its impact on mortality- the age, gene/environment susceptibility Reykjavik study

B. Kambo, M. Asani, J. Jaho, K. Bardhi ALBANIA The control of the effectiveness of Avastin intravitreal injection therapy in wet AMD treatment

M. Karliychuk, S. Pinchuk, M. Zubovych UKRAINE Clinical follow-up of statins` use in complex treatment of exudative form of age-related macular degeneration

I. Karska-Basta, A. Kubicka-Trząska, P. Oleksy, J. Miniewicz-Kurkowska, B. Romanowska-Dixon POLAND Visual and anatomical outcomes of intravitreal aflibercept in eyes resistant to ranibizumab and bevacizumab in patients with exudative age-related macular degeneration

G. Kaya, Y. Yılmaz, H. Sımsek TURKEY Comparison of ranibizumab and pegabtanib sodium monotherapies in terms of rates of stabilization after the first 3 doses

G. Kaya, Y. Yılmaz, H. Sımsek TURKEY Comparison of efficacy between anti-VEGF agents alone and in combination with photodynamic therapy in the treatment of choroidalneovascularization secondary to age-related macular degeneration

S. Kelly, A. Ferreira, R. Hashmonay, J. Lu, E. Souied UK Endophthalmitis following ranibizumab or aflibercept treatment in patients with neovascular age-related macular degeneration- a retrospective US database analysis

A. Khafagy, H. Elmekawey EGYPT Intravitreal ranibizumab (Lucentis®) injection for cases with exudative age-related macular degeneration complicated with retinal pigment epithelial detachment

A. Khanani, G. Cohen, R. Zawadzski USA Evaluation of intraocular inflammation and pain post intravitreal injection of ranibizumab or aflibercept- the PLANET study

A. Khanani USA Intravitreal aflibercept for wet age-related macular degeneration on a fixed bimonthly regimen (every 8 weeks) may not be adequate for all patients

H. Kim SOUTH KOREA Correlation of foveal microstructural changes with vision after anti–VEGF therapy in age-related macular degeneration

J. Kim, Y. Sung You SOUTH KOREA Longitudinal changes in retinal nerve fiber layer thickness after intravitreal anti-vascular endothelial growth factor therapy

A. Kogiantis, F. Barampouti, M. Karampelas UK Aflibercept treatment for exudative age-related macular degeneration in patients who exhibited incomplete response to multiple ranibizumab injections

E-POSTER PRESENTATIONS

A. Korol, N. Pasyechnikova, A. Korol, O. Zadorozhnyy, I. Nasinnyk, A. Nevska UKRAINE Triamcinolone acetonide in treatment of patients with serous of the retinal pigment epithelium detachment associated with age-related macular degeneration (follow-up 32 months)

A. Korol, V. Naumenko, O. Zadorozhnyy, I. Nasinnyk UKRAINE The subgroup analysis of efficacy of aflibercept in treatment of patients with wet age-related macular degeneration

A. Kubicka-Trząska, I. Karska-Basta, B. Romanowska-Dixon POLAND Serum anti-endothelial cell antibodies (AECA) in patients with exudative age-related macular degeneration treated with intravitreal injections of bevacizumab

T. Lai, T. Wong, P. Lanzetta, N. Heinrichs, S. Pilz, K. Ohno-Matsui HONG KONG Ranibizumab in patients with visual impairment due to myopic choroidal neovascularization- a subgroup analysis of East Asian and Caucasian patients from the Radiance study

A. Leal, M. Cachulo, I. Laíns, S. Nunes, C. Lobo, J. Figueira, R. Silva PORTUGAL The prevalence of fundus diseases in the Portuguese population over 55 years of age

A. Liaska, T. Pallantzas, E. Makri, V. Dimopoulou, S. Stamelou, K. Andrianopoulou GREECE Exudative age-related macular degeneration-continuation of anti-VEGF treatment based on disease activity

M. Lindner, A. Bezatis, J. Czauderna, R. Fimmes, S. Schmitz-Valckenberg, F. Holz, M. Fleckenstein GERMANY Choroidal thickness in geographic atrophy

D. Loganathan, A. Krishnan, M. Damani UK Microbial isolates in endophthalmitis following intravitreal injections in the treatment room setting

M. Losada, N. Manresa, J. Mulero, J. Sanchez, P. Zafrilla SPAIN Effect of antiangiogenic treatments on total antioxidant status and antioxidant enzymes in patients with age related macular degeneration

M. Losada, P. Zafrilla, N. Manresa, J. Mulero SPAIN Effect of antiangiogenic treatments on biomarkers of oxidative stress in patients with age related macular degeneration

J. Luttrull, D. Chang, D. Luttrull USA Laser re-sensitization of medically unresponsive CNVM in AMD. Efficacy and implications

S. Mahmood UK 1 year real-world outcomes of ranibizumab in wet age-related macular degeneration- interim results from the LUMINOUS study

T. Marakis, K. Xatzistefanou, Y. Tountas, C. Koutsandrea GREECE Quality of life of patients with wet age-related macular degeneration in Greece

N. Marques, S. Barros, A. Cardoso, J. Cardoso, A. Miranda, N. Donaire, N. Campos PORTUGAL Macular pigment density avaliation and its relation with risk factors for age-related macular degeneration

I. Martins de Almeida, R. Soares, C. Costa Ferreira, M. Monteiro, T. Painhas, J. Chibante Pedro PORTUGAL Thinking beyond age-related macular degeneration…fundus flavimaculatus, an uncommon presentation

72


V. Matuskova, P. Kolář, D. Vysloužilová, E. Vlková, L. Dušek, J. Jarkovský CZECH REPUBLIC Ranibizumab in the AMD wet form treatment – 2 year results obtained from the AMADEuS registry

S. McAtamney, J. Ng, Z. Koshy UK Is the lack of a posterior vitreous detachment associated with the need for recurrent treatment with ranibizumab in wet age related macular degeneration?

C. Meillon, P. Koehrer, R. Isaico, A. Bonnabel, C. Creuzot-Garcher, A. Bron FRANCE Intravitreal ranibizumab for neovascular age-related macular degeneration with an inject and extend regimen- anatomical and functional results

L. Mendonca, N. Gomes, E. Conde PORTUGAL Visual and anatomic outcomes of intravitreal aflibercept in eyes with persistent fluid despite previous treatments with ranibizumab and bevacizumab in patients with neovascular age-related macular degeneration

G. Menon, Y. Yang, B. Reeves, F. Ghanchi, U. Chakravarthy UK Predictors of visual acuity outcome and time to lesion reactivation when using anti-VEGF drugs to treat wet AMD

M. Mikhail, A. Sallam, Q. Mohamed, E. Fletcher, R. Johnston UK Intravitreal injections of ranibizumab for eyes with neovascular age-related macular degeneration (nAMD) and poor baseline vision

P. Mitchell, J. Gilhotra, B. Vote, M. Walsh, C. Woodcock, N. Kurstjens AUSTRALIA A cohort of 938 Australian patients with wet AMD in the LUMINOUS trial

A. Mohite, J. Sardar UK 2 year outcomes of pro re nata ranibizumab monotherapy for neovascular age-related macular degeneration (AMD) in a district general hospital in the United Kingdom

J. Montero-Moreno, A. Merino-Iglesias, J. Ruiz-Moreno, J. Ruiz-Medrano, I. Flores-Moreno SPAIN Effects of topical ophthalmic and systemic medication on exudative age related macular degeneration treated by intravitreal bevacizumab

J. Montero-Moreno, A. Merino-Iglesias, J. Ruiz-Moreno, J. Ruiz-Medrano, I. Flores-Moreno SPAIN Macular hole after intravitreal bevacizumab in exudative age related macular degeneration

J. Morarji, M. Michelotti, D. Zacks, E. Sioras, P. Lee, S. Kelly UK Comparison of intravitreal injections in the United States of America and the United Kingdom based on observations of ophthalmic trainees

M. Morkhat, T. Katulskaya, N. Korolkova, M. Shkudnova BELARUS Diagnostic value of fundus autofluorescence in exudative age-related macular degeneration treatment with intravitreal bevacizumab

E-POSTER PRESENTATIONS

A. Needham, C. Southern, J. Lane, T. Singh UK A retrospective audit of visual and anatomic outcomes in 205 treatment naïve and treatment recalcitrant patients with neovascular age-related macular degeneration (AMD) treated for 6–12 months with a PRN dosing schedule of intravitreal aflibercept

P. Nemec, J. Ernest, L. Rejmont, K. Manethova CZECH REPUBLIC Combined photodynamic therapy with verteporfin and intravitreal ranibizumab for choroidal neovascularization in age-related macular degeneration

A. Neves, A. Campos, J. Campos, S. Mendes, L. Violante, J. Sousa PORTUGAL The importance of diagnosis in anti-vascular endothelial growth factor (anti-VEGF) non-responders- the role of green indocianin angiography (ICG)

V. Okur, O. Cetin, E. Cetin, E. Tepeli, Y. Bulgu, C. Yildirim TURKEY HIF1A as a major VEGF regulator- does its polymorphisms have an association with AMD?

A. Oner, O. Polat, N. Sinim TURKEY Choroidal thickness in dry age-related macular degeneration

A. Ozkaya, Z. Alkin, I. Perente, K. Yuksel, O. Baz, C. Alagoz, A. Yazici TURKEY Comparison of intravitreal bevacizumab treatment between phakic and pseudophakic neovascular age-related macular degeneration patients

A. Ozkaya, Z. Alkin, Y. Karakucuk, A. Yazici, A. Demirok TURKEY Time-domain OCT and spectral domain OCT in neovascular age-related macular degeneration

K. Pachkoria, M. Masih, S. Farrel, R. Desai, K. Karia, A. Stein, A. Lobo UK 1 year results of allied health personnel led age related macular degeneration (AMD) clinic in a community AMD center

N. Patel UK Baseline characteristics of diabetic macular edema patients enrolled within the LUMINOUS study

E. Pearce, Y. Elizabeth, J. Harvey, M. Richardson, S. Sivaprasad, V. Chong UK Subfoveal choroidal thickness is not correlated with retinal sensitivity but with age in the fellow eye of patients with neovascular age-related macular degeneration

E. Pedanova, G. Kachalina, D. Buryakov RUSSIA Value of microperimetry for evaluating the effectiveness of treatment in patients with age-related macular degeneration with very low visual functions

G. Pekel, S. Acer, E. Çetin, R. Yağcı, A. Kaşıkçı, A. Çevik TURKEY Influence of intravitreal ranibizumab on ocular pulse amplitude in wet AMD

A. Pollack, Z. Dvashi ISRAEL TAK-1 inhibition accelerates cellular senescence of retinal pigment epithelial cells, possible new pathway causing early stages of AMD

73


E-POSTER PRESENTATIONS74

S. Pushpoth, M. Fitzpatrick, S. Young, S. Talks, Y. Yang, G. Wallace UK Metabolomic analysis in patients with age related macular degeneration

J. Quintyn FRANCE Prevalence of apnea syndrome in patients with age macular degeneration

A. Rehman, A. Kaintatzis, K. Fotis, H. Eleftheriadisis, M. Majid UK Management of endophthalmitis following intra-vitreal treatments

S. Rezar, K. Eibenberger, M. Georgopoulos, C. Schütze, C. Hitzenberger, U. Schmidt-Erfurth, S. Sacu AUSTRIA Multimodal characteristics of persistent or recurrent choroidal neovascularization in age-related macular degeneration

P. Romera Romero, X. Valldeperas Belmonte, M. Carbonell Puig, A. Sabala Llopart SPAIN Drusen morphology changes in nonexudative age-related degeneration using spectral domain optical coherence tomography after oral antioxidants supplementation -1 year results

A. Saatci, R. Yıldırım, M. Parlak, G. Cetin, A. Yaman TURKEY Retinal tears and rhegmatogenous retinal detachment after intravitreal injections- its' prevalence and case reports

S. Sakhnov, A. Zabolotniy, A. Malafeev, A. Bronskaya RUSSIA Morphology of pigment epithelium detachment as a factor of treatment outcomes predicting an optimal mode determination for the a-VEGF therapy of AMD wet form

A. Sarmad, A. Kumar, N. Din, S. Elsherbiny, P. Stavrou, P. Lip, B. Mushtaq UK Fighting for sight- our story so far

A. Sato, E. Fukui, N. Senda, A. Koshino, K. Ohta JAPAN Identification of choroidal neovascularization in eyes with cuticular drusen by spectral-domain optical coherence tomography

N. Saxena, B. Ghosh, V. Garg, A. Seth, S. Arora INDIA Growth pattern of choroidal neovascular membranes secondary to central serous chorioretinopathy- a spectral domain optical coherence tomography study

P. Schlottmann, H. Shapiro, L. Tuomi ARGENTINA Early vs delayed 20/40 vision achievers with ranibizumab treatment in the 24 month HARBOR study

T. Shaimov, I. Panova RUSSIA Diagnostic capabilities of polypoidal choroidal vasculopathy in the absence of indocyanine green angiography

M. Sharma, N. Yadav, A. Banker, A. Naik, S. Sarkar INDIA Effect of ranibizumab on health-related quality of life in patients with neovascular age-related macular degeneration in Indian population- results from UNVEIL study

H. Sımsek, G. Kaya, Y. Yılmaz TURKEY Efficacy of intravitreal ranibizumab injection for treatment of diabetic macular edema

H. Sımsek, G. Kaya, Y. Yılmaz TURKEY Sterile endophthalmitis after intravitreal ranibizumab injection

P. Sin, E. Lo, A. Young HONG KONG An atypical case of polypoidal choroidal vasculopathy presented as a choroidal mass in a patient with history of breast cancer

K. Sousa, L. Mendonça, R. Gentil, R. Leite, J. Mendes, R. Silva, N. Gomes PORTUGAL Electrophysiology results in age-related choroidal atrophy

L. Tan, M. Johnson, D. Knight, P. Johnstone UK Mixed (Q3M 12m + PRN 12m) versus pro re nata (PRN 24m) dosing regime- 24 month visual outcomes of ranibizumab treatment for wet age related macular degeneration (wAMD)

J. Tavares-Ferreira, Â. Carneiro, M. Falcão, P. Freitas-Costa, J. Pinheiro-Costa, E. Brandão, F. Falcão-Reis PORTUGAL Chronic central serous chorioretinopathy or age-related macular degeneration?

A. Tufail, Y. Chen, H. Gon Yu, N. Leveziel, C. Leteneux, S. Pilz, F. G. Holz UK Ranibizumab in patients with visual impairment due to myopic choroidal neovascularization- subgroup analyses of the Radiance study by baseline ocular characteristics

E. Turan-Vural, R. Bolac, M. Yenerel, A. Ersanli TURKEY Subfoveal choroid thickness assesment in chronic heavy cigarette smoking

P. Udaondo, R. Martinez-Costa, A. Cisneros-Lanuza SPAIN Aflibercept good results in refractory ranibizumab cases

C. Ünlü, G. Erdogan, B. Onal Gunay, B. Sezgin Akcay, E. Guney Kardes TURKEY Subfoveal choroidal thickness changes after intravitreal bevacizumab therapy for neovascular age-related macular degeneration

E. Vazquez, J. Salazar, J. Lopez, J. Corcostegui, E. Noguera SPAIN Combined treatment with photodynamic therapy and intravitreal ranibizumab in refractory neovascular age related macular degeneration- reduced fluence versus standard fluence

B. Vote, S. Ewe, R. Abell, E. Darian-Smith, N. Kerr, P. Allen AUSTRALIA Geographic atrophy trends in patients treated with ranibizumab for choroidal neovascularization

B. Vote, S. Ewe, R. Abell, N. Ker, P. Allen AUSTRALIA Intravitreal injections- is there a benefit for a theatre setting?

B. Vote, S. Ewe, R. Abell, D. Lim, N. Kerr, P. Allen AUSTRALIA Ranibizumab for neovascular age-related macular degeneration in a real world clinical setting

S. Waldstein, J. Wright, J. Warburton, P. Margaron, C. Simader, U. Schmidt-Erfurth AUSTRIA Predictive value of retinal morphology on the visual outcome of different injection frequencies of ranibizumab in patients with neovascular age-related macular degeneration

P. Xanthopoulou, J. Yfantopoulos, A. Rouvas, A. Chantzaras, P. Theodosiadis GREECE Outcomes of patients with neovascular age-related macular degeneration (wet-AMD) in Greece under ranibizumab (Lucentis®)



Y. Yang, E. Souied, N. Narendran, P. Margaron, R. Hashmonay, J. Warburton UK Retinal thinning does not correlate with visual acuity in patients with wet age-related macular degeneration- a post-hoc analysis of the EXCITE study

A. Yazici, A. Ozkaya, Z. Alkin, O. Baz TURKEY Results of treatment with bevacizumab alone or ranibizumab alone for low visual acuity due to neovascular age-related macular degeneration

J. Zarranz-Ventura, S. Fernandez-Perez, P. Tsangaris, M. Brelen, R. Haynes UK Clinical outcomes of subretinal and intravitreal recombinant tissue plasminogen activator (r-TPA) in macular haemorrages

Anterior/Posterior Segment SurgeryA. Abraham INDIA Conservative management of panophthalmitis

K. Anastasilakis, A. Mourgela, D. Kaniouras, D. Sakellaris, K. Moschou GREECE Lens-iris diaphragm retropulsion syndrome during phacoemulsification post vitrectomy

D. Balakrishnan, S. Jalali, R. Pappuru INDIA Clinical profile and surgical outcomes of operated cases of PHPV with vitreoretinal intervention

A. Cabugueira, A. Vicente, R. Anjos, L. Pinto, R. Flores, M. Reina PORTUGAL Bilateral hypotony maculopathy associated with trabeculectomy- a case report

R. Domínguez Fernández, A. Govetto, R. Lorente Moore SPAIN Intravitreal ranibizumab in the treatment of refractory pseudophakic cystoid macular edema following cataract surgery

C. Efterpi, K. Moschonas, K. Tsakiris GREECE Results of intravitreal injections of triamcinolone and ranibizumab in 6 patients with Irvine - Gass syndrome

A. Gomez Escobar, J. Cubero Parra, I. Relimpio Lopez, E. Esteban Gonzalez SPAIN Present the case of a traumatic cataract with superior subluxation of lens

J. Gonzalez-Cortes, A. Martinez, E. Treviño, J. Lozano, J. Mohamed MEXICO Iridocorneal angle in phacovitrectomy with silicone

P. Gowda, V. Kadri, N. Yadav, R. Shetty INDIA Treatment of traumatic sub macular haemorrhage with pneumatic displacement without tissue plasminogen activator- case series

A. Iakimov, V. Zaika RUSSIA Fibrotic adhesion of luxated lens and detached retina after severe contusion

T. Kamalden, E. Chan, M. Naser, C. Chee MALAYSIA Repositioning of Ozurdex implant in the anterior chamber

N. Kanchanaranya, D. Rojdamrongratana, P. Piyasoonthorn THAILAND Incidence of post-intravitreal anti-VEGF endophthalmitis at Thammasat University Hospital

H. Kaymak, D. Breyer, K. Klabe, C. Pohl GERMANY Clinical outcome after implantation of premium-intraocular (IOL) in combination with macula pucker

D. Khatri, M. Rajan, K. Nachiappan, R. P J, S. Gopal, S. Sawant, J. Chhablani INDIA Management of vitreous loss and dropped nucleus during cataract surgery

P. Kiryttopoulos, M. Moschos, A. Jaulim, N. Antonopoulos, E. Tzaferis, P. Mitropoulos, I. Chatziralli GREECE Subconjunctival haemorrhage as an indication of gastrointestinal bleeding

E. Kontou, D. Alonistiotis, N. Karachalios, N. Tsilimpokou, A. Takis, P. Stavrakas, P. Theodossiadis GREECE Incidence of post-operative cystoid macular edema after phacoemulsification in previously vitrectomized eyes of non-diabetic patients

F. Kretz, A. Fitting, K. Linz, M. Safwat, G. Auffarth GERMANY Evaluation of a segment multifocal intraocular lens (sMIOL) with a +8.0 D near addition for visual rehabilitation in patients with maculopathy

X. Lumi, H. Skačej Friedrich SLOVENIA Visual outcome and macular changes evaluated by OCT after retropupillary iris-claw lens implantation

H. Makled, A. El-Sawy Habib, H. Yassin, H. Tulla Makled EGYPT Topical anesthesia clear corneal phacoemulsification versus topical with sedation and topical with cryoanalgesia

C. Menezes, J. Lemos, R. Gonçalves, P. Coelho, J. Serino, B. Cardoso Vieira, R. Carvalho PORTUGAL Microscope-induced photic retinopathy in cataract surgery- a case report

A. Novolodsky, V. Bury, T. Iureva, A. Shchuko RUSSIA Differentiated approach in the treatment of patients with traumatic cataract and intraocular foreign body

M. Núñez, M. Mendivil SPAIN Peripheral scotoma´s progression after peeling of epiretinal membrane

K. Okuyama, V. Pavlenko JAPAN A case report of mono-vision after PRK correction of severe myopia SE-23D

M. Ratkovic, V. Cerovic CROATIA Fundus changes and anterior lenticonus in Alport's syndrome

M. Stopa, P. Rakowicz, M. Liwacz POLAND Results of sutureless intrascleral posterior chamber IOL fixation in patients with insufficient capsule support

A. Sudhalkar, A. Sudhalkar INDIA Radial buckle surgery for multiple tears- long term follow-up

S. Sukavatcharin, N. Tranti, W. Prasartritta, R. Olarn THAILAND Comparative of subretinal injection of tissue plasminogen activator and pneumatic displacement in the treatment of thick submacular hemorrhage

P. Susvar, L. Therese, G. Ramasubban, B. Srinivasan, G. Lingam INDIA Surgical management of culture-proven non-keratitic nocardia infection



R. Bastos, Â. M Carneiro, C. Ferreira, E. Brandão, F. Falcão-Reis PORTUGAL Multimodal image analysis in acquired vitelliform lesions and adult-onset foveomacular vitelliform dystrophy

F. Batıoğlu, P. Bingol Kızıltunc, S. Demirel, E. Ozmert TURKEY Evaluation of different phenotypic features and progression of stargardt – fundus flavimaculatus disease with fundus autofluorescence imaging

J. Beato, C. Ferreira, M. Falcão, S. Penas, E. Brandão, F. Falcão-Reis, A. Carneiro PORTUGAL Choroidal thickness and morphology evaluation in a control population using EDI-OCT

S. Ben Yahia, N. Abroug, W. Ammari, M. Hani, S. Najjar, S. Zaouali, M. Khairallah TUNISIA Relevance of indocyanine green angiography for the diagnosis of noninflammatory chorioretinal diseases

G. Calvão-Santos, L. Mendonça, R. Gentil, N. Gomes, R. Leite, K. Sousa, F. Vaz PORTUGAL Maternally inherited diabetes and deafness (MIDD) and macular dystrophy- a case report

G. Calvão-Santos, L. Mendonça, R. Gentil, R. Leite, K. Oliveira, N. Gomes, F. Vaz PORTUGAL A familiar case of cone dystrophy

E. Cetin, S. Acer, M. Hıraali, S. Ozdemir, M. Fenkci TURKEY Posterior segment changes as assessed by optical coherence tomography in patients with Graves’ disease without ophthalmic involvement

E. Cetin, S. Acer, T. Tahtacı, G. Pekel, R. Yağcı TURKEY Assessment of peripapillary retinal nerve fiber layer after uneventful phacoemulsification in patients without co-existent systemic diseases

E. Cetin, S. Ergin, S. Acer, G. Pekel, A. Bahar, L. Tasli, R. Yagci TURKEY Assessment of the change in central macular thickness and peripapillary retinal nerve fiber layer after phototherapy and photochemotherapy for dermatologic diseases

F. Chait Diaz, P. Morales, V. Llorens, M. Mesquida, A. Adan SPAIN Ocular toxocariasis. Imaging in the diagnosis and follow up of an atypical case with spontaneous resolution

C. Chan, A. Young, E. Lo, H. Sin HONG KONG A young man with macular lesion

J. Chhablani, D. MJ, M. Tyagi, R. Narayanan, I. Kozak INDIA Fluorescein angiography and optical coherence tomography in myopic choroidal neovascularization

A. Ciardella ITALY SD-OCT study of persistent subretinal blebs after retinal detachment repair

M. Colaço, M. Franco, C. Pereira, S. Rodrigues, M. Vila Franca, J. Maia Seco, L. Coutinho Santos PORTUGAL Clinical spectrum of best vitelliform macular dystrophy – extreme ocular phenotypes in the same family

F. Corvi, G. Querques, C. La Spina, R. Lattanzio, G. Zerbini, F. Bandello ITALY Patients with retinal vein occlusion have a reduced retinal vascular dilation to flicker light

V. Tkachev RUSSIA Silicon oil tamponade in cases of violation of the integrity of the irido-lens diaphragm. Specially designed IOL

N. Yenerel, N. Erçalık, H. Sanisoğlu, E. Türkseven Kumral TURKEY Comparison of intraoperative and postoperative complications of phacoemulsification between sequential and combined procedures of 23-gauge vitrectomy and cataract surgery

S. Yong SINGAPORE Rescue and scleral fixation of a posteriorly dislocated multifocal intra-ocular lens (IOL) implant

W. Zbiba, E. Bouayed, I. Ammous, A. Baba, M. Korbi TUNISIA Comparison of macular thickness changes after two methods of cataract surgery- the preliminary results of prospective study

ImagingA. Abraham INDIA Altitudinal field defects in optic disc drusen

R. Abreu, M. Alonso, P. Abreu SPAIN Spectral domain optical coherence tomography in diagnosis and follow-up of a secondary to paintball contuse trauma conmotio retinae

S. Acer, A. Oğuzhanoğlu, E. Çetin, N. Ongun, G. Pekel, R. Yağcı TURKEY Ocular pulse amplitude and posterior pole asymmetry analysis in migraine

S. Acer, G. Pekel, A. Karabulut, E. Cetin, A. Kaşıkcı, R. Yağcı, A. Avunduk TURKEY Assessment of ocular pulse amplitude and central macular thickness during pregnancy

J. Afonso, C. Ângela, B. Elisete, F. Fernando PORTUGAL Multimodal study of multiple idiopathic retinal pigment ephithelium detachments- a case report

S. Akca Bayar, F. Corak Eroglu, L. Asena, A. Kal, C. Simsek, G. Yilmaz TURKEY Evaluation of choroidal thickness using enhanced depth imaging by spectral-domain optical coherence tomography in patients with Pseudoexfoliation syndrome

I. Ammous, I. Letaif, Z. Walid, E. Kalil, S. Hela, M. Manel, M. Boussen- Ilhem TUNISIA Endotholial cell abnormalities in patients with several stages of diabetic retinopathy- case-control study

H. Arifoglu, B. Alabay, A. Karatepe Hashas, Y. Yuce, G. Kızılcay, T. Ersekerci, M. Atas TURKEY Full thickness macular hole after intravitreal ranibizumab injection for diabetic macular edema

F. Ascaso, C. Almenara, L. Lavilla, K. Zabadani, L. Herrera, I. Pinilla, J. Cristóbal SPAIN Evolution of hiperreflective foci on RVO-associated macular edema after an intravitreal dexamethasone implant injection

C. Azrak, M. Baeza Díaz, J. Martínez Toldos, C. Hernández Martínez, A. Palazón Bru, D. Orozco Beltran, V. Gil Guillen SPAIN Optical coherence tomography to rule out or confirm diabetic macular edema



R. Couceiro, C. Loureiro, S. Vaz-Pereira PORTUGAL Multimodality imaging in solar maculopathy

G. De Salvo, S. Vaz-Pereira, M. Sagoo UK Spectral domain optical coherence tomography of polypoidal choroidal vasculopathy associated with benign choroidal nevus

S. Degli Esposti, O. Comyn, P. Hykin, P. Patel UK Limits of agreement between 'fast' and 'dense' spectralis optical coherence tomography scans in diabetic macular edema

C. Doefler Poulsen, J. Grauslund, T. Peto DENMARK Retinal changes detected by wide-field autofluorescence imaging of patients with primary rhegmatogenous retinal detachment

R. Dolz-Marco, S. Pagliarini, M. Cozzi, D. Pardo-López, M. Andreu-Fenoll, N. García-Marín, R. Gallego-Pinazo SPAIN Central serous chorioretinopathy spectrum- characterisation of retinal pigment epithelium changes by multicolour imaging

S. Dsouza, R. Battu, R. Shetty, B. Shetty INDIA Spectral domain optical coherence tomography analysis in natural course of bests vitelliform dystrophy

C. Dysli, S. Wolf, M. Zinkernagel SWITZERLAND Fluorescence lifetime measurement in central artery occlusion

B. Erden, S. Bölükbaşı, Ö. Kuru, M. Elçioğlu TURKEY Comparison of OCT findings in multiple sclerosis patients with a healthy population

V. Felcida, P. Kumar UK Tamoxifen retinopathy

P. Fernandez Avellaneda, M. Mendivil Soto, I. Bearan Maria, M. Ramos Barrios, I. Henares Fernandez, O. Guergué SPAIN Diagnosis of pseudoxanthoma elasticum with OCT-SD pathognomonic findings- one case report without cardiovascular neither cutaneous manifestations

I. Flores-Moreno, J. Ruiz-Medrano, P. Peña-García, J. Montero, L. Arias-Barquet, J. Ruiz-Moreno SPAIN Correlation between macular retinal and choroidal thicknesses in normal eyes measured by swept-source optical coherence tomography

I. Flores-Moreno, L. Arias-Barquet, M. Rubio-Caso, E. Cobos-Martín, J. Catalá-Mora, J. Ruiz-Moreno, J. Camina-lmitjana SPAIN Study of retinal pigment epithelium detachment in age related macular degeneration using swept-source OCT

R. Gallego-Pinazo, R. Dolz-Marco, S. Pagliarini, M. Cozzi, M. Andreu-Fenoll, N. Garcia-Martin SPAIN Characterisation of drusen by multicolour imaging findings and correlation with conventional imaging methods

M. Gkika, N. Vallabh, C. Parkes, G. Hebbar, J. Sahni UK In vivo spectral imaging characteristics of choroidal naevi

A. Goktas TURKEY Flourescein angiographically confirmed reperfusion of occluded branch retinal artery following treatment

P. Gouveia, S. Estrela-Silva, F. Falcão-Reis PORTUGAL Vascular factor as a cause for open-angle glaucoma progression

P. Gouveia, S. Estrela-Silva, E. Brandão, F. Falcão-Reis PORTUGAL Leber hereditary optic neuropathy- a case report

A. Gruener, Z. El Housseini, M. Jeffries, M. Mohamed, L. Whitefield UK Rising incidence of 'poppers maculopathy' in the south of England

R. Prabhu, A. Patel, R. Sivaraj UK Choroidal and retinal findings in a patient with immunotactoid glomerulonephritis

L. Gutiérrez Benítez, M. Rubio Caso, L. Arias Barquet, J. Caminal Mitjana SPAIN An easy method to measure en face damaged macular area by spectral domain optical coherence tomography

M. Guzey, Y. Isik, O. Yilmaz, E. Dogan TURKEY Comparison of heidelberg retinal tomograph III and optical coherence tomography in the assessment of diabetic diffuse macular edema

L. Herrera, I. Pinilla, I. Perez, D. Perez, C. Almenara, K. Zabadani, J. Ascaso SPAIN Choroidal thickness in normal paediatric population meassured by enhanced depth imaging optical coherence tomography

L. Herrera, N. Cruz, K. Zabadani, J. Ascaso, C. Caramello, I. Pinilla, C. Almenara SPAIN Optical coherence tomography as a progression marker in mild cognitive impairment and Alzheimer's disease

T. Hidalgo Diaz, M. Morillo Sanchez, R. Kamal Salah SPAIN Macular changes in tilted disk syndrome

M. Hood, J. Calzada, E. Sigler, P. Brennen USA Localized inner macular atrophy as a predictor of neovascularization in sickle cell retinopathy

H. Huang, S. Wei, Y. Zhang CHINA Pananeoplastic retinopathy and optic neuropathy- the first Chinese study

Y. Imamura, K. Hashizume, T. Fujiwara, S. Machida, M. Ishida, D. Kurosaka JAPAN Choroidal thickness and retinal pigment epithelium striations in Vogt-Koyanagi-Harada disease as detected by enhanced depth imaging optical coherence tomography

A. Ivanescu, A. Tinu, M. Hiranandani, R. Kanitkar, D. Assheton, D. Yussuf UK The importance of a careful analysis of the visual field test and the management of urgent neurosurgical treatment

V. Jaksic, M. Stamenkovic, M. Mavija, D. Risimic, I. Sencanic SERBIA Fundus autofluorescence findings in pigmented paravenous chorioretinal atrophy

J. Jolly, M. Groppe, R. MacLaren UK Repeatability of qualitative analysis of autofluorescence imaging in patients with choroideremia

R. Kamal Salah, M. Morillo Sánchez, T. Hidalgo Díaz, A. Gonzalez Escobar SPAIN The effect of peripapillary detachment on retinal nerve fibre layer measurement in high myopia

S. Khochtali, I. Ksiaa, R. Kahloun, J. Nemria, S. Ben Yahia, S. Zaouali, M. Khairallah TUNISIA Indocyanine green angiography findings in patients with hereditary hemorrhagic telangiectasia syndrome - 2 cases



A. Kidess, D. Trivedi, A. El Salloukh, P. Dutt, P. Keane, M. Tsaloumas, A. Denniston UK Measurement bias between optical coherence tomography instruments in diabetic macular edema- implications for treatment

S. Koshy, S. Efraimidis, H. Eleftheriadis UK Inner nuclear layer microcysts in eyes with chronic optic neuropathy

S. Kucukbay Yilmaz, M. Ture, M. Helvacioglu, A. Saklamaz TURKEY Morphologic changes in the foveal photoreceptor layer before and after laser treatment vs bevacizumab treatment in acute central serous chorioretinopathy documented in spectral-domain optical coherence tomography

P. Kumar, A. Brent, T. Empselidis UK Central serous chorioretinopathy (CSR) secondary to a shuttlecock injury

T. Lalias, E. Kanonidou GREECE Complete stationary night blindness with normal fundus, moderate myopia and no visual acuity reduction. The significance of electrodiagnostics and genetic testing and counselling

S. Lee, L. Lim, G. Cheung SINGAPORE Enhanced visualisation of retinal and choroidal changes in myopic eyes with SS-OCT

V. Loo, Y. Yew, V. Subrayan MALAYSIA In-vivo choroidal thickness assessment in patients with type II diabetes mellitus

E. Loukianou CYPRUS Nicotinic acid maculopathy- case report

E. Loukianou CYPRUS Basal laminar drusen- case presentation

L. Low, K. Oswal, A. Lau, S. Rauz UK Screening for hydroxychloroquine toxicity

J. Marin, I. Yago SPAIN Intraoperative OCT findings in two cases of bilateral macular coloboma in children

J. Mentes, Z. Oztas, H. Ates, S. Nalcacı TURKEY Three-dimensional optical coherence tomography imaging of glaucomatous optic nerve head associated with schsis-like maculopathy

S. Natarajan, D. Gupta, P. Kulkarni, P. Valvekar, J. Garg, R. Krishnan INDIA Utility of an indigenous portable fundus camera for the screening of diabetic retinopathy in the diabetic population in slum areas of Mumbai

S. Nath, J. Sherman, S. Hossain, M. Ambwani, A. Nath, K. Nath USA Hyper-pigmentation underlying areas of epicenters of epi-retinal membrane (ERM) have not been defined before. RHA multi- spectral en face imager is a new LED device that uses mono chromatic spectral imaging to pick up early RPE abnormalities

P. Neves, R. Brito, C. Bacalhau, M. Santos, D. Martins PORTUGAL The role of OCT in the early diagnosis of arterial branch occlusions- a case report

M. Núñez, M. Mendivil, I. Bearan SPAIN Review of serpiginous choroiditis in our service

Y. Okamoto, F. Okamoto, S. Nakano, T. Oshika JAPAN Ultrasound biomicroscopic morphometric analysis of normal human ciliary body

K. Örnek, Z. Onaran, R. Oğurel TURKEY Retinoschisis and multifocal retinal detachment associated with tilted disc syndrome

S. Pastor-Idoate, M. Gil-Martinez, N. Crim, S. Charles, S. Biswas, D. McLeod, P. Stanga UK Sweep-source optical coherence tomography and wide-field fundus fluorescein angiography imaging of retinal cavernous haemangioma- a new diagnostic imaging gold standard?

M. Pefkianaki, A. Moore UK Optic disc pit maculopathy in children – findings-management

I. Perente, Z. Alkin, A. Ozkaya, A. Yazici, A. Demirok TURKEY Early visual and morphologic changes after half-fluence photodynamic therapy in chronic central serous chorioretinopathy

F. Pichi, F. Bonsignore, P. Carrai, A. Scorza, P. Nucci ITALY Wide-field spectral-domain optical coherence tomography

N. Rachwani, M. Morillo-Sánchez SPAIN Optical coherence tomography features in the evolution of acute central serous chorioretinopathy with spontaneous resolution

M. Richardson, R. Mathew, S. Sivaprasad UK Optimum pattern acquisition using spectral domain optical coherence tomography for mild diabetic macular edema

M. Rubio Caso, E. Cobos Martin, I. Flores Moreno, M. Vidal Martí, A. Muñoz Blanco, L. Arias Barquet, J. Caminal Mitjana SPAIN Choroidal thickness in retinal dystrophies. A swept-source optical coherence tomography study

J. Ruiz-Medrano, I. Flores-Moreno, J. Montero-Moreno, J. Ruiz-Moreno SPAIN Findings in the study of optic disc colobomas by swept-source optical coherence tomography

A. Sengul, R. Rasier, O. Artunay TURKEY Influence of flickering light on the retinal vessels in patients with subconjunctival hemorrhage

G. Seymenoglu, F. Ballı, E. Başer TURKEY The natural history of lamellar macular holes- a spectral domain optical coherence tomography study

A. Sharma, J. Sheth, R. Madhusudan, N. Vidhya, S. Sundaramoorthy, J. Patil INDIA Prevalence of pigment epithelial detachment in cases of central serous retinopathy (CSR) in Asian Indians

R. Singh, A. Invernizzi, A. Agarwal, N. Kumari, A. Gupta INDIA Enhanced depth imaging spectral domain optical coherence tomography versus ultrasonography B-scan for measuring retinochoroidal thickness in normal eyes

K. Spiteri Cornish, P. Chua, V. McBain UK Fundus autofluorescence in the diagnosis of pattern dystrophy

K. Spiteri Cornish, P. Chua, V. McBain UK The natural progression of pattern dystrophy on autofluorescence



A. Tan, R. Png, A. Chia SINGAPORE The diagnosis and assessment of visual function in children with electrophysiology

D. Taye, A. Sharma, B. Tyagi INDIA Bilateral nanophthalmos, uveal effusion and optic disc drusens- a rare presentation

J. Torres-Peña, J. Campos-Pavón SPAIN Choroidal neovascularitazion secondary to choroideremia

Y. Totan, M. Dervişoğulları, E. Güler, A. Yüce TURKEY Tomographic analysis of retinal nerve fiber and ganglion cell layers in chronic heavy smokers

N. Ulyanova UKRAINE New approach to the macula morphometric evaluation in high axial myopia by spectral optical coherence tomography

Z. Vatavuk, L. Dujmovic, G. Bencic, B. Andrijevic Derk CROATIA The role of widefield angiography in evaluation of retinal changes in patients with retinitis pigmentosa

L. Vieira, M. Lisboa, A. Cabugueira, R. Lino, A. Amaral, M. Marques, R. Flores PORTUGAL Choroidal thickness in branch retinal vein occlusion

Y. Yamaguchi, T. Otani, S. Kishi JAPAN En face image of macular capillary network

I. Yeung, C. Cheung, T. Chan, L. Lu, N. Fung, Y. Hwang, I. Wong HONG KONG Ultra-widefield (Optos) fluorescein angiography in cytomegalovirus (CMV) retinitis

S. Zachariah, W. Wykes UK Does optical coherence tomography make retinal screening in diabetes more efficient?

M. Zapata, G. Arcos, A. Fonollosa SPAIN OPTretina, telemedicine for a broad population screening of retinal diseases from optical centers- one ophthalmologist behind each non-mydriatic camera

Intraocular TumoursM. Abrishami, F. Ghassemi, Z. Vahedian IRAN Anterior chamber keratinous horn

A. Arora, V. Cohen, J. Hungerford UK 'A tale of two tumours' - conjunctival melanoma with PAM presenting in a patient with treated choroidal melanoma

A. Arora, K. Hammamji, E. Reich, E. Pavlidou, K. Kopsidas, V. Cohen, M. Sagoo UK Visual loss from choroidal melanoma mimicking neurological syndrome

A. Arora, V. Papastefanou, J. Hungerford, V. Cohen UK Choroidal metastasis from follicular cell thyroid carcinoma masquerading as circumscribed choroidal haemangioma

C. Bacalhau, M. Santos, R. Brito, P. Neves, D. Martins PORTUGAL Choroidal pigmented lesions – EDI-OCT and en face OCT

D. Balatsoukas, E. Kanonidou, I. Zampros GREECE Incidental isolated occurence of retinal astrocytoma without other ocular or systemic comorbidity

P. Beirão Cardoso Quadrado Gil, E. Costa, J. Pires, R. Matos, M. Mariano PORTUGAL Ophthalmological signs as a first clue to an atypical von-Hippel-Lindau presentation

E. Chan, L. Shen, G. Sundar, C. Chee SINGAPORE Retinoblastoma incidence trends in Singapore from 1968 to 2012- data from the Singapore cancer registry

P. Coelho, R. Carvalho, J. Serino, B. Vieira, C. Menezes, J. Lemos, R. Gonçalves PORTUGAL Optic disc melanocytoma – Three clinical cases with a brief review

B. Eldem, S. Kadayifcilar TURKEY Choroidal neovascularization in choroidal osteoma

C. Ferreira, J. Pinheiro-Costa, M. Falcão, S. Penas, T. Bragança, E. Brandão, Â. Carneiro PORTUGAL Diagnostic challenge in retina

S. Ganesan, V. Khetan, T. Sharma INDIA Intraocular infection masquerading as retinoblastoma clinically and in magnetic resonance imaging – diagnostic challenge

J. Kalliath, D. Shukla INDIA Fundus autofluorescence findings in combined hamartoma of retina and retinal pigment epithelium

L. Konstantinidis, E. Damato, H. Heimann, S. Coupland, B. Damato UK Choroidal schwannoma

S. Lee, H. Kim, C. Lee, J. Lee, H. Kang SOUTH KOREA Pars plana vitrectomy for vitreoretinal complications in Korean patients with choroidal melanoma after ruthenium-106 brachytherapy

D. Maris, K. Karathanou, E. Tsironi GREECE Blurred vision as an initial presentation of lung malignancy. A case presentation

C. Menezes, J. Martins, R. Carvalho, C. Teixeira, M. H Abreu, A. Rodrigues, M. Soares PORTUGAL Bilateral diffuse uveal melanocytic proliferation (BDUMP)- markedly asymmetric presentation and response to systemic chemotherapy

P. Morales, F. Chait, F. Spencer, M. Navarro SPAIN Effective criotherapy for treatment of retinal choroidal hemangioma in Von Hippel-Lindau disease, a 12 month follow-up

N. Qureshi, S. Zafar, A. Pathan, S. Islam, N. Qureshi PAKISTAN Incidence and observation of clinical manifestation and course of choroidal osteoma in a community setting based on a tertiary care eye hospital

N. Qureshi, S. Zafar, A. Pathan, S. Islam, N. Qureshi PAKISTAN Clinical manifestation and therapeutic implication of combined effects of laser photocoagulation,intravitreal bevacizumab and post subtenon triamcinolone acetonide in cases of retinal capillary haemangioma

P. Rao UNITED ARAB EMIRATES Combination of photodynamic therapy using verteporfin and intravitreal ranibizumab injection used for the treatment of symptomatic circumscribed choroidal hemangioma



F. Rodrigues, M. Ruão, F. Trindade, R. Pereira, S. Moniz PORTUGAL Uveal metastasis- Initial demonstration of a lung cancer

M. Santiago, M. Bande Rodriguez, M. Blanco-Teijeiro, P. Mera, C. Capeans, M. Pardo Perez, A. Pineiro Ces SPAIN Silencing of PARK7/DJ-1 gene by siRNA inhibits uveal melanoma cell proliferation in vitro

I. Seibel, A. Hager, A. Riechardt, J. Klein, A. Joussen GERMANY Long-term results after proton beam therapy for papillary capillary hemangioma

MiscellaneousM. Carbonell Puig, S. Ruiz Bilbao, P. Romera Romero SPAIN Retinal vascular occlusion as the first manifestation of Takayasu's arteritis

T. Empeslidis, V. Konidaris, K. Tsaousis, P. Kumar UK Dexamethasone 0.7mg intravitreal implant in non infectious uveitis

N. Farmakakis, M. Papalamprou, O. Makri, C. Georgakopoulos, A. Exarchou GREECE Batten disease/juvenile neyronal ceroid lipofuscinoses (JNCL)- case report and literature review

I. Gama, L. Almeida, M. Monteiro-Grillo PORTUGAL Stargardt disease - an interesting clinical case

A. Hajjar, E. Ortega, E. Salinas, N. Mendieta, M. De Las Heras, S. Eguiza SPAIN First results after photodynamic therapy for a symptomatic choroidal hemangioma previously masquerading as amblyopia and later mimicking best vitelliform dystrophy

M. Kadifachi, M. Dogromaci, S. Rassam UK Retinal arterial shunts- a new finding

T. Kida, N. Ishizaki, S. Morishita, M. Fukumoto, H. Suzuki, T. Ikeda JAPAN Changes of macular OCT findings in retinal arterial occlusion

H. Kim, H. Kang, D. Lee, C. Lee, J. Lee, S. Lee SOUTH KOREA Therapeutic outcomes of retinal capillary hemangioblastomas

G. Levytska UKRAINE Increased concentration of amino acids in the vitreous fluid in patients with rhegmatogenous retinal detachment after vitrectomy

G. Pappas, A. Agelakis, G. Bastakis GREECE The aflibercept action in registrant to treat AMD cases

P. Rao UNITED ARAB EMIRATES Intravitreal ranibizumab in choroidal neovascularisation in children and adolescents

M. Stefaniotou, E. Christodoulou, K. Gorgoli, A. Dimitriou, E. Vourda GREECE Accidental macular laser burn in physics laboratory

M. Stefaniotou, E. Christodoulou, I. Koumpoulis, K. Gorgoli, M. Papakitsos GREECE Pneumatic retinopexy for the treatment of retinal detachment in phakic and pseudophakic eyes

P. Szurman, S. Kazerounian, M. Waizel, K. Boden GERMANY A single-centre study of ocriplasmin in a homogenous group of patients with vitreomacular traction

L. Vieira, N. Silva, A. Vicente, A. Cabugueira, R. Anjos, R. Flores, V. Maduro PORTUGAL Bilateral serous macular detachment- a presenting sign of acute lymphoblastic leukemia

L. Vieira, A. Cabugueira, N. Silva, B. Borges, L. Lima, P. Afonso, R. Flores PORTUGAL Valsalva retinopathy in pregnancy- a case report

New Drug Treatment and TechnologyR. Abreu, L. Solé, D. Hernández, M. Alonso, M. Gil, P. Abreu SPAIN Prevalence of vitreomacular traction, associated or not to a macular hole, in a Spanish reference hospital

I. Alarcón Valero, D. Vilaplana i Blanch, V. Poposki, O. Martínez-Giralt, X. Acebes Roldan SPAIN The role of photodynamic therapy in central serous chorioretinopathy

C. Arndt, T. Garcia, C. Radoi FRANCE Intravitreal triamcinolone injections in non arteritic anterior ischemic optic neuropathy

A. Aurora INDIA Clinical and lab evaluation of novel needle trocar cannula with proprietary metallic trocar cannula

M. Barman, H. Bhattacharjee, S. Deka, R. Soibam INDIA Intravitreal dexamethasone implant in central retinal vein occlusion (CRVO)- efficacy and safety

T. Bertelmann, T. Stief, S. Schulze, W. Sekundo GERMANY Intravitreal soluble opsins

T. Bicer, M. Cakar Ozdal TURKEY Retrobulbar neuritis related to duloxetine usage

A. Brent, S. Ch'ng, L. Lebens, J. Riley, S. Banerjee UK A dummies guide to setting up an ocriplasmin service in a UK hospital. There is more that meets the eye than just a needle!

P. Busatto, G. Driussi, G. Beltrame ITALY The use of dexamethasone slow-release implant in chronic macular edema of vitrectomized eyes previously affected by macular pucker

J. Chhablani, R. Narayanan, A. Mathai, R. Pappuru, S. Jalali INDIA Outcomes of intravitreal dexamethasone implant in real-life situations

J. Chhablani, A. Mathai, P. Kumari, F. Arevalo, V. Gupta, I. Kozak INDIA Comparison between navigated pattern and conventional pattern for pan retinal photocoagulation

J. Chhablani, P. Rani, A. Mathai, S. Jalali, I. Kozak INDIA Navigated focal laser photocoagulation for central serous chorioretinopathy



M. Colaço, M. Franco, C. Pereira, J. Neves, I. Gomes, R. Pinto, J. Maia Seco PORTUGAL Atypical optical coherence tomography findings in tamoxifen retinopathy

I. Contreras SPAIN Ozurdex for macular edema in retinitis pigmentosa-a case report

L. Di Antonio, P. Mattei, A. Mastrocola, C. De Nicola, A. Mastropasqua, L. Mastropasqua ITALY Intravitreal dexamethasone implants in patients with treatment naïve diabetic macular edema- a morphofunctional evaluation

T. Diago, J. Tomás, C. Vilela, M. Diago SPAIN Study of the retina of patients with Hepatitis C virus treated with direct-acting antiviral (new drug)- preliminary results

V. Gogia, A. Kumar, N. Midha INDIA Efficacy of oral valproic acid in patients with retinitis pigmentosa

A. Goktas TURKEY Splitting of a dexamethasone implant (Ozurdex) immediately after the injection

A. González-Gómez, M. Morillo Sánchez, A. Soler García SPAIN Choroidal neovascularization secondary to pseudoxanthoma elasticum treated with ranibizumab- evolution during 40 months

A. Grzybowski POLAND Edward Nettleship (1845-1913) – important British ophthalmologist in 100 years since his death

A. Insausti-García SPAIN Approach of subretinal and suprachoroidal space. Experimental study

S. Jha, N. Panwar, C. Malik INDIA ' Laser –i' an ophthalmic teaching device

S. Kadayifcilar, B. Eldem TURKEY Treatment of macular edema secondary to retinitis pigmentosa with intravitreal dexamethasone implant

V. Kanyukov, D. Ilyukhin RUSSIA Lasik in correction of hypermetropic refraction after previous radial keratotomy. Case report

Z. Koshy UK In vivo dispersion of intravitreal injection in eyes without a vitreous detachment

F. Kretz, K. Linz, G. Auffarth GERMANY Fluocinolone acetonide intravitreal implant for diabetic macular edema- a case report of a patient with a therapy resistant diabetic maculopathy

C. Kucukerdonmez, E. Cinar, M. Zengin, S. Selim, E. Erakgun TURKEY Effectiveness of dexamethasone intravitreal implant in refractory macular edema due to retinitis pigmentosa

M. Kuze, M. Ayaki, K. Tsubota, T. Morita JAPAN Effect of age on the electroretinogram from intrinsically photosensitive retinal ganglion cells in humans

P. Lanzetta ITALY Improved vision-related functionality in patients with symptomatic vitreomacular adhesion, after intravitreal ocriplasmin injection – analyses from TG-MV-006 and TG-MV-007

V. Lozano-Lopez, M. Serrano-Garcia, A. Abreu-Reyes, C. Pinto-Herrera SPAIN Treatment of infantile idiopathic juxtafoveolar telangiectasia, in the spectrum of Coats’ disease

L. Lu, Y. Shweikh, D. Mitry, R. Zakir UK Anatomical and visual outcomes following intravitreal Ocriplasmin® treatment for symptomatic vitreomacular traction

P. Lyskin, O. Lozinskaya RUSSIA Normal self-renewal of human vitreous fibrils as a result of the synthesizing activity of vitreous hyalocytes (in view of the human hyalocytes morphofunctional analysis findings)

S. Michels, S. Lacey, J. Michaud, J. Sigg, L. Boado, M. Picci SWITZERLAND Characteristics and potential benefits of the ranibizumab pre-filled syringe

S. Mishra, A. Gupta, J. Parihar, R. Maggon, S. Kumar, A. Singh INDIA Combination therapy with bevacizumab and dexamethasone intravitreal implant vs dexamethasone implant alone in patients with retinal vein occlusion(RVO)

J. Montero-Moreno, A. Merino-Iglesias, S. Perez-Martin, C. González Urueña SPAIN Factors affecting changes in intraocular pressure after intravitreal injection of bevacizumab

S. Nath, S. Hossain, J. Sherman, M. Ambwani, K. Nath, A. Nath USA Adding decadron to kenalog for intravitreal injection reduces the risk of sterile iritis and hypopyon

K. Ornek, İ. Erbahçeci Timur, T. Oğurel TURKEY Intravitreal dexamethasone implant (Ozurdex) for refractory macular edema secondary to retinitis pigmentosa

T. Ozturk, N. Kocak, M. Kaya, O. Takes, S. Kaynak TURKEY Acute retinal necrosis developed after intravitreal Ozurdex implantation

T. Park, S. Lee, Y. Ohn SOUTH KOREA Time dependent changes of cellular components proliferation after laser photocoagulation in mouse chorioretinal tissue

V. Poposki, D. Vilaplana, I. Jürgens, D. Poposka, A. Dyrda, G. Londoño, M. Castilla SPAIN Stabilizing the blood-retinal barrier with topical treatment

A. Ramezani, B. Safarpour Lima, M. Soheilian, A. Rastegarpoor, D. Roshandel, S. Sayanjali IRAN A successful management of diffuse unilateral subacute neuroretinitis with intravitreal triamcinolone followed by laser photocoagulation

M. Regenbogen, E. Moisseiev, M. Goldstein, A. Loewenstein ISRAEL Evaluation of pain during intravitreal Ozurdex injections versus intravitreal bevacizumab injections

A. Salehi IRAN A double blind clinical trial on the efficacy of honey drop in vernal keratoconjunctivitis

Y. Sullu, N. Kocak, O. Eksi TURKEY Half-dose photodynamic therapy in chronic central serous chorioretinopathy



C. Teixeira, Â. Carneiro, J. Nascimento PORTUGAL Ocriplasmin - the first 3 cases injected in Portugal

N. Umanets, N. Pasyechnikova, U. Vadim, M. Eduard, G. Levitskaya, R. Nazaretyan R, V. Zavodnaya UKRAINE Chorioretinal complex changes after exposure of different modes of high-frequency electric welding of biological tissues compared with diode endolaser coagulation (experimental study)

C. Ünlü, G. Erdogan, T. Aydogan, E. Guney Kardes, B. Sezgin Akcay, T. Bozkurt TURKEY Subfoveal choroidal thickness changes after intravitreal bevacizumab therapy for central serous chorioretinopathy

C. Vale, M. Furtado, M. Macedo, M. Lume, A. Meireles PORTUGAL Long-term results with intravitreal ranibizumab and photodynamic therapy in the management of choroidal neovascularization secondary to angiod streaks

UveitisA. Abraham INDIA Management of intermediate uveitis with a single dose of intravitreal triamcinolone alone

M. Agarwal, V. Jha INDIA Rapidly blinding posterior tubercular uveitis

M. Agarwal, V. Jha INDIA Varied manifestations of ocular tuberculosis

I. Alarcón Valero, G. Londoño, D. Vilaplana i Blanch, V. Poposki, X. Acebes Roldan, J. Blanch SPAIN Panuveitis secondary to actinobacillus actinomycetecomitans endocarditis

J. Beato, L. Figueira, H. Costa, S. Penas, A. Carneiro, E. Brandão, F. Falcão-Reis PORTUGAL Fulminant ocular presentation of subacute sclerosing panencephalitis

J. Beato, L. Figueira, M. Falcão, S. Penas, A. Carneiro, E. Brandão, F. Falcão-Reis PORTUGAL 'White dot syndrome' presenting as cilioretinal occlusion

R. Belfort Jr, C. Muccioli, C. Silveira, R. Nussenblatt BRAZIL The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis – 10 years of follow-up

N. Berker, B. Ceran, P. Ozdal TURKEY An atypical form of ocular toxoplasmosis in a 14-year-old child

O. Budakoglu, M. Cakar Ozdal TURKEY Cat scratch neuroretinitis with severe vision loss

J. Caballero Agudo, I. Yago, M. Hernandez, J. Marin SPAIN Anatomical-functional correlation in acute zonal occult outer retinopathy

C. Chee, A. Kamalden SINGAPORE A case of sympathetic ophthalmia 27 years after initial trauma

E. Coskun, P. Celemler, B. Kisacik, I. Erbagci, U. Aksoy, G. Kimyon, A. Onat TURKEY The results of intravitreal injection of 0.7 mg dexamethasone implant in eyes with active posterior uveitis associated with Behcet's disease

E. Czaplicka, M. KarolczakKulesza, A. Brazert, J. Kociecki POLAND Optic disc granuloma in the course of systemic diseases – diagnostic problems

X. Dameria INDONESIA A case of non-infectious posterior uveitis treated with posterior sub-tenon’s dexamethasone injection

S. Das, D. Das, P. Bhende INDIA Clinical profile and outcome of patients with complicated uveitis undergoing pars plana vitrectomy

S. Das, D. Das, J. Biswas INDIA Clinical profile of posterior scleritis in a tertiary eye centre in Southern India

R. Dolz-Marco, P. Hernández-Martínez, I. Pascual-Camps, M. Andreu-Fenoll, F. Esteves, R. Gallego-Pinazo SPAIN Retinal and choroidal thickness in patients with unilateral multifocal choroiditis

M. Gajdošová, M. Ondrejková SLOVAKIA Optic disc neovascularisation in uveitis associated with juvenile chronic arthritis (JCA)

R. Gonçalves, P. Rodrigues, C. Menezes, J. Lemos, P. Coelho, B. Vieira, J. Serino PORTUGAL Insidious uveitis as a presenting manifestation of sarcoidosis- a case report

A. Gonzalez Escobar, A. Chinchurreta Capote, M. Lorenzo Soto, S. Gismero Moreno, R. Kamal Salah SPAIN Importance of early diagnosis of cytomegalovirus (CMV) retinitis in acquired immunodeficiency syndrome patient (AIDS)

P. Gouveia, L. Torrão, L. Figueira, S. Penas, Â. Carneiro, F. Falcão-Reis PORTUGAL Acute syphilitic posterior placoid chorioretinopathy- spectral domain optical coherence tomography findings

R. Hamam, R. Antonios LEBANON Optic neuritis with severe loss of vision as a first manifestation of Rosai Dorfman disease

L. Hejsek, J. Dusova, A. Stepanov, J. Marak, P. Rozsival CZECH REPUBLIC Pars plana vitrectomy in non-infectious uveitis of the posterior segment

A. Ivanescu, M. Hiranandani, A. Tinu, R. Kanitkar, D. Assheton UK Successful management of presumed candida endogenous endophthalmitis with oral fluconazole

B. Jelliti, R. Kahloun, O. Kharrat, A. Bouabana, R. Messaoud, S. Ben Yahia, M. Khairallah TUNISIA Multimodal imaging for the diagnosis of acute Vogt-Koyanagi-Harada disease without clinically evident exudative retinal detachment

M. Johnson, J. Vallance UK Clinical features of uveitis associated with tattoo inflammation- case series

R. Kahloun, W. Ammari, O. Haj Taher, A. Khlifi, S. Attia, R. Messaoud, M. Khairallah TUNISIA Pattern of acute retinal necrosis in a referral center in Tunisia, North Africa



C. Kalogeropoulos, K. Gorgoli, M. Stefaniotou, A. Christodoulou, I. Koumpoulis, M. Aspiotis GREECE Incidence of macular epiretinal membrane in patients with uveitis- a 5-year retrospective study

R. Kamal Salah, E. Jimenez Rodriguez, P. Rivera de Zea SPAIN Effectiveness and possible complications of Ozurdex® as a treatment of noninfectious posterior uveitis

E. Kanonidou, P. Kikas, I. Salonikou, A. Alexandrakis, G. Sakkias GREECE Acute progressive visual loss related to intraocular inflammation. The return of the 'great imitator'

E. Kanonidou, I. Salonikiou, P. Kikas, F. Lahanas, G. Sakkias GREECE Uveitis related to antiglaucoma medication, pressure lowering effect fluctuation and glaucoma surgery. Management dilemmas

A. Karatay Arsan, A. Oflaz, C. Agalar, M. Şimsek TURKEY Long term follow-up of CMV retinitis treated with oral valganciclovir in a young immunocompetent patient

M. Khairallah, S. Khochtali, F. Gatfaoui, M. Chaabane, A. Ben Abdallah, S. Attia, R. Messaoud TUNISIA Pattern of Vogt-Koyanagi-Harada disease in children

H. Khalil, H. Raafat EGYPT The effectiveness of infliximab in controlling uveitis in Behçet's disease following vitrectomy operation

Y. Khan, E. Carreno, S. Fernandez-Perz, H. Von Lany, R. Lee, A. Dick, A. Ross UK Immune mediated chorioretinopathy secondary to ipilimumab therapy

D. Khatri, M. Rajan, K. Nachiappan, R. P J, S. Gopal, N. Madhivanan, R. Agarwal INDIA Advances in endophthalmitis management

S. Khochtali, S. Anene, N. Ben Abdesslem, N. Lahmar, B. Jelliti, S. Zaouali, M. Khairallah TUNISIA Choroidal neovascularization associated with uveitis in a referral center in Tunisia

H. Kolli, M. Mohyudin, P. Stavrou, H. Kolli UK Subtenon triamcinalone injection in the management of macular edema in uveitis

D. Kovacevic Pavicevic, A. Radosavljevic, A. Ilic, N. Kosanovic Jakovic, I. Kovacevic, Z. Abazi SERBIA Systemic corticosteroids in treatment of punctate inner choroidopathy

D. Kovacevic Pavicevic, A. Radosavljevic, A. Ilic, N. Kosanovic Jakovic, I. Kovacevic, Z. Abazi SERBIA Combined corticosteroid and immunosuppressive therapy in treatment of serpiginous choroiditis

M. La Cava, P. Tortorella, E. D'Ambrosio, F. De Marco, E. Santoro, L. Iannetti ITALY Correlation between visual acuity and inner segment/outer segment junction and cone outer segment tips line integrity in uveitic macular edema

I. Leal, C. Loureiro, A. Fonseca, E. Neto, C. Ferreira PORTUGAL Sympathetic ophthalmia following orbital exenteration- an unusual case report

V. Lemos, A. Cabugueira, M. Noronha, R. Flores, P. Ferreira, J. Branco PORTUGAL Tuberculosis presenting as retinal vasculitis

G. Lopez Valverde, M. Cordero Coma, P. Ibañez Ayuso, N. Spagnoli Santa Cruz, L. Monje Fernandez SPAIN Macular ischaemia in posterior uveitis

S. Mahmood, J. de Zaeytijd, M. Michaelides, A. Moore UK Benign retinal pigmentary changes with sensorineural deafness

S. Mahuli, V. Arora INDIA Intravitreal dexamethasone implant in sympathetic ophthalmia

F. March, P. López Lizárraga, M. Pedrosa SPAIN Bilateral necrotizing scleritis in a patient with Syphilis

F. March, P. Lopez Lizarraga, A. March de Ribot, F. Graue Wiechers SPAIN Bilateral diffuse granulomatous intraocular inflammation after an anterior segment intervention

K. Mousavi, M. Rodriguez, J. Gallardo, M. Barbany, J. Casado, S. Moreno SPAIN Effectiveness of infliximab in refractory serpiginous choroiditis

M. Munk, R. Ram, V. Setlur, A. Rademaker, F. Chau, U. Schmidt-Erfurth, D. Goldstein AUSTRIA Influence of the vitreomacular interface on the efficacy of intravitreal therapy for uveitis associated cystoid macular edema

N. Munoz Sanz SPAIN A case of Susac syndrome- a rare autoimmune microangiopathy

G. Murthy, S. Deshpande, P. Solanki INDIA Post infectious neuro retinintis -to treat or not?

A. Neves, A. Cardoso, S. Mendes, J. Campos, A. Campos, J. Sousa PORTUGAL Unilateral Vogt-Koyanagi-Harada (VKH) disease- a clinical case report

J. Nobre-Cardoso, A. Cardoso, A. Miranda, N. Marques, S. Barros, B. Beltrán, N. Campos PORTUGAL Treatment of an atypical case of posterior uveitis with anti-TNF in a paediatric patient with ocular sarcoidosis

P. Ozdal, F. Koc, H. Tırhıs TURKEY Dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion or non-infectious uveitis

T. Ozturk, N. Kocak, M. Kaya, O. Takes, S. Kaynak TURKEY Evaluation of intraretinal hyperreflective foci density with SD-OCT after intravitreal ozurdex implantation in patients with macular edema secondary to uveitis

Y. Ozyazgan, E. Seyahi, D. Ucar, S. Ugurlu, V. Hamuryudan, H. Yazici TURKEY Interferon treatment in Behçet’s syndrome (BS) with severe ocular involvement

A. Pastor Vivas, F. García-Franco Zuniga SPAIN Debut with an anterior ischemic optic neuropathy in a patient with neurosyphilis

C. Pereira, M. Franco, L. Colaço, J. Neves, S. Rodrigues, F. Fraga, H. Prior Filipe PORTUGAL Ocular syphilis- case report



A. Radosavljevic, D. Kovacevic Pavicevic, A. Ilic, D. Risimic, N. Kosanovic Jakovic SERBIA Multifocal tuberculous choroiditis complicated by choroidal neovascular membrane

P. Rao UNITED ARAB EMIRATES Stenotrophomonas maltophilia endophthalmitis after intraocular lens implantation

M. Rego, M. Almeida, A. Travassos, C. Canha, J. Veríssimo, R. Proença PORTUGAL Clinical features of tuberculous serpiginous-like choroiditis versus autoimmune serpiginous choroiditis

P. Romera Romero, S. Ruiz Bilbao, M. Carbonell Puig SPAIN Retinal involvement in a patient with Burkitt lymphoma

F. Rosales Villalobos, P. Rivera de Zea, A. González Gómez, J. Sandoval Codoni SPAIN Neurosensory macular detachment in multiple evanescent white dot syndrome

O. Ruiz-Moreno, P. Calvo, B. Abadia, J. Leciñena, C. Torrón SPAIN Intravitreal ranibizumab for the treatment of choroidal neovascularization in multifocal choroiditis

M. Soylu, F. Uzunoğlu TURKEY Corticosteroid-induced central serous chorioretinopathy in patients with ocular toxoplasmosis

A. Subramanyam, S. Sawant, V. Dave INDIA Prevalence and treatment outcomes of ocular tuberculosis(TB) in Western India

A. Tomi, I. Stefan, D. Nastase ROMANIA Bilateral chorioretinal scars – a case report

A. Vicente, A. Santos, A. Cabugueira, B. Borges, R. Anjos, M. Lisboa, I. Domingues PORTUGAL Toxoplasma uveitis in HIV-positive patients- a retrospective comparative study

I. Yago, J. Marin, A. Minguez SPAIN Choroidal neovascularisation of inflammatory origin in early infancy- differential diagnosis

I. Yago, J. Caballero Agudo, A. Piñero, J. Marin SPAIN Atypical presentation of Vogt-Koyanagi-Harada syndrome (VKH) in infancy

O. Zborovska, N. Pasyechnikova, O. Dorokhova, D. Elena UKRAINE Clinical study of the effectiveness of photodynamic therapy in treatment of inflammatory diseases of eye

Vascular Diseases and Diabetic RetinopathyM. Abdul Karim, R. Singh, P. Ashwin UK Spontaneous closure of macular retinoshisis resulting from an optic disc cleft associated with a myopic disc

R. Abreu, L. Pérez, L. Solé, M. Alonso, M. Gil, P. Abreu SPAIN Serum hemoglobin (HbA1c) influence and diabetic macular edema improvement measured by OCT in patients treated with intravitreal ranibizumab

M. Abrishami, N. Shoeibi, M. Balali-Mood IRAN Sulfur mustard exposure and non ischemic central retinal vein occlusion

M. Abushaala, C. Sanghvi UK Intravitreal ranibizumab in treating diabetic macular edema

M. Abushaala, C. Sanghvi UK The effect of intravitreal ranibizumab in treating diabetic macular edema

A. Ahmed, R. Staff, P. Gibbs, S. Philip UK Referable maculopathy prediction using texture analysis in retinal images of screening data

S. Aki, A. Altun, A. Arsan, H. Kokcen, S. Kurna TURKEY Comparing short term effectiveness of intravitreal bevacizumab and dexamethasone implant in retinal vein occlusion

R. Almeida, F. Rodrigues, M. Ruão, M. Amorim, J. Chibante-Pedro PORTUGAL Central retinal vein occlusion in an 18-year-old girl- a case report

R. Almeida, M. Ruão, F. Rodrigues, M. Amorim, J. Chibante-Pedro PORTUGAL Hypertensive retinopathy- case report

H. Ainashar EGYPT The role of optical coherence tomography in the diagnosis of ischemic diabetic maculopathy

R. Arroyo, N. Olivier, E. Quintanilla SPAIN Evaluation of a teleophthalmology programme for diabetic retinopathy screening

O. Artunay, A. Sengul, A. Koytak, E. Ayıntap, E. Oner TURKEY Comparison of intravitreal injection of triamcinolone acetonide versus dexamethasone intravitreal implant in patients with macular edema due to central retinal vein occlusion

T. Asai, Y. Ikuno, K. Nishida JAPAN Switching to intravitreal aflibercept in poor responders to multiple bevacizumab for myopic choroidal neovascularization

F. Ascaso, K. Zabadani, L. Herrera, C. Caramello, C. Almenara, N. Cruz, J. Cristóbal SPAIN Choroidal changes in relation to levels of hemoglobin A1c and duration of disease in diabetic macular edema

E. Aydin TURKEY Intravitreal bevacizumab combined with or without 532 nm transpupillary laser therapy for Type I retinopathy of prematurity

B. Bakbak, B. Turgut Ozturk, S. Gedik, S. Gonul, S. Okudan TURKEY Bilateral occlusive perivasculitis

D. Balakrishnan, A. Sudhalkar, S. Jalali, R. Narayanan INDIA Role of systemic steroids in the management of idiopathic polypoidal choroidal vasculopathy (IPCV) – a comparative case study

D. Balatsoukas, E. Kanonidou, C. Skatharoudi, I. Zampros GREECE Degenerative myopia. Does fundus related pathology threaten the optimal vision correction by refractive surgery?

J. Bleier, S. Régnier UK Frequency of ophthalmologist visits for patients starting ranibizumab treatment for visual impairment due to macular edema secondary to central retinal vein occlusion- an analysis of US clinical practice data



P. Bompastor Ramos, S. Carrasquinho, S. Teixeira, J. Rosendo, O. Berens, A. Pepo, A. Candeias PORTUGAL Retinopathy of prematurity screening – challenges and opportunities with Retcam

P. Bompastor Ramos, A. Ramalho, J. Rosendo, A. Pepo, A. Candeias PORTUGAL Choroideremia- differences between carriers and affected members

I. Boras, V. Cerovic CROATIA Intraoperative bevacizumab application for treatment of diabetic macular edema

T. Borges, M. Neves, R. Massa, M. Furtado, M. Gomes, M. Lume, A. Meireles PORTUGAL Long-term outcomes in patients with branch retinal vein oclusion treated with anti-VEGF

T. Borges, S. Monteiro, I. Casal, M. Furtado, M. Gomes, M. Lume, A. Meireles PORTUGAL Half-dose photodynamic therapy for acute central serous chorioretinopathy

D. Branisteanu, D. Costin, A. Moraru ROMANIA Vitrectomy influence on persistent non-tractional diabetic macular edema

R. Brito, C. Bacalhau, P. Neves, M. Ornelas, D. Martins PORTUGAL Quinine toxicity – two rare clinical cases

R. Brito, C. Bacalhau, N. Pedro, O. Mário, D. Martins PORTUGAL Malignant hypertension – two clinical cases

I. Byon, M. Shin, S. Park, J. Lee SOUTH KOREA Choroidal thickness in branch retinal vein occlusion with macular edema

A. Cabugueira, B. Borges, V. Lemos, M. Cardoso, R. Flores, M. Marques PORTUGAL Sickle cell retinopathy- two case-reports

Z. Cebeci, D. Yildiz Ekinci, N. Kir TURKEY Familial exudative vitreoretinopathy- our follow-up and treatment outcomes

N. Celik, J. Kopitz, G. Auffarth, S. Dithmar GERMANY Vitreal levels of pro- and anti-inflammatory cytokines in patients with idiopathic epiretinal membrane and macular hole

I. Chatziralli, A. Agorastos, M. Charalambidis, Z. Migkos, P. Dimitriadis, M. Moschos, P. Kiryttopoulos GREECE Malondialdeyde as an index of oxidative stress in insulin-dependent type II diabetic patients with diabetic retinopathy

I. Chatziralli, T. Sergentanis, M. Moschos, A. Jaulim, P. Dimitriadis, P. Mitropoulos, P. Kiryttopoulos GREECE Intravitreal ranibizumab for central serous chorioretinopathy

S. Chawla INDIA Efficacy of dexamethasone implant in diabetic macular edema – a retrospective real world evidence

S. Choi, K. Hong, Y. Kim, K. Kim SOUTH KOREA Management of macular edema and/or macular detachment secondary to retinal artery macroaneurysms

H. Cilliers, U. Thakur UK Intra-vitreal dexamethasone / Ozurdex implant in retinal vein occlusions review of efficacy and safety in clinical practice 1 year results

H. Cilliers, U. Thakur UK Intra-vitreal dexamethasone / Ozurdex implant in retinal vein occlusions review of efficacy and safety in clinical practice 1 and 2 year results

A. Cordes, H. Furjani, H. Koch GERMANY Efficacy of dexamethasone implant (Ozurdex©) after failed anti-VEGF therapy in a patient with chronic diabetic macular edema

R. Couceiro, C. Loureiro, A. Fonseca, H. Proença, M. Monteiro Grillo PORTUGAL Simultaneous arterial and venous retinal occlusions- a case report

R. Crosby-Nwaobi, K. Bibi, V. Rocco, M. Clemo, P. Hykin, S. Sivaprasad UK Response of visual functions in patients with retinal diseases after multiple xanthophyll supplementation

K. Darrad, W. Fusi-Rubiano, B. Gonglore, A. Bhatnagar UK Intravitreal ranibizumab for diabetic macular oedema (DMO) – initial results in a clinical setting in the UK

A. De Casas, S. Abenza, J. Elvira SPAIN Interferon beta 1a retinopathy in a patient with multiple sclerosis

N. Demircan, E. Esen, S. Sizmaz TURKEY Two cases of acute endophthalmitis following intravitreal dexamethasone implant injection

L. Di Anotonio, L. Toto, R. Mastropasqua, S. Sergiacomo, A. Mastropasqua, E. Doronzo, L. Mastropasqua ITALY MicroRNAs in the modulation of diabetic retinopathy

A. Dias-Santos, M. Cardoso, V. Lemos, J. Cunha, L. Abegão Pinto, J. Ferreira PORTUGAL Diabetic retinopathy- neurodegenerative disease before vascular disease?

A. Dias-Santos, R. Rosa, M. Cardoso, B. Borges, B. Carvalho, J. Ferreira, J. Cunha PORTUGAL Macular and optic disc edema and retinal vascular leakage in familial amyloid polyneuropathy with a transthyretin Val30Met mutation- a case report

N. Doi, N. Kakiuchi, T. Mizushima JAPAN Long-term follow-up results of pars plana vitrectomy for non-tractional diabetic macular edema

Y. Dong, M. Elgohary, M. Syrimi, V. Sivagnanavel UK Intravitreal dexamethasone implant in retinal vein occlusion- clinical outcome using as-required repeat injections

M. Douvali, I. Chatziralli, P. Theodossiadis, V. Liarakos, K. Chatzistefanou, E. Giannakaki, A. Rouvas GREECE The effect of macular ischemia on intravitreal ranibizumab treatment for diabetic macular edema

M. Dunaieva, V. Serdiuk, S. Ustimenko, L. Bereznyuk UKRAINE Retinal hemodynamic in diabetic macular edema treated with ranibizumab

D. Epstein, A. Kvanta, P. Lindqvist SWEDEN An enlightening hypothesis of a blinding disease – a population based study on the seasonality and incidence of central retinal vein occlusion

I. Erbagci, E. Ozcan, E. Coskun, B. Oren, S. Okumus TURKEY Changes of intraocular pressure in early period after intravitreal administration of 0.7 mg dexamethasone implant



G. Gulkilik, S. Karaman, M. Ozbek, C. Tanriverdio, G. Demirci, M. Odabasi, M. Ozsutcu TURKEY Pars plana vitrectomy with intravitreal dexamethasone implant for severe diabetic macular edema with taut posterior hyaloid- short term results

E. Gusson, G. Martini, G. Marchini ITALY Retinopathy of prematurity in extremely low birth weight infants in Verona, Italy

D. Güven, A. Mavi Yıldız, R. Erol, Y. Altuntaş TURKEY Effect of serum 25 hydroxy vitamin D level on macular edema in patients with nonproliferative diabetic retinopathy (NPDR)

M. Guzey TURKEY Pain response of short exposure time (light) photocoagulation vs conventional photocoagulation in diabetic retinopathy

D. Hanumunthadu, S. Arghandawi, P. Prakash UK Efficacy of intravitreal dexamethasone implants for macular edema secondary to retinal vein occlusion – in day to day NHS practice

R. Healy, F. Alkherdahji, A. Salam, Q. Mohamed, E. Fletcher, R. Johnston UK A real world study of intravitreal ranibizumab treatment of diabetic macular edema

C. Hernaez-Ortega, J. Pinies, E. Soto-Pedre SPAIN Validation of an individual risk assessment algorithm to optimize screening frequency for diabetic retinopathy

C. Hernaez-Ortega, A. Navea, E. Soto-Pedre, J. Morales, S. Millan, P. Perez, C. Desco SPAIN Evaluation of an automated image analysis software for the detection of diabetic retinopathy to reduce the ophthalmologist workload

A. Hulpus, I. Idris, P. Richardson UK Bariatric surgery in diabetic patients- changes to visual acuity and retinopathy

M. Idrees SAUDI ARABIA Treating subhyaloid premacular bleed with argon laser

T. Ikeda, M. Sakamoto, K. Nakamura, M. Shibata JAPAN Magnetic resonance imaging findings of a Terson’s syndrome patient suggestive of the mechanism of vitreous hemorrhage

T. Imshenetskaya, V. Yarmak, G. Vashkevich BELARUS Ischemic optic neuropathy and macular hole with its spontaneous closure following nasal septoplasty

M. Ingolotti, M. Gabin, J. Ayerza, M. Iglicki, B. Schlaen, M. Saravia ARGENTINA Angioid streaks and pseudoxanthoma elasticum- a familial case report

T. Josifova, P. Henrich SWITZERLAND Treatment of persistent macular edema after internal limiting membrane peeling

P. Kalouda, E. Kanonidou, I. Zampros, C. Skatharoudi, E. Zopounidou, D. Balatsoukas GREECE Neovascular age-related macular degeneration and intravitreal ranibizumab. Our experience

P. Kalouda, E. Kanonidou, C. Skatharoudi, I. Zampros, E. Zopounidou, D. Balatsoukas GREECE Intravitreal ranibizumab treatment for ocular pathology other than neovascular age-related macular degeneration

E. Esen, S. Sizmaz, G. Simdivar, N. Demircan TURKEY The efficacy of intravitreal ranibizumab treatment in diabetic macular edema

N. Farmakakis, O. Makri, P. Plotas, N. Farmakakis, A. Exarchou GREECE Efficacy of topical ofloxacin 0.3 % administration on conjunctival bacterial flora in diabetic patients undergoing intravitreal injections

S. Fernandez-Perez, G. Vafidis UK Optical coherence tomography findings in stable treated proliferative diabetic retinopathy

C. Ferreira, J. Breda, A. Magalhães, R. Santos-Silva, Â. Carneiro, A. Rocha-Sousa, F. Falcão-Reis PORTUGAL Extreme prematurity and its impact on visual development

M. Figurska, K. Krix-Jachym, A. Siemiątkowska, J. Wierzbowska, M. Rękas POLAND Uveal effusion with secondary serous retinal detachment and acute angle closure glaucoma – case report

M. Franco, C. Pereira, L. Colaço, J. Neves, R. Seldon PORTUGAL Bilateral retinal branch vein occlusion-case report

M. Franco, L. Colaço, C. Pereira, I. Gomes, R. Seldon PORTUGAL Radiation retinopathy – case report

R. Gallego-Pinazo, I. Pascual-Camps, J. Ruiz, P. Hernández-Martínez, M. Cuéllar, R. Dolz-Marco, M. Andreu-Fenoll SPAIN Morphometric and functional results after switching to aflibercept in diabetic macular edema suboptimally responding to conventional treatment

I. Gardasevic Topcic, M. Sustar, J. Brecelj, M. Hawlina, P. Jaki Mekjavic SLOVENIA Intravitreal bevacizumab for macular edema secondary to central retinal vein occlusion- clinical, anatomic and electrophysiologic outcome of a prospective clinical trial

F. Ghassemi IRAN Cytomegalovirus, herpes simplex antibodies and hypercoagulopathy state study in coats disease

R. Gonçalves, J. Serino, J. Lemos, C. Menezes, P. Coelho, B. Vieira, P. Tenedório PORTUGAL Central retinal artery occlusion with cilioretinal artery sparing- a case report

B. Gonglore, W. Fusi-Rubiano, K. Darrad, A. Bhatnagar UK The one stop DMO clinic – an innovative approach for patients with diabetic macular oedema (DMO) requiring intravitreal treatment in a high volume clinical setting

S. Gonul, B. Ozturk, B. Bakbak, S. Okudan TURKEY The effect of a single dose of intravitreal dexamethasone implant in patients with persistent diabetic macular edema

S. Gudsoorkar, S. Hale UK Proliferative diabetic retinopathy referrals from diabetic retinopathy screening service Wales (DRSSW) – role of fast track referral system

G. Gulkilik, G. Demirci, S. Karaman, M. Ozbek, M. Odabasi, M. Ozsutcu, S. Kocabora TURKEY Intravitreal dexamethasone implant for DME unresponsive to prior treatments



N. Kanchanaranya, W. Tansiricharoenkul THAILAND To perform a survey of the retina specialists regarding the practice patterns in treatment of diabetic macular edema and macular edema secondary to retinal vein occlusion in Thailand

D. Karagiannis, G. Kontadakis, N. Klados, I. Tsoumpris, A. Kandarakis, E. Parikakis, M. Tsilimbaris GREECE Central retinal vein occlusion and pseudoexfoliation syndrome

M. Karolczak-Kulesza, E. Czaplicka, A. Brazert, J. Kociecki POLAND Bilateral papilloedema in course of otitis media in a 5-year-old boy – diagnostic problems

I. Karska-Basta, A. Kubicka-Trząska, P. Oleksy, B. Romanowska-Dixon POLAND Ranibizumab for the treatment of macular edema secondary to retinal vein occlusion – a 6 month follow-up

C. Kaur, G. Rathnasamy SINGAPORE Glutamate mediated retinal ganglion cell death in hypoxic neonatal retina – a special emphasis on insulin growth factor-1 signalling pathway

H. Kaymak, D. Breyer, K. Klabe, C. Pohl GERMANY Clinical outcome after treatment of chronical diabetic macula edema with dexamethasone implants

A. Khattab, M. Torkey, A. Saeed, A. Ellakkanny EGYPT Outcomes of intravitreal bevacizumab injection versus conventional laser as first line treatment in stage III retinopathy of prematurity

J. Kim, C. Kim, Y. Lee, J. Kim SOUTH KOREA Dietary grape seed supplement prevents diabetes-induced retinal vascular injury

N. Kir, Z. Cebeci, B. Tanyildiz TURKEY Efficacy of indocyanine green angiography guided half-fluence photodynamic therapy in central serous chorioretinopathy

J. Kirk, K. Witts, I. Stratton, P. Scanlon, Q. Mohamed UK Retrospective comparison of spectralis and cirrus spectral domain optical coherence tomography in quantifying macular thickness in patients with centre involving diabetic macular edema

P. Kiryttopoulos, A. Agorastos, M. Charalambidis, E. Kotsifou, E. Paphianou, M. Moschos, I. Chatziralli GREECE The effect of vitamin E on oxidative stress in insulin dependent type II diabetic patients with retinopathy

A. Kocak Altintas, V. Cankurtaran, K. Tekin, G. Koklu TURKEY Macular edema in nonproliferative diabetic retinopathy and its relation with blood glucose and lipid levels

A. Kocak Altintas, V. Cankurtaran, K. Tekin, G. Koklu TURKEY Macular edema treatment with dexamethasone implantation

O. Kolenko, E. Sorokin, V. Egorov, M. Pshenichnov RUSSIA 5 years' experience of laser treatment of aggressive posterior retinopathy of prematurity

S. Koshy, E. Vrizidou, H. Eleftheriadis UK 6 months real life results of treatment of diabetic macular oedema with intravitreal injections of ranibizumab

M. Lafuente, J. Guindo, M. Argente, L. Ortín, J. Lajara, F. Fenoy, D. López Bernal SPAIN Effect of oral supplementation with docosahexaenoic acid (DHA) in self-reported vision-targeted health status in patients with diabetic macular edema (DME) treated with intravitreal (IV) ranibizumab

M. Lafuente, J. Guindo, M. Argente, L. Ortín, J. Domingo, J. Lopez Roman, D. López Bernal SPAIN 1 year efficacy of ranibizumab+ docosahexaenoic acid (DHA) treatment in patients with diabetic macular edema

D. Lee, Y. Cho, H. Koh, M. Kim SOUTH KOREA Comparison of intravitreal bevacizumb and dexamethasone implant for the treatment of macula edema associated with branch retinal vein occlusion

J. Lin, M. Lai TAIWAN Long-acting insulin analogues and diabetic retinopathy- a retrospective cohort study

B. Loh SINGAPORE Pattern scan laser photocoagulation of familial exudative vitreoretinopathy in two paediatric cases

G. Lopez Valverde, F. Cruz Gonzalez, D. Kyriakou, F. Prieto Martín SPAIN Chronic central serous chorioretinopathy. Combined treatment with ranibizumab and photodynamic therapy

K. Madan, S. Mittal INDIA Intravitreal bevacizumab in the management of purtscher’s retinopathy

S. Mahapatra INDIA A rare case of diabetic macular edema (DME) with central serous choroidoretinopathy (CSCR) presenting as pseudohypopyon over macula

S. Mahuli, V. Arora INDIA Annular migratory necrotizing scleritis caused by proteus following pars plana vitrectomy

S. Malhotra, D. Agarwal INDIA Dexamethasone intravitreal implant for treatment of patients with recalcitrant diabetic macular edema

S. Malhotra, D. Agarwal INDIA Dexamethasone intravitreal implant in combination with modified grid laser photocoagulation for patients with macular edema due to central retinal vein occlusion-a pilot study

E. Mangunkusumo, S. Raymond Chee Seong, C. Ka Lin Caroline SINGAPORE Multiple unilateral branch and central artery occlusion after failed thrombolysis on hemorrhagic stroke

J. Marques, J. Costa, I. Pires, M. Cachulo, R. Silva, J. Figueira PORTUGAL BRVO associated changes in the perifoveal RNFL thickness analyzed by spectralis® SD-OCT

N. Marques, S. Barros, A. Cardoso, J. Cardoso, A. Miranda, N. Donaire, N. Campos PORTUGAL Retinal artery central occlusion in patient with proliferative diabetic retinopathy and hyperhomocysteinemia

N. Marques, S. Barros, A. Cardoso, J. Cardoso, A. Miranda, N. Donaire, N. Campos PORTUGAL Different ocular presentations of hypertensive retinopathy



I. Martins de Almeida, C. Costa Ferreira, A. Gomes Rocha, J. Chibante Pedro PORTUGAL Pseudophakic cystoid macular edema – a disabling complication treated with intravitreal triamcinolone

G. Martone, C. Traversi, E. Nuti, P. Pichierri, A. Tarantello ITALY Analysis of choroidal thickness in eyes with diabetic macular edema treated with resveratrol and ranibizumab using SD-OCT

G. Martone, C. Traversi, E. Nuti, P. Pichierri, G. Cartocci ITALY Comparison of CT of healthy and diabetic eyes obtained by two different spectral-domain OCT instruments

M. Mavija, Z. Mavija, V. Jaksic, M. Stamenkovic, E. Ignjatic, S. Smoljanovic, D. Risimic BOSNIA AND HERZEGOVINA Purtscher's retinopathy- a case of bilateral visual loss after chest compression

N. Menassa, R. Edirisinghe, S. Jalpota UK Outcomes of intravitreal ranibizumab injections for treating diabetic macular edema – departmental audit and comparison with published data

M. Méndez, J. Polo Simon, P. Mena Toja, P. Maqueda González SPAIN Chorodial and retinal vascular changes documented by angiography in a case of fibromyalgia with associated visual symptoms

L. Mendonca, K. Sousa, R. Leite, J. Mendes, F. Vaz PORTUGAL Methylene tetrahydrofolate reductase (MTHFR) gene mutations associated with retinal vein occlusion (RVO)

C. Meyer, Z. Liu, C. . Brinkmann, E. Rodrigues, T. Bertelmann SWITZERLAND Penetration force, geometry and cutting profile of the novel and old Ozurdex needle- the MONO-study

K. Michalska-Małecka, A. Kabiesz POLAND The use of biodegradable intravitreal implant of dexamethasone in the treatment of a patient with cystoid macular oedema (CMO) secondary to lower branch retinal vein occlusion (BRVO) – a case report

E. Mingorance Moya, M. Bassaganyas Vilarrasa, J. Díaz Cascajosa, J. Vela Segarra, J. Crespí Vilimelis, T. Marieges Jubany SPAIN Our experience after 2 years of Ozurdex treatment

A. Miranda, J. Cardoso, N. Marques, A. Cardoso, S. Barros, P. Telles, N. Campos PORTUGAL Vitreous hemorrhage and retinopathy in a patient with waldenstrom macroglobulinemia and severe hyperviscosity syndrome

M. Moatez Billah, S. Yahiaoui ALGERIA Emergency management of retinal arterial embolism by anterior chamber paracentesis and genupectoral position

A. Mohite, M. Denmark, S. Shafquat UK The efficacy of intravitreal Ozurdex for macular edema following retinal vein occlusions- outcomes in a district general hospital

S. Mukherjee, R. Roy, D. Das INDIA Spectral domain optical coherence tomography (SD-OCT) predictors of visual outcome in patients with macular oedema (MO) due to branch retinal vein occlusion (BRVO) treated with intravitreal ranibizumab injections

N. Munoz Sanz SPAIN Severe ischemic retinopathy and macular edema due to pegylated Interferon α in a patient with Hepatitis C

G. Murthy, S. Deshpande, D. Satish INDIA Can a single injection of avastin treat BRVO related macular edema

R. Narayanan, J. Chhablani, A. Sudhalkar, I. Kozak, G. Jonnadula, P. Rao, A. Venkata INDIA Choroidal thickness in diabetic patients of Indian ethnicity

M. Naser, C. Chee SINGAPORE Case report- choroidal ischemia as initial and sole ophthalmic presentation of giant cell arteritis in an elderly male

S. Nowilaty, A. Al-Bakri, L. Abu Safieh, F. Alkuraya SAUDI ARABIA Familial retinal arterial macroaneurysms can be associated with major systemic and coronary arterial disease

M. Onen, Z. Yazar, N. Ucgun, H. Sarikatipoglu TURKEY Intravitreal anti-vascular endothelial growth factor injections for idiopathic choroidal neovascularization- long-term visual outcome

H. Oner, T. Ozturk, G. Arikan, Z. Ozbek TURKEY Herpetic keratouveitis following intravitreal ranibizumab injection in a case with diabetic macular edema

T. Otani, Y. Yamaguchi, S. Kishi JAPAN Factors affecting disruption of the photoreceptor inner/outer segments in diabetic macular edema

F. Ozturk, F. Koc TURKEY Ocular adverse events of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion

T. Painhas, F. Esteves, I. Almeida, R. Soares, J. Chibante-Pedro PORTUGAL Choroidal neovascularization secondary to angioid streaks- a report of two cases

I. Papandreou, C. Leak, M. Ting, E. Mensah UK Results from the consecutive treatment of refractory diabetic macular edema with bevacizumab and ranibizumab in a clinical setting

I. Pastukh, N. Goncharova, N. Stremovskaya UKRAINE Ranibizumab for the treatment of diabetic macular edema

G. Pekel, M. Doğu, H. Sarı, S. Acer, R. Yağcı, A. Kaşıkçı TURKEY Subfoveal choroidal thickness and ocular pulse amplitude measurements in patients with essential thrombocythemia

S. Penas, J. Araújo, P. Faria, E. Brandão, F. Falcão-Reis PORTUGAL Half-dose photodynamic therapy in central serous chorioretinopathy- timing as a determinant factor in anatomic and functional long-term results

C. Pereira, M. Franco, L. Colaço, D. Cristovão, J. Neves, M. Vila-Franca, H. Filipe PORTUGAL Sub-retinal vein occlusion- case report

C. Perpétua, R. Couceiro, R. Amorim, I. Leal, N. Pinto Ferreira, J. Prates Canelas, M. Monteiro Grillo PORTUGAL The effect of glucose regulation on the treatment for diabetic macular edema



O. Plevachuk, T. Smal UKRAINE Comparing the effectiveness of micropulse infrared (810 nanometer) diode laser coagulation for diabetic macular edema treatment in period during 2010-2011 and in 2012

A. Poli, H. Muhiddin, B. Manyyu INDONESIA Analysis of patomechanism of diabetic retinopathy – a study of HbA1c, diabetic mellitus duration, endothelin-1, nitric oxide and retinal vessel calibre

J. Portelinha, A. Marques, M. Picoto, F. Isidro, F. Vaz PORTUGAL Retinal vein occlusion- real-life clinical practice in a central hospital

J. Portelinha, M. Picoto, A. Marques, F. Isidro, F. Vaz PORTUGAL Retinal vein occlusion – clinical profile of the patients at baseline in a central hospital

V. Prabhu INDIA Successful use of Intravitreal bevacizumab (Avastin) in a paediatric case of secondary (traumatic) choroidal neovascular membrane (CNVM)

V. Prabhu INDIA Central retinal vein occlusion (CRVO) secondary to oral contraceptive pill (OCP) in invitro fertilization (IVF) patient

P. Prakash, D. Hanumunthadu, S. Arghandawi UK Long term efficacy intravitreal dexamethasone implants for macular edema secondary to retinal vein occlusion

W. Prasartritha, S. Sukavatcharin, B. Tipsuriyaporn THAILAND Intravitreal anti-VEGF for idiopathic juxtafoveal telangiectasia treatment

C. Putri, A. Jain, A. Hoi Ki Lo, M. Wasim UK Evaluation of effectiveness and safety of Ozurdex implant for treatment of macular edema secondary to retinal vein occlusion and diabetic retinopathy

A. Ramezani, H. Mughaddasifar, H. Nikkhah, B. Nasri Razin IRAN A case of ocular tuberculosis presenting as papillophlebitis

F. Razi, R. Muniraju UK Referral outcomes and the level of agreement in grading between photographic screening programme and hospital eye service for patients with diabetic eye disease

S. Régnier, W. Malcolm, F. Allen, J. Wright SWITZERLAND Efficacy comparison of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema- a systematic review and network meta-analysis

F. Rodrigues, I. Almeida, F. Trindade, R. Pereira, S. Moniz PORTUGAL Bull eye maculopathy case report

I. Romina RUSSIA Myopia and CNV – new possibility in pathogenic therapy

F. Rosales Villalobos, I. Baquero Aranda, J. Sandoval Codoni SPAIN Correlation between structural changes and visual acuity in diabetic macular edema

R. Rothwell, S. Fonseca, L. Ribeiro, L. Silva, M. Queirós, A. Brandão, L. Agrelos PORTUGAL Comparison of bevacizumab and ranibizumab in the treatment of macular edema due to retinal vein occlusion

Z. Rozanova, N. Umanets, M. Alzein UKRAINE Comparative efficiency of intravitreal ranibizumab and its combination with selective laser coagulation of pigment epithelium in the treatment of diabetic cystoid macular edema

O. Ruiz-Moreno, P. Calvo, B. Abadia, J. Leciñena, C. Torrón SPAIN Long-term outcomes of standard-fluence photodynamic therapy in chronic central serous chorioretinopathy

S. Saha INDIA Prognostic factors in central retinal vein occlusion (CRVO)-a retrospective study

Y. Sakalar, T. Yilmaz, A. Yilmaz, A. Karci, D. Esen TURKEY Short-term optical coherence tomographic changes after intravitreal dexamethasone implant in retinal vein occlusion

N. Saxena, B. Ghosh, V. Garg, S. Arora, A. Seth, M. Thakkar INDIA Sub-threshold micropulse diode laser in the treatment of chronic central serous chorioretinopathy(CCSC)

N. Saxena, B. Ghosh, V. Garg, A. Seth, S. Arora INDIA Morphological features of chronic central serous chorioretinopathy(CSC) evaluated by spectral-domain optical coherence tomography(SD-OCT)

M. Sekeroglu, H. Tirhis, F. Koc, P. Yilmazbas TURKEY Intralenticular sustained-release dexamethasone implant- is it effective on macular edema or not?

M. Sekeroglu, M. Anayol, H. Tirhis, P. Yilmazbas TURKEY Sub-inner limiting membrane hemorrhage of the fovea following the labour- early surgery or observation

A. Sharma, J. Sheth, R. Madhusudan, N. Vidhya, S. Sundaramoorthy, J. Patil INDIA Severe retinal ischemia caused by clonazepam overdose

Y. Shweikh, L. Lu, L. Gate, R. Miller, M. Rosenthal, S. Althauser UK Improving care in the treatment of diabetic retinopathy – introducing the health POD service- psychology, ophthalmology and diabetes

M. Siddique, M. Musadiq, J. Bowyer UK Anterior segment ischemia

R. Singh, V. Menon UK Central retinal artery occlusion with thrombocytosis and JAK 2 kinase mutation

I. Sobral, M. Cachulo, J. Figueira, I. Pires, P. Melo, R. Silva PORTUGAL Sialidosis – a clinical case

A. Soler-Garcia, A. Gonzalez-Gomez, J. Sandoval SPAIN Correlation between external layers integrity by optical coherence tomography and visual prognosis in diabetic macular edema

M. Stahel, P. Ciechanowski, M. Becker, S. Michels SWITZERLAND Systemic interleukin 1-β (IL 1-β) inhibition in proliferative diabetic retinopathy (PDR)- interim analysis of a prospective clinical study

S. Strong, E. Papamichael, M. Ting, E. Mensah UK Dexamethasone intravitreal implant (Ozurdex®) as a treatment for macular edema secondary to retinal vein occlusion – a district general hospital experience



Y. Sugiura, F. Okamoto, Y. Okamoto, T. Oshika JAPAN Visual function following vitrectomy for diabetic macular edema

Y. Toklu, M. Arıkan Yorgun, H. Çakmak, M. Mutlu, S. Uysal, N. Çağıl TURKEY İntravitreal ranibizumab for macular edema due to central retinal vein occlusion

Y. Totan, E. Güler TURKEY Dexamethasone intravitreal implant for diabetic macular edema resistant to bevacizumab treatment

C. Traversi, G. Martone, E. Nuti, P. Pichierri, E. Latronico ITALY Analysis of macular and choroidal thickness in eyes with diabetic macular edema treated with grid laser photocoagulation and anti-vascular endothelial growth factor agents

D. Trivedi, A. Kidess, S. Carless, E. Maher, A. Denniston, M. Tsaloumas UK Characterisation of systemic and ocular features in Von Hippel Lindau syndrome from a supraregional service in the UK

N. Ucgun, Y. Atalay, Z. Yazar, M. Onen, H. Sarikatipoglu TURKEY Short term intraocular pressure alterations after intravitreal ranibizumab injection and efficacy of prophylactic anti-glaucomatous treatment

N. Ucgun, A. Uysal, M. Onen, Z. Yazar, H. Sarikatipoglu TURKEY Comparison of ranibizumab and bevacizumab effectiveness for diabetic macular edema

P. Udaondo, R. Martinez-Costa, A. Cisneros-Lanuza SPAIN Efficacy of dexamethasone implant in naïve DME patients

O. Uhumwangho, Y. Israel-Aina NIGERIA Knowledge and attitude of retinopathy of prematurity among paediatricians in Nigeria

N. Unlu, G. Uney, M. Acar, D. Hazirolan, F. Ornek TURKEY Association of baseline OCT thickness and final visual acuity 1 year after treatment for diabetic macular edema with ranibizumab

K. Vandekerckhove SWITZERLAND Aflibercept versus ranibizumab in diabetic macular edema

S. Vaz-Pereira, P. Pacheco, S. Gandhi, A. Kulasekararaj, J. Marsh, B. Pal, G. Mufti PORTUGAL Bilateral retinal vasculopathy associated with autosomal dominant dyskeratosis congenita

N. Vilà, V. Bravo-Filho, P. Zoroquiain, J. Chen, J. Galic, J. Deschênes, M. Burnier CANADA Histopathological features of vitreous samples in diabetic patients

M. Vinkovic, G. DeSalvo, M. Bradvica CROATIA Preretinal hemorrhages masquerading as intraocular cysts

I. Walid EGYPT Single 0.7ml dose of ranibizumab for treatment of macular edema caused by non ischemic branch or central retinal vein occlusion

I. Wong, I. Yeung, N. Fung, I. Wong HONG KONG Combination therapy of intravitreal ranibizumab and dexamethasone implant for macular oedema due to retinal vein occlusions

T. Xirou, O. Georgiadis, G. Batsos, V. Xirou, E. Feretis, S. Kabanarou GREECE Hypertensive retinopathy complicated with bilateral retinal neovascularization- PRP versus intravitreal anti-VEGF treatment

L. Xu CHINA GLIS3 gene polymorphisms associated with diabetic retinopathy in type 2 diabetes in Northeast China

Z. Yazar, H. Çağatay, G. Gökçe, Y. Koban, M. Ekinci, E. Durgunlu TURKEY Efficacy of intravitreal dexamethasone implant for the treatment of macular edema secondary to retinal vein occlusion

N. Yenerel, E. Türkseven Kumral, N. Erçalık, E. Turan Vural, Ö. Aydın Öncü TURKEY Mean platelet volume and neutrophil/lymphocyte ratio in branch retinal vein occlusion

Y. Yilmaz, G. Kaya TURKEY To evaluate retinal thickness in diabetic retinopathy using optical coherence tomography (OCT)

Y. Yilmaz, G. Kaya TURKEY To evaluate improvement visual acuity and retinal thickness after laser treatment

R. Zakri, N. Kumaran, A. Sieunarine, S. Walker, N. Patel UK Oxygenation of retinal vessels before and after laser therapy in diabetic macula

S. Zaouali, S. Mbarek, S. Zina, R. Attia, R. Messaoud, B. Jelliti, M. Khairallah TUNISIA Branch retinal vein occlusion in young patients

Vitreoretinal SurgeryM. Abouammoh, S. Alsulaiman, A. Mousa, V. Gupta, F. Arevalo SAUDI ARABIA Pars plana vitrectomy with juxtapapillary laser photocoagulation (JLP) versus without JLP for the treatment of optic disc pit maculopathy- functional and anatomic outcomes

D. Abulon, M. Charles USA The impact of valved and non-valved cannula on intraoperative fluid dynamics and vitreous

N. Acar TURKEY Active silicone oil removal transconjunctivally with a simple method-surgical technique

V. Agrawal, K. Khilnani, R. Saini, P. Foujdar INDIA Spectral domain OCT based macular analysis post primary retinal detachment repair

O. Ali EGYPT Wide angle viewing system and twinlight assisted pneumatic retinopexy

K. Alshehri, S. Waheeb SAUDI ARABIA Incidence of retinopathy of prematurity ROP at two tertiary centers,King Faisal Specialist Hospital and King Abdulaziz University Hospital in Jeddah, Saudi Arabia

I. Alvarez, S. Abengoechea SPAIN Myopic traction maculopathy progression post intravitreal ranibizumab injection



C. Amantea, P. Ceruti, G. Marchini ITALY Recurrent retinal detachment in Schwartz-Matsuo syndrome, case report

R. Avci, S. Yilmaz, B. Kaderli, U. Ubeyt Inan, H. Ozcetin TURKEY Comparative outcomes of long-acting gas and silicone oil tamponades in cases with rhegmatogenous retinal detachment complicated by severe proliferative vitreoretinopathy

R. Aydin, S. Kaynak, E. Karahan TURKEY Correlation of foveal thickness and photoreceptor integrity with visual acuity in idiopathic epiretinal membrane

S. Babovic, M. Stamenkovic, I. Sencanic SERBIA Intraocular pressure changes after vitrectomy with silicone oil tamponade

R. Balasubramanian, E. Ng, P. Polkinghorne NEW ZEALAND Persistent sub retinal fluid following retinal re-attachment surgery

R. Balasubramanian, E. Ng, M. Fisk, N. Ahmad, S. Welch, P. Hadden, P. Polkinghorne NEW ZEALAND Trends and features of a high volume 1-year vitreo-retinal fellowship at the New Zealand national eye centre

G. Bamonte THE NETHERLANDS Vitreous base visualisation through trans-scleral illumination with a standard 25-gauge light probe

S. Batta Arora, G. Bhushan, N. Goel, A. Seth, N. Saxena, S. Thirumalai, B. Ghosh INDIA Protection of retinal nerve fibre layer thickness with whole blood in macular hole surgery

M. Bhende, A. Karpe, S. Arunachalam, L. Therese INDIA Endogenous endophthalmitis due to roseomonas mucosa presenting as subretinal abscess

K. Brosh, I. Strassman, M. Seelenfreund ISRAEL High intraocular pressure in four vitrectomized eyes with intravitreal C3F8 without high altitude travel

S. Caprani, S. Donati, E. Gibin, C. Gandolfi, C. Azzolini ITALY OCT study of macular structure after vitreoretinal surgery for retinal detachment

M. Cardoso, V. Lemos, A. Vicente, R. Anjos, N. Marques, F. Trincão, J. Branco PORTUGAL Massive suprachoroidal hemorrhage- vitreoretinal surgical approach and outcome

M. Cascella, F. Liuzzi, A. Acquaviva ITALY Our experiences in passive and active silicon oil removal (SOR) with transcongiunctival 23 and 25 gauge trocars

V. Cerovic, I. Boras, M. Ratkovic CROATIA Macular pucker- surgical approach

J. Chae SOUTH KOREA Changes of accommodative power in vitrectomized eyes with crystalline lenses without presbyopia

H. Chao, J. Liu TAIWAN Macular pucker- peel or injection

S. Cho, S. Yoo, C. Kim SOUTH KOREA Two types of idiopathic epiretinal membrane (ERM) during surgery. Can it be recognized pre-operatively with spectral domain-optical coherence tomography (SD-OCT)?

M. Colaço, R. Pinto, S. Silva, S. Barrão, J. Nascimento PORTUGAL Subfoveal deposits secondary to idiopathic epiretinal membrane – same surgical technique but different clinical outcomes in the same patient

M. Coppola ITALY New ESA (entry-site alignment) system device

J. Costa, F. Gil, M. Marques, J. Marques, M. Cachulo, R. Silva, J. Figueira PORTUGAL Efficacy of post-vitrectomy intravitreal anti-VEGF therapy

L. Dravitsa, Y. Belkevich, N. Samohvalova, F. Biriukov BELARUS Drainage of macular cyst in patients with diabetic proliferative retinopathy

L. Dravitsa, F. Biriukov, Y. Belkevich, N. Samohvalova BELARUS Treatment of local tractional-rhegmatogenous retinal detachment by 2-port focal vitrectomy at repeated surgery

M. Elgohary, P. Banerjee, A. Chandra, L. Wickham, D. Charteris, B. Aylward UK Recurrent retinal detachment following pars plana vitrectomy and gas tamponade- causes and outcome of secondary surgical intervention

B. Erden, Ö. Mutluer, S. Bölükbaşı, M. Elçioğlu TURKEY Evaluation of foveal microstructure with OCT following retinal detachment surgery

R. Fayzrakhmanov, M. Bikbov, T. Gilmanshin RUSSIA Comprehensive approach to the therapy of hidden neovascularization in combination with retinal pigment epithelium detachment.

V. Felcida, A. Kumar, A. Kumar, A. Mitra, A. Tyagi, S. Banerjee UK Spontaneous closure of full thickness macular hole – a case series

A. Figueiredo, C. Vale, D. Dias, N. Ferreira, A. Meireles PORTUGAL Vitrectomy and chorioretinectomy in perforating eye injuries

O. Findl, C. Leisser, C. Hackl, N. Hirnschall AUSTRIA Changes of the subfoveal hyporeflective zone after membrane peeling with air tamponade

W. Fusi-Rubiano, M. Awad, I. Elaraoud, R. Manjunath, N. Narendran, Y. Yang UK The rate of encountering eyes with vitreo-macular traction in a high-throughput retinal imaging service

M. Gaber, H. Mortada, T. Macky, M. Amr EGYPT Primary rhegmatogenous retinal detachment at Kasr Al-Aini Hospital- predisposing factors and clinical features

M. García SPAIN Management of submacular hemorrhage by pars plana vitrectomy and air-fluid exchange, associated with a subretinal injection of tissue plasminogen activator and bevacizumab

F. Gil, S. Brito, J. Costa, M. Marques, I. Regadas, J. Varela, J. Figueira PORTUGAL Bilateral giant macular hole in patient with Alport syndrome

T. Gilmanshin, M. Bikbov, R. Fayzrakhmanov RUSSIA The macular diabetic edema changes dynamics under the influence of anti-VEGF therapy

T. Gilmanshin, M. Bikbov, R. Fayzrakhmanov, A. Yarmukhametova RUSSIA The evaluation of morphological parameters of macular pathology



N. Gomes, K. Sousa, L. Mendonça, R. Gentil, G. Calvão-Santos, R. Leite, J. Mendes PORTUGAL Effect of triamcinolone intravitreal injection in previously vitrectomized eyes

J. Gonzalez-Cortes, E. Treviño, C. Azuara, J. Davila, J. Mohamed MEXICO 25 gauge vitrectomy for small intraocular foreign bodies removal

A. Grzybowski, K. Kupidura-Majewski POLAND Continuation of anti-coagulant and anti-platelet therapy during vitreoretinal surgery

Y. Jo, H. Chin SOUTH KOREA The effect of internal limiting membrane peeling on macular thickness in rhegmatogenous retinal detachment involving macula

V. Kanyukov, A. Kazennov, A. Gorbunov, I. Kazennova RUSSIA Surgical treatment of traction retinal detachment due to perforated injury of sclera by injection needle in the long term- case report

D. Kar INDIA Comparison of outcome of early 25g sutureless vitrectomy versus intravitreal injections in endophthalmitis

G. Karastatiras, M. Bindra, B. James, R. Bates, K. Manucheri UK Combined vitrectomy-phacoemulsification-vitrectomy for the management of aqueousmisdirection syndrome

O. Kayikcioglu, S. Bilgin, H. Öztürk, M. Kaskaloglu TURKEY Results of idiopathic and secondary epiretinal membrane removal surgery

O. Kayikcioglu, S. Bilgin, H. Öztürk, M. Kaskaloglu TURKEY Subfoveal perflorocarbon bubble following retinal detachment surgery

M. Khalife LEBANON Traumatic submacular haemmorrhage removal- a new technique

A. Khattab EGYPT Does demarcation laser photocoagulation really barricade the macula sparing symptomatic and asymptomatic clinical rhegmatogenous retinal detachment?

A. Khera, F. Bakhridinova, D. Arnopolskaya UZBEKISTAN Panretinal laserocoagulation in diabetic eyes with indication for vitreoretinal surgery

O. Kolenko, A. Khudiakov, A. Vasiliev RUSSIA The analysis of clinical efficiency of surgical treatment at various clinical forms of persistant primary hyperplastic vitreous

I. Kumar, A. Kamal UK Efficacy of pneumatic displacement of sub-macular haemorrhage (SMH) secondary to wet AMD in non-vitrectomised eyes

E. Lee, M. Lee, H. Ku, W. Rhim SOUTH KOREA Hyperreflective invasive lesions in optical coherence tomography in cases of epiretinal membranes with a firm foveal adherence

V. Lemos, M. Sá Cardoso, N. Marques, J. Branco PORTUGAL Visual and structural outcome of macular hole surgery

J. Lemos, C. Teixeira, C. Menezes, J. Serino, B. Vieira PORTUGAL Rhegmatogenous retinal detachment associated with retinoschisis and complicated by a retinal capillary hemangioma in a highly myopic patient

T. Leong, C. Kon UK Rubeosis - have we forgotten about cryo?

S. Malhorta, D. Agarwal, S. Chatterjee INDIA Anatomical and visual outcomes in postcataract cluster endophthalmitis after pars plana vitrectomy and intraocular antibiotics

R. Manriquez, R. Moya, P. Suarez CHILE Results of vitrectomy surgery in traumatic macular hole

A. Mercanti, A. Renna, P. Lanzetta ITALY Significant and stable visual recovery in a 18-month follow-up patient with retained subfoveal perfluorocarbon liquid after pars plana vitrectomy for rhegmatogenous macula-off retinal detachment- a case report

F. Minaya, L. Arellano, J. Hernanz, V. Molina, A. Antón SPAIN Novel heavy blue dye for vitreoretinal surgery

S. Mokadam, M. Joglekar INDIA A retrospective study of pneumatic retinopexy in for post-vitrectomy retinal detachment

A. Moraru, D. Costin, D. Branisteanu ROMANIA Terson syndrome- surgical approach

P. Neves, R. Brito, C. Bacalhau, M. Santos, D. Martins PORTUGAL En face OCT and microperimetry in epiretinal membranes- a study of functional correlation

D. Odrobina, I. Laudańska-Olszewska POLAND Analysis of the time and location of the silicone oil emulsification by spectral-domain optical coherence tomography after silicone oil tamponade

H. Ohno, S. Hori, K. Inoue JAPAN Preoperative morphologic finding-based analysis of surgical outcomes in myopic macular hole

K. Ohta, N. Senda, A. Sato, E. Fukui, A. Koshino JAPAN Foveal contour after macular hole surgery with internal limiting membrane peeling

F. Okamoto, Y. Sugiura, Y. Okamoto, T. Oshika JAPAN Time course of changes in aniseikonia and visual function following vitrectomy for epiretinal membrane

O. Okonkwo, A. Hassan, O. Oderinlo NIGERIA Macular edema post macular hole surgery

M. Onen, M. Ucer, Z. Yazar, N. Ucgun, H. Sarikatipoglu, O. Evren Kemer TURKEY Foveal morphologic changes in patients who underwent 25-gauge primary vitrectomy for rhegmatogenous retinal detachment- imaging analysis by optical coherence tomography

B. Özkan, M. Gök, M. Aslan, L. Karabaş TURKEY Surgical outcomes and prognostic factors of idiopathic macular hole surgery

E. Özmert, S. Demirel, F. Batioglu TURKEY Ophthalmic microendoscope- assisted vitreoretinal surgery in trauma cases

S. Parikh, N. Bijlani INDIA Epiretinal membrane removal surgery with additional internal limiting membrane removal

S. Parikh, K. Sanghvi, K. Shah, A. Singh INDIA Intraocular foreign body – characteristics, management and prognostic factors



A. Pastor Vivas, F. García-Franco Zuniga SPAIN Exophthalmos and ophthalmoplegia in postoperative vitrectomy

C. Pinto, P. Ruiz, L. Cordovés, P. Rocha, J. Abreu SPAIN Surgical management of symptomatic optic disc pit. Case report

O. Putienko UKRAINE Results of treatment of post vitrectomy vitreous hemorrhage in patients with proliferative diabetic retinopathy with the use of ranibizumab

P. Rao UNITED ARAB EMIRATES Combined phacoemulsification 25gauge vitrectomy for severe proliferative diabetic retinopathy

R. Rekik, M. Ben Gharbia, A. Mhenni TUNISIA Vitrectomy under air

S. Rizvi PAKISTAN Vitreo-macular interface surgery in vitreo-macular traction syndrome

P. Romero-Aroca, M. Baget-Bernaldiz, J. Mercado, C. Blasco-Suñe SPAIN Assessment of changes in combined surgery using new equipment over the last 12 years

S. Sakhnov, A. Zabolotniy, A. Malafeev RUSSIA Surgical treatment of the macular zone ophthalmopathology in patients with pigmentary retinal abiotrophy as a method of supportive rehabilitation treatment

T. Sakurai, G. Takaoka, T. Kinoshita, T. Mano JAPAN Pars plana vitrectomy with hemi-inverted internal limiting membrane flap technique for macular hole- 1 year results

J. Sandoval Codoni, A. Soler García, J. Mora Castilla, R. Luque Aranda SPAIN Scwartz-Matsuo syndrome in a pseudophakic patient

G. Seymenoglu, C. Cansız, E. Başer TURKEY Anatomic and functional outcome of triamcinolone-assisted 23-gauge vitrectomy in vitreomacular tractionsyndrome

M. Siddique, U. Mahmood UK Mishaps/challenging cases in VR surgery

O. Sinyavskiy, R. Troyanovskiy, P. Ivanov, A. Golovin, A. Tibilov, S. Solonina, V. Ilyushchenkov RUSSIA Endoresection of medium and large-sized uveal melanoma after gamma-knife application- features of operation

A. Soliman, D. Ghalwash EGYPT Epiretinal membranes in vitrectomized eyes after gunshot injuries, is it related to type of tamponade?

V. Stebnev, V. Malov, S. Stebnev RUSSIA Effectiveness of the combined episcleral-endovitreal surgery for rhegmatogenous retinal detachment

P. Suarez, R. Manriquez, R. Moya CHILE Paedriatric post-traumatic endophthalmitis at the ocular trauma unit of Chile

Y. Toklu, M. Arıkan Yorgun, H. Çakmak, M. Mutlu, S. Uysal, N. Çağıl TURKEY Endophthalmitis following sustained-release dexamethasone intravitreal implant- a case report

Y. Totan, E. Güler, A. Yüce, F. Gürağaç, A. Tenlik TURKEY Tomographic analysis of retinal nerve fiber and ganglion cell layers after epiretinal membrane surgery

P. Turkcuoglu, C. Taskapan TURKEY The origin of subretinal fluid in optic disc pit maculopathy

E. Ünsal, K. Eltutar, O. Kızılay, B. Karini, H. Güngel TURKEY Evaluation of the anterior segment changes using ultrasonic biomicroscopic imaging after pars plana vitrectomy

C. Vale, A. Figueiredo, N. Ferreira, T. Coelho PORTUGAL Specific ocular changes in compound heterozygotes TTRVal30Met/TTRThr119Met in familial amyloid polyneuropayhy (FAP) patients

S. Valsero Franco, J. Sanchez Aparicio, S. Pinar Sueiro, N. Martinez Alday SPAIN A clincal presentation and outcome of bilateral chorioretinitis sclopetaria – a case report

I. Walid, A. Omer EGYPT Wide angle viewing system with twin light assisted scleral buckling for rhegmatogenous retinal detachment (RRD )surgery

X. Yang, S. Du, H. Ren CHINA Extraction 21 intraocular cilium during endoscope–assisted vitrectomy in 12 eyes

Z. Yazar, M. Önen, Y. Atalay, H. Sarıkatipoğlu TURKEY Comparing intraocular pressure measurements in vitrectomized eyes given C3F8 tamponade or air using different tonometries

A. Yazici, A. Ozkaya, S. Erbildim, K. Yuksel, Z. Alkin, C. Alagoz TURKEY Comparison of epiretinal membrane surgery with or without internal limiting membrane peeling in diabetic patients

H. Yetik, C. Dogan, S. Sirop, K. Ayvatoglu TURKEY A new intraocular foreign body (IOFB) removal technique- polytetrafluoroethylene (PTFE / TEFLON) wrapping

O. Yevsyukova, A. Petrunya, L. Goryaev UKRAINE Our experience in idiopathic macular holes surgical treatment

P. Yip, C. Tsang, M. Brelen HONG KONG The use of L-shaped macular buckle in recurrent myopic macular hole retinal detachment

V. Zaika, A. Iakimov, T. Iureva RUSSIA Prediction of functional outcome in patients after surgical treatment of rhegmatogenous retinal detachment

Y. Bayborodov RUSSIA Second attempt- surgical treatment is not closed after the first surgery macular hole

R. Yamakawa, H. Oshima, C. Taguchi JAPAN A rare case of foveal retinoschisis in a patient with retinitis pigmentosa


EURETINA VIDEO COMPETITION94

M. Agarwal INDIARemoval of a large intraocular foreign body after a firecracker injury

V. Agrawal INDIAThe life & times of internal limiting membrane- ILM peel techniques in detachment surgery

K. Anastasilakis GREECE25g plus vitrectomy for the management of proliferative diabetic retinopathy and epimacular membare

J. Argaya Amigo SPAINRemoval of retained subfoveal perfluorocarbon liquid (PFCL)

F. Balta ROMANIAEndosection for choroidal melanoma

C. Bhatt INDIAMassive sub retinal blood removal

G. Bhushan INDIATwo posterior dislocated intra ocular lens (IOL)- a unique surgical challenge

B. Casco Silva SPAINFull-thickness sclerotomy with sclera implant for recurrent uveal effusion syndrome

D. Chakraborty INDIARetropupillary implantation of the iris claw lens

S. Chakraborty INDIAPre-macular haemorrhage- where is it?

S. Chawla INDIAThe creepy crawly, macular hole repair with worm removal

J. Chhablani INDIAManagement of retinal detachment with intraocular foreign body - bimanual technique

S. Das INDIARamayaba in the eye - bow shaped copper foreign body removal from the eye

A. Dmitrii RUSSIAClinical aspects of preretinal changes in the vitreous body. The role of vitritis in pathogenesis of epiretinal fibrosis

R. Dolz-Marco SPAINDealing with real-life patients care in the unit of macular diseases

I. Dooley UKCut, suck or pull? Surgical pearls for pars plana vitrectomy in proliferative diabetic retinopathy

M. Francesc SPAINThe unexpected in a combined procedure

M. Francesc SPAINSuprachoroidal haemorrhage in a cataract surgery using femtosecond

G. Garay-Aramburu SPAINRetinal detachment surgery after intravitreal dexamethasone implant

A. Gupta INDIAMystery unfolds

C. Jay INDIAScleral re-fixated intraocular lens- a minimally invasive approach for intraocular lens rescue

Y. Ji SOUTH KOREAModified scleral fixation of foldable intraocular lens (enVista) with eyelets located at the optic-haptic junction

O. Kayikcioglu TURKEYPhacoemulsification after anterior capsullar rupture (Argentinian flag sign) in a single eyed patient with Ahmed glaucoma valve

V. Kazaykin RUSSIAThe method of selective staining of the internal limiting membrane in macular hole surgery

D. Kohn ISRAELSurgical approach to hemorrhagic maculopathy induced by blue laser pointer

L. Konstantinidis UK25-gauge transretinal choroidal tumor biopsy - the beauty of simplicity

I. Kozak SAUDI ARABIANavigated pattern panretinal laser photocoagulation of the human retina

A. Leal PORTUGALCombined surgery using femtosecond laser in cataract surgery and vitrectomy 27g

M. Lezrek MOROCCOCombined penetrating keratoplasty and pars plana vitrectomy in traumatic corneal opacity, lens luxation and longstanding intraocular foreign body with siderosis

S. Mahapatra INDIA Multiple intraocular caterpillar hairs

S. Mahapatra INDIALive intravitreal gnathostoma spinigerum - a case report

P. Mainardi ITALYSubmacular perfluorocarbon liquid (PFCL)- surgical displacement

S. Malhorta INDIAConjunctival rhinosporidiosis with scleral melting, ciliary staphyloma and retinal detachment - treated with excision biopsy, staphylectomy, scleral graft, and vitrectomy

S. Malhorta INDIAParasites in the posterior segment

J. Marques PORTUGALILM staining with retidyne- the green effect

Videos submitted to the EURETINA Video Competition 2014 are available for viewing at the ePoster & Video Terminals.The Competition winners will be announced at the Opening Ceremony

taking place from 16.00 – 17.00 in Auditorium (Level 0) on Thursday 11 September.


EURETINA VIDEO COMPETITION 95

D. Martins PORTUGALInnovative technique of epiretinal membrane peeling

L. Mendonca PORTUGALOcular Trauma – rescue & salvage mission

A. Mourgela GREECEHigh viscosity silicone oil removal via sutureless vitrectomy systems

S. Natarajan INDIA25G proportional vit in a PDR patient with TRD

H. Oliphant UKA ‘no-speculum’ technique for intravitreal injections

S. Parikh INDIAInternal limiting membrane peeling in retinal detachment surgery. Pros and cons of various techniques

M. Relimpio Lopez SPAINPartial lamellar sclerouvectomy of two ciliary body tumors. Two surgical techniques

M. Relimpio Lopez SPAINSurgical technique for management of dislocated posterior chamber intraocular lens+morcher capsular tension ring

I. Shandurkov BULGARIALuxated monoblock intraocular lens in a patient with endothelial keratoplasty

M. Siddique UKModified cryo buckle surgery for retinal detachment

R. Singh INDIA25-gauge active aspiration soft tip needle assisted glass and other intraocular foreign body removal

T. Sinha INDIAClose chamber makes horizon open

S. Sizmaz TURKEYA novel technique for phacoemulsification in vitrectomized eyes- iris hooks

A. Sudhalkar INDIARadial placement of circumferential buckles

S. Tavassoli UKVideo demonstrating top ten intravitreal injection tips

P. Turkcuoglu TURKEYSuprachoroidal hemorrhage during pars plana vitrectomy in previously vitrectomized eye

J. Yepez VENEZUELAExPRESS-Shunt for choroidal fluid drainage in uveal effusion syndrome (UES)- a novel technique

H. Yetik TURKEYA new intraocular foreign body (IOFB) removal technique- polytetrafluoroethylene (PTFE / TEFLON) wrapping

J. Zarranz-Ventura UKBow-string technique for iris pupilloplasty and posterior iris-claw Artisan® intraocular lens implant in traumatic aphakia with associated iris defect

UNLOCK A WORLD OF BENEFITS INCLUDING:

embershipm

www.euretina.org

Reduced Registration Fees

Annual EURETINA Membership Directory

Access to EURETINA on Demand

Access to OphthalmologicaThe Offi cial Journal of EURETINA

Access to Online Members Area

GENERAL INFORMATION

&EXHIBITION

97



98

VenueExCeL London One Western Gateway, Royal Victoria Dock, London E16 1XL, United Kingdom

CurrencyThe official currency of the Congress is the Euro.

InsuranceDelegates are advised to take out travel insurance to cover medical expenses, accidents, loss etc. No responsibility will be accepted by the Congress Organisers.

Opening HoursRegistration

Location: Registration Hall

Wednesday 10 September 15.00 – 18.00

Thursday 11 September 07.00 – 18.00

Friday 12 September 07.00 – 18.00

Saturday 13 September 07.00 – 18.00

Sunday 14 September 07.00 – 18.00

Speaker Check-In

Location: Registration Hall

Wednesday 10 September 15.00 – 18.00





Exhibition

Location: Exhibition Hall




App KioskRegistration Hall

Visit the App Kiosk for assistance in downloading and using the Congress App

Boarding Pass Printing StationBoulevard, beneath flight display screen

Business CentreLevel 0, access from Boulevard

CafesBoulevard & Exhibition Hall (please see exhibition plan for exact locations)

CloakroomLevel 0, adjacent to Auditorium

CME CreditsEuropean Credits

Information on EACCME credits is available at www.euretina.org. In order to claim credits delegates will be required to complete an online evaluation form when they collect their congress certificate of attendance.

In addition, delegates must complete an evaluation form for every course that they attend. These forms must be completed at the end of the course and given to the hostess at the entrance to the course room. Alternatively forms can be processed electronically through the Congress App.

Each delegate should contact his/her national CME body directly in order to claim their credits for the Congress.

GENERAL INFORMATION


99

Coffee BreaksExhibition Hall

Friday 12 September (Breakfast with the Exhibitors) 10.00 – 11.00 16.00 – 16.30

Saturday 13 September 10.30 – 11.00 16.00 – 16.30


General AssemblyBoulevard E, Level 1

Friday 12 September, 09.30 - 10.30Open to EURETINA Members

EURETINA Resource Centre Exhibition Hall, Booth B01

ePosters Adjacent to Boulevard C, D & E, Level 1

First AidLevel 0, access from Boulevard

Kuoni Hotel DeskRegistration Hall

Welcome ReceptionAuditorium Foyer, Level 0


WiFiWiFi is available free of charge throughout the congress centre.

GENERAL INFORMATION


100

EURETINA would like to thank the following sponsors for their support:

SPONSORS

EURETINA would also like to thank the following companies for their support of the Surgical Skills Training Courses:

Duckworth & KentO p h t h a l m i c I n s t r u m e n t

M a n u f a c t u r e r

Join us for Breakfast in theExhibition Hall

Friday 12 September, 10.00 – 11.00

HOW DOYOU LIKEYOURS?

Enjoy a relaxed breakfast with exhibitors and fellow delegates.

Discover new ideas, meet your peers, surround yourself with

cutting edge technology and innovative research.


102 CONGRESS CENTRE

Bo

ulev

ard

D

Bo

ulev

ard

E

Bo

ulev

ard

C

ePosters

Exh

ibit

ion

Bo

ulev

ard

G

Bo

ulev

ard

H

Bo

ulev

ard

F

Bo

ulev

ard

I

Reg

istr

atio

n&

Sp

eake

r C

heck

-In

Ro

omWetlabs

Leve

l 1

Bo

ulev

ard

Bo

ulev

ard

So

uth

Gal

lery

Ro

om

s 1

- 33

Wes

tE

ntra

nce

Inte

rnet

A

rea

EU

RE

TIN

AR

eso

urce

Cen

tre

To L

evel

0

Aud

ito

rium

Leve

l 0

Leve

l 0

Leve

l 0

To L

evel

0

Eas

tE

ntra

nce

Bo

ulev

ard

B

● In clinical trials, a single injection of JETREA® (ocriplasmin) Intravitreal (IVT) Injection was shown to resolve VMT and to help close macular hole as compared to placebo7

● 26.5% of patients treated with JETREA® achieved resolution of VMT at Day 28 (vs 10.1% with placebo)7

● 40.6% of patients treated with JETREA® with full-thickness macular hole (associatedwith VMT) achieved closure of macular hole of diameter ≤400 μm at Day 28 (vs 10.6% with placebo)7

● VMT is sight-threatening. When VMT progresses, it can lead to further retinal damage such as macular hole. VMT progression can lead to vision loss. 1-3

● Symptoms of VMT and macular hole include metamorphopsia, reduced visual acuity and central vision defect and can affect activities of daily living and quality of life 4-5

● Until very recently, there have been only two options: (1) Watch and wait; (2) Vitrectomy

JETREA® (ocriplasmin) Intravitreal (IVT) InjectionThe fi rst pharmacologic treatment for vitreomacular traction (VMT) in adults, including when associated with macular hole of diameter ≤400 µm6

INTRODUCING

and

One injection of JETREA may help resolve VMT and improve patient’s vision and quality of life7

(ocriplasmin)Concentrate for solution for injection, 0.5mg/0.2ml

REFERENCES: 1. Reese AB, Jones IS, Cooper WC. Macular changes secondary to vitreous traction. Trans Am Ophthalmol Soc. 1966;64:123-134. 2. Smiddy WE, Michels RG, Glaser BM, deButros S. Vitrectomy for macular traction caused by incomplete vitreous separation. Arch Ophthalmol. 1988;106(5):624-628. 3. Schneider EW, Johnson MW. Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a review. Clin Ophthalmol. 2011;5:1151-1165. 4. Bottos J, Elizalde J, et al. Vitreomacular traction syndrome. J Ophthalmic Vis Res. 2012;7(2):148-161. 5. Steel DHW, Lotery AJ. Idiopathic vitreomacular traction and macular hole: a comprehensive review of pathophysiology, diagnosis, and treatment. Eye. 2013;27:S1-S21. 6. ThromboGenics NV. JETREA® (ocriplasmin) Summary of Product Characteristics March 2014. 7. Stalmans P, Benz MS, Gandorfer A, Kampik A, et al. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular hole. N Engl J Med. 2012;367(7):606-615.

JETREA is a registered trademark of ThromboGenics N.V., licensed to Alcon.EURETINA/RET/001/2014July 2014

J ETREA® 0.5mg/0.2ml concentrate for Summary of Product Characteristics (SmPC) before prescribing)Presentation: Type I glass vial containing 0.2ml concentrate for solution for injection. Afterdilution with 0.2ml sodium chloride 0.9% solution for injection, 0.1ml of the diluted solution contains 0.125mg ocriplasmin.Indication(s): Treatment of vitreomacular traction (VMT) in adults, including when associated with macular hole of diameter less than or equal to 400 microns. Posology and method of administration: Adults, including the elderly: Intravitreal injection of 0.125mg (0.1ml of the diluted solution) to the a� ected eye once only as a single dose. Children and adolescents: Not recommended. Hepatic and renal impairment: No dosage adjustment necessary. Contra-indications: Hypersensitivity to ocriplasmin or any of the excipients. Active or suspectedocular or periocular infections. Warnings and precautions: Proper aseptic injection techniques must always be used and patients should be monitored for any side e� ects such as intraocularin� ammation/infection and elevation in IOP. Patients should be instructed to report symptoms ofintraocular in� ammation/infection or any other visual/ocular symptoms without delay. Concurrent administration to both eyes or repeated administration in the same eye is not recommended. Clinicaldata is not available on concomitant use with VEGF-inhibitors. Treatment is not recommended inpatients with a large diameter macular hole, high myopia, aphakia, history of rhegmatogenous retinal detachment, lens zonule instability, recent ocular surgery or intraocular injection (including laser therapy), proliferative diabetic retinopathy, ischaemic retinopathies, retinal vein occlusions,exudative age-related macular degeneration (AMD) and vitreous haemorrhage. There is potential forlens subluxation or phacodonesis. Exercise caution if treating patients with non-proliferative diabetic retinopathy, history of uveitis or signi� cant eye trauma. Ocriplasmin e� cacy is reduced in patients with an epiretinal membrane or a diameter of VMA >1500 microns. Due to potentialincrease in tractional forces, there is a risk of occurrence of new or enlarged macular holes. There is a risk of signi� cant but transient loss of visual acuity during the � rst week after the injection. Interactions: Formal studies have not been performed. Systemic interactions are not anticipated. Administration in close temporal association, in the same eye as other medicinal

products, may a� ect the activity of both products and is not recommended. Pregnancy and lactation: Do not use unless clearly necessary. Fertility: No fertility data are available. E� ects on abilityto drive and use machines: If visual disturbances occur, wait until vision clears before driving or operating machinery. Undesirable e� ects: Very common: vitreous � oaters, eye pain, conjunctival haemorrhage. Common: reduced visual acuity, visual impairment, blurred vision, increased intraocular pressure, metamorphopsia, conjunctival oedema, eyelid oedema, photopsia, conjunctival hyperaemia, ocular hyperaemia, retinogram abnormal, eye irritation, dry eye, foreign body sensation in eyes, eyepruritus, ocular discomfort, photophobia, chromatopsia. Serious: retinal haemorrhage, vitreous haemorrhage, retinal tear, retinal detachment, macular hole, macular degeneration, retinal degeneration, macular oedema, retinal oedema, retinal pigment epitheliopathy, vitreous adhesions, vitritis, anterior chamber cell, anterior chamber � are, iritis, vitreous detachment, transient blindness, lens subluxation, scotoma, visual � eld defect, hyphaema, pupils unequal, corneal abrasion, anterior chamber in� ammation. In addition: diplopia, miosis, eye in� ammation, conjunctival irritation. Prescribers should consult the SmPC in relation to the side e� ects. Overdose: Clinical data are limited. If an overdose occurs, close monitoring is recommended. Incompatibilities: Must not be mixed with other medicinal products except for the speci� ed diluent.Special Precautions for Storage: Store frozen at -20°C ±5°C. Legal Category: POM. Package Quantitiesand Basic NHS Costs: 1 x 0.2ml vial £2,500. Ireland Price: €3,099. MA Number(s): EU/1/13/819/001. Further information available from the MA holder: ThromboGenics NV, Gaston Geenslaan 1, B-3001 Leuven, Belgium. Distributor: Alcon Laboratories (UK) Limited, Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR. Date of preparation: June 2013 (V2).

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Alcon Medical Information.Tel: 0871 376 1402. Email: [email protected]

Euretina 8/14

86821 JET/OCR_HCP 059-03/13-AL (A).indd 1 7/18/14 11:01 AM


104 EXHIBITION

F11 B40

B29

B41

B39

C04

C06

C07

C08E04

G04

G03

G02

G01

F02 F01 E01 D01AD01B

E06

E05A

D01 B03 B02 B01EURETINA Resource

Centre

A01

A02

A03

A04

A06

A07

A08

A09

A05

G08

H08

I07I08

J13A

J13

J14J15K19

J16

J17

J34

J35

J36

J38

J37

J27K22

L15

L13

L16L17

L18

J28

J29

J33

J32

J30

J31

K34

K33

K31

K32

J12J21

J26

K23

K24

K27

K26

K25

K28

K15

K17

K18

K20

K21

K29L

14

L23

L19

L22

L21

L20

L24

M12

M11

M10

M09

M08

M07

M06

M05

M04

M02A

M01 K03 K02 I01 H03H04 H02 H

01K01

J01

M03

M02

K30

K16

J22

J25

J24

J23

J11

K09

K11

K13

K10

J18J19

J20K14

K08

J05

J03

J08J0

7J0

6

J04

K12

J10

H09

H06 H07

G06G

12G11

G09

G10 G

07

G05

E03

E02

E05

C05

C03

B38

B37

B30

B36

B42

B43

B45

B44

B32

B35

B33

B34

B22

B25

B23

B24

B12

B15

B13

B14

A29

A30

A32

A31

B31

B26

B21

B16

B17

A12A13

A23 A

24

A22

A21

B11

A27

A11

A10

A26

A25

A28A24A

B10B

B18

B10A

B27

B20

B28

B19

C14

C15

C13

C12C10

C09 C11

D02

E12

E11

E10

E07

E09

E08

E13

D03 C01

D05

D04

E14F08

F07F09

F06

F03

F05G13

H11H14

J09

H13

H05AH05I02

I03

J02

I05

I06

L12

L09

L11

L10 I10

I11

I15I16I18I17

I12

I09

I04

K07

K04

K06

K05

L04

L01

L03

L02

L08

L05

L07

L06H12

H10F04

G14H17H16H15G15

B10

A20

A17

A16

A15

A14

B09B07B06

B04B05B08

A19

A18

E17

E18

E16E19

E15E20

E23

E25E24

E22F10G16

H24

H20H21

H26H27

H22H23H19H18

K35 K36

K38 K37

D09 D06

D08

D10

D11 D07

D13

D14

D12D15

D15A

D16

D17

Boulevard BoulevardEast

EntranceWestEntrance

Entrance Entrance Entrance Entrance Entrance Entrance

Catering & Seating Area Catering & Seating Area Catering & Seating Area Catering & Seating Area


105EXHIBITION

F11 B40

B29

B41

B39

C04

C06

C07

C08E04

G04

G03

G02

G01

F02 F01 E01 D01AD01B

E06

E05A

D01 B03 B02 B01EURETINA Resource

Centre

A01

A02

A03

A04

A06

A07

A08

A09

A05

G08

H08

I07I08

J13A

J13

J14J15K19

J16

J17

J34

J35

J36

J38

J37

J27K22

L15

L13

L16L17

L18

J28

J29

J33

J32

J30

J31

K34

K33

K31

K32

J12J21

J26

K23

K24

K27

K26

K25

K28

K15

K17

K18

K20

K21

K29L

14

L23

L19

L22

L21

L20

L24

M12

M11

M10

M09

M08

M07

M06

M05

M04

M02A

M01 K03 K02 I01 H03H04 H02 H

01K01

J01

M03

M02

K30

K16

J22

J25

J24

J23

J11

K09

K11

K13

K10

J18J19

J20K14

K08

J05

J03

J08J0

7J0

6

J04

K12

J10

H09

H06 H07

G06G

12G11

G09

G10 G

07

G05

E03

E02

E05

C05

C03

B38

B37

B30

B36

B42

B43

B45

B44

B32

B35

B33

B34

B22

B25

B23

B24

B12

B15

B13

B14

A29

A30

A32

A31

B31

B26

B21

B16

B17

A12A13

A23 A

24A22

A21

B11A

27

A11

A10

A26

A25

A28A24A

B10B

B18

B10A

B27

B20

B28

B19

C14

C15

C13

C12C10

C09 C11

D02

E12

E11

E10

E07

E09

E08

E13

D03 C01

D05

D04

E14F08

F07F09

F06

F03

F05G13

H11H14

J09

H13

H05AH05I02

I03

J02

I05

I06

L12

L09

L11

L10 I10

I11

I15I16I18I17

I12

I09

I04

K07

K04

K06

K05

L04

L01

L03

L02

L08

L05

L07

L06H12

H10F04

G14H17H16H15G15

B10

A20

A17

A16

A15

A14

B09B07B06

B04B05B08

A19

A18

E17

E18

E16E19

E15E20

E23

E25E24

E22F10G16

H24

H20H21

H26H27

H22H23H19H18

K35 K36

K38 K37

D09 D06

D08

D10

D11 D07

D13

D14

D12D15

D15A

D16

D17

Boulevard BoulevardEast

EntranceWestEntrance

Entrance Entrance Entrance Entrance Entrance Entrance

Catering & Seating Area Catering & Seating Area Catering & Seating Area Catering & Seating Area

eval

uatio

n fo

rmsposter search

exhibition add your notes

programme schedulenotifications

speaker search

favo

urite

s

EURETINA APP

Sponsored by

‘EURETINA London 2014’ Any web enabled device

Free wi-fi throughout the congress centre

m.euretina.org

App Password: EURETINA


107

1stQ Deutschland GmbH & Co. KG H22

66 VISION TECH CO., LTD. A10

9Glens® Medical Limited E23

A.R.C. Laser GmbH D02

Abbott Medical Optics G13

Accutome G12

AcuFocus, Inc. C01

Aeon Astron Europe B.V. M09

AIVIMED GmbH B36

AJL OPHTHALMIC S.A. K37

akrus J34

AKtive S.r.l. B25

AL.CHI.MI.A. S.r.l. A25

Albert Heiss GmbH & Co. KG E01

Albomed GmbH E23

ALCON B10

Alimera Sciences Ltd. C09

Allergan C15

American Academy of Ophthalmology (AAO) H04

APACRS E05A

APPASAMY ASSOCIATES M02

ARCADOPHTA D12

ASCRS E05

ASICO LLC H19

AST Products, Inc. K35

Asuzna Instrument Co. B43

Aurolab E15

Avedro, Inc. F08

Bausch + Lomb Technolas F03

Bayer HealthCare D04

Beaver Visitec International F05

Beijing SonopTek Co., Ltd. L18

Benz Research & Development E12

Better (Jiangsu) Medical Device Co., Ltd. M12

Biomed Device s.r.l. A24A

Biotech Vision Care Pvt. Ltd. K15

Bio-Tissue A09

Blink Medical Ltd. H06

Block Optic Ltd. D13

Bohus BioTech AB A28

bon Optic H23

brumaba GmbH & Co. KG C06

C.I.O.M. srl J15

C.S.O. H23

Calhoun Vision I09

Canon Europa N.V. H10

Cardivon Surgical K27

Care Group M02A

Carl Zeiss Meditec AG E14, E22

Ceatus Media Group G01

Centervue SpA I04

ChongQing KangHuaRuiMing Science Technology Co.,Ltd. L14

ChongQing SunKingdom Medical Instrument Co.,Ltd. M11

Cilita Ltd. B18

Clarity Medical Systems I03

Contamac K18

Contateq K18

Cristalens Industrie D10

Croma-Pharma GmbH G16

CRST Europe J21

Daud Jee Mfg. Co. B14

Diamatrix Ltd. J24

DIOPTEX GmbH H03

Domilens GmbH A03

D.O.R.C. E07

Duckworth & Kent Ltd. I06

e.janach srl B40

Eagle Labs B19

Eagle Optics Pvt. Ltd. J26

Ellegi Medical Optics Srl B41

Ellex H11

Endo Optiks, Inc. G07

Entod Research Cell UK Ltd. L15

Epsilon USA G05

ESASO B27

ESCRS Resource Centre J09

ESCRS Clinical Survey H24

EuCornea D01B

EURETINA Resource Centre B01

European Journal of Ophthalmology B37

LIST OF EXHIBITORS

LIST OF EXHIBITORS

EVER B21

Excel Optics (Pvt ) Ltd. J32

Eye Technology Ltd. H21

EyeBag Company A32

Eyekon Medical J01

Eyeol UK Limited L02

Eyetec GmbH D14

Eyezoom UK Ltd. J38

FCI SAS B39

Forus Health K24

Frastema S.r.l. B28

Freedom Ophthalmic Pvt., Ltd. B34

Gebauer Medizintechnik GmbH H18

Geuder AG H15

Glaukos G03

Haag-Streit Diagnostics F09

Haag-Streit Surgical F09

Hanita Lenses C12

Heidelberg Engineering GmbH G14

HEINE OPTOTECHNIK GmbH & Co. KG C10

Horus Pharma E18

Howard Instruments, Inc. D17

HOYA Surgical Optics GmbH H17

HumanOptics AG B08

Huvitz Co., Ltd. D07

Icare Finland Oy B05

ifa systems AG A02

Imagine Eyes B23

i-Medical Ophthalmic International GmbH L05

Inami & Co., Ltd. J29

Indo Webal Surgical Pvt. Ltd. J25

International Conference on Ocular Infections K01

Insight Instruments, Inc. B20

Interact Medical K33

International Sight Restoration Eye Bank I15

International Society of Refractive Surgery (ISRS) H04

iolAMD L07

i-Optics B.V. M03

IOPtima K22

IRIDEX K17

IROC Innocross J04

Iscon Surgicals Ltd. B35

iSTAR Medical B33

iVis Technologies L08

Jamjoom Pharma H14

JingMing Science & Technology Co.,Ltd. Shanghai L18

John Weiss International F09

JP Medical Ltd. M06

Kai Europe GmbH B06

Karger Publishers A22

Karl Kaps GmbH & Co. KG J03

Katana Technologies F02

Katena Products, Inc. L09

Keeler K05

Kemin Pharmaceutica Lda I12

Keratoconus Solutions I07

Konan Medical USA K14

Koryoeyetech Co.,Ltd. B32

Kowa Optimed Europe Ltd. B03

Lacrivera E24

Lambda-X S.A. J07

LCA Pharmaceutical K13

Leica Microsystems AG A17

Lenstec A05

Lifeline Medical Devices Pvt. Ltd. K21

LightMed Corporation K16

LKC Technologies, Inc. B45

Lucid Korea Co., Ltd. K38

Lumenis (Germany) GmbH A14

Luneau I10

M.E.D. Medical Products GmbH E02

MacuVision Europe Ltd. E25

Madhu Instruments Pvt. Ltd. D16

Malosa Medical B04

Mani, Inc. B10B

MDT Sp. z o.o. I11

Meccanottica Mazza S.r.l. K08

MEDA Co., Ltd. I08

Medeuronet A11

Medicel AG K04


108

50©2014, Oraya Therapeutics, Inc. All rights reserved. PMAF2014-176Oraya Therapy and I-Guide are trademarks and IRay is a registered trademark of Oraya Therapeutics, Inc.Stratus OCT is a trademark of Carl Zeiss Meditec, Inc.

The IRay is a CE-marked medical device. The IRay is not available for sale in the United States. For additional details, including safety and risk information, please see the Oraya website at www.orayainc.com.

Visit the Oraya Therapy Booth #C 11

*The INTREPID 2-year results were presented at the 2013 EURETINA Congress in Hamburg, Germany. The targeted population includes wet AMD patients with lesion size ≤ 4 mm and macular volume >7.4 mm3 as measured by Stratus OCT™.

www.orayainc.com

Half5555tio5500s55the patients required only one injection in two years*55%55r00i00Saturday, September 13, 2014 | Time: 10:00 – 11:00am | Room: Boulevard H

Please Join Us at the Oraya Satellite Seminar

PresentationSpeaker

ModeratorT. Jackson (UK)

Review of 3 year INTREPID safety resultsU. Chakravarthy (UK)

Safety aspects of using radiotherapy for treating the retinaI. Rennie (UK)

SEE THE IMPACT OF ORAYA THERAPY™ ON WET AMD PATIENTS

One year patient results and observations in the UKT. Aslam (UK)

Register Today http://www.euretina.org/London2014/satellite-meetings.asp

One year patient results and observations in SwitzerlandK. Hatz (CH), I. Keslikaslan (CH)

Patient selection for best wet AMD outcomesS. Grisanti (DE)

Oraya Therapy in the NHS and treatment of the naive patientC. Brand (UK)

EURETINA is delightedto announce the 3rd Retina Race

Date: Saturday 13 September(Registration opens at 6.30am)

Location: ExCeL Congress Centre (East Entrance), London

Registration Fee: £25 in aid of Orbis

For more information, to register or to collect registration packs visitthe Novartis & Alcon Booth (B10)


111

MEDICEM International CR, s.r.o. H20

Medicontur International S.A. H16

Medimaging Integrated Solution, Inc. B42

Mediphacos G15

Medisoft Limited B15

MED-LOGICS, INC. K19

MedOne Surgical, Inc. C08

Meridian AG K12

Metrovision B12

Micro Medical Devices, Inc. H07

MID Labs , Inc. G04

Millennium Biomedical, Inc. (MBI) D08

Moorfields Pharmaceuticals J13

MORCHER GmbH E10

MORIA F06

Moss Vision, Inc. I05

MoVu, Inc. M04

MST (MicroSurgical Technology) C07

NanoVision Group D11

Neitz Instruments Co.,Ltd. M07

NeoMedix Corporation A29

Network Medical Products Ltd. B29

Network Technology Development Ltd. B13

New Vision, Inc. K26

New World Medical, Inc. E19

NIDEK CO., LTD. E13

Nordset GmbH & Co.KG B31

Novartis Pharma AG B10

OASIS Medical, Inc. G09

Ocular Instruments, Inc. E03

Ocular Surgery News Europe Edition and Healio.com by SLACK Incorporated E16

Oculentis GmbH D06

OCULUS Optikgeräte GmbH A15

OD-OS GmbH A20

Oertli Instrumente AG B09

Oftagen Surgical srl E17

Okuvision GmbH A27

Omni Lens Pvt. Ltd. J31

Ophmed Co., Ltd. K20

Ophsurin Co., Ltd. A24

Ophtec H12

Ophthalmology Times Europe B44

Optico Ltd. J05

Optikon 2000 SpA H05

Optimal Saglik Urunleri San. ve Dis Tic. Ltd. Sti. E20

Optimed A26

Optomed Oy (Ltd.) C04

Optos plc F07

Optotek d.o.o. A19

Optovue, Inc. F10

Oraya Therapeutics, Inc. C11

Orbis A01

OXFAM A01

OXYMAP ehf D15A

Peschke Trade GmbH H07

pfm medical ag G02

Phakos A30

Phronema srl E04

PhysIOL SA H13

Plusoptix GmbH G08

Polytech Ophthalmologie GmbH A03

Prescott’s, Inc. B22

Quantel Medical I02

Rapid Pathogen Screening, Inc. (RPS) J23

Rayner Intraocular Lenses E11, J02

Refocus Group L10

Reichert, Inc. L01

Reper-NN K34

R.E.T., Inc. A08

Retina Implant AG A27

Retina Today J21

ReVision Optics, Inc. K07

Rhein Medical, Inc. C03

Righton - Right MFG. Co., Ltd. B38

Rini Ergoteknik AB K10

Roland Consult B16

Rumex International Co. K09

Ryazan State Instrument-Making Enterprise B24

Santen Oy F04

LIST OF EXHIBITORS


112 LIST OF EXHIBITORS

SCHWIND eye-tech-solutions GmbH & Co.KG C13

SciCan Ltd. L04

Scope Ophthalmics H27

Second Sight Medical Products A04

Sensimed AG K11

Sensor Medical Technology K25

Shanghai MediWorks Precision Instruments Co., Ltd. K36

Sharpoint - Surgical Specialties Corporation H08

SHIN-NIPPON (Rexxam Co.,Ltd.) I01

SIFI MEDTECH J10

SIFI SpA J11

SOE 2015 B11

SOLEKO SPA A21

SolGent Co., Ltd. J30

Sonomed Escalon J27

SOOFT italia Spa D01

SpaMedica J37

Speedway Surgical Co. J33

STAAR Surgical AG C14

Stem Alpha S.A. K29

Stereo Optical Company, Inc. C05

Sterimedix Limited G10

SurgiCube International B.V. J18

Surgistar E08

Surgitrac Ltd. E09

Susruta Instruments Pvt. Ltd. K30

Synergetics A07

Takagi Europe Ltd. & Takagi Seiko H05A

Tissue Banks International J36

TearLab Corp A06

TearScience K06

Tecfen Medical B17

Teknomek Medikal Malz. San. ve Tic. Ltd. Sti J08

The Angiogenesis Foundation L17

The Ophthalmologist L13

THÉA F11

Tianjin Jingming New Technological Development Co., Ltd. I16

Tianjin Suowei Electronic Technology Co.,Ltd. B10A

Titan Medical LLC K28

Titan Surgical E06

Tomey GmbH D09

Topcon Europe Medical B.V. D05

Tracey Technologies B30

TRB Chemedica International SA J20

TRIOPTICS GmbH J17

Tristel Solutions Limited D15

Trusetal Verbandstoffwerk GmbH A23

TTI Medical F14

U.S. IOL INC. / Stephens Instruments G11

UFSK-International OSYS GmbH B07

UNILIFE K32

Ursapharm Arzneimittel GmbH D03

Valon Lasers Oy A18

VectorVision G01

Vindico Medical Education J19

Visiometrics, S.L. B26

Vision Share G06

VisionCare Ophthalmic Technologies, Inc. J22

Volk Optical K05

Voptica J12

VRmagic GmbH J28

VSY Biotechnology L06

WaveTec Vision Systems, Inc. H26

Wexler Surgical, Inc. J06

Wisepress Bookshop F01

Xuzhou Kaixin Electronic Intrument Co.,Ltd. M10

Yuratek Ltd. Sti. K02

Zabby’s A31

Ziemer Ophthalmic Systems AG A16

New Books in Ophthalmology

ESASO Course Series

F. Bandello, B. Corcóstegui

Vol. 3

CataractEditor

J.L. Güell

Developments in Ophthalmology, Vol. 50 Glaucoma Surgery Editors: Bettin, P. (Milan); Khaw, P.T. (London) XII + 188 p., 45 fig., 38 in color, 8 tab., hard cover, 2012 CHF 198.00 /EUR 165.00 / USD 233.00 ISBN 978–3–8055–9937–5

Prices subject to changeEur price for Germany,

USD price for USA and Latin America only

ESASO Course Series


Vol. 2

Surgical RetinaEditors

F. BandelloM. Battaglia Parodi

Developments in Ophthalmology

Editor: F. Bandello

Vol. 52

Ophthalmic Radiation Therapy Techniques and Applications

Editors

A.D. SinghD.E. PelayesS. SeregardR. Macklis

ESASO Course Series


Vol. 1

Medical RetinaEditors

F. BandelloG. Querques


Editor: F. Bandello

Vol. 50

GlaucomaSurgeryEditors

P. BettinP.T. Khaw


Editor: F. Bandello

Vol. 51

New Treatments in Noninfectious UveitisEditors

E. MiserocchiG. ModoratiC.S. Foster

ESASO Course Series, Vol. 3CataractEditor: Güell, J.L. (Barcelona)VIII + 140 p., 178 fig., 168 in color, 5 tab., soft cover, 2013CHF 98.00 / EUR 82.00 / USD 115.00ISBN 978–3–318–02410–4

ESASO Course Series, Vol. 2 Surgical Retina ESASO modules 2009 and 2010:Selected contributions Editors: Bandello, F. (Milan); Battaglia Parodi, M. (Milan) X + 178 p., 89 fig., 56 in color, 23 tab., soft cover, 2012 CHF 98.00 / EUR 82.00 / USD 115.00 ISBN 978–3–318–02158–5

ESASO Course Series, Vol. 1Medical Retina ESASO modules 2009 and 2010: Selected contributions Editors: Bandello, F. (Milan); Querques, G. (Paris) X + 160 p., 88 fig., 68 in color, 10 tab., soft cover, 2012 CHF 98.00 / EUR 82.00 / USD 115.00 ISBN 978–3–8055–9990–0

Developments in Ophthalmology, Vol. 52Ophthalmic Radiation TherapyTechniques and Applications

Editors: Singh, A.D. (Cleveland, Ohio); Pelayes, D. (Buenos Aires); Seregard, S. (Stockholm); Macklis, R. (Cleveland, Ohio)XIV + 126 p., 49 fig., 42 in color, 7 tab., hard cover, 2013CHF 189.00 / EUR 158.00 / USD 222.00 ISBN 978–3–318–02440–1

Developments in Ophthalmology, Vol. 51 New Treatments in Noninfectious Uveitis Editors: Miserocchi, E. (Milan); Modorati, G. (Milan); Foster, C.S. (Cambridge, Mass.) XII + 166 p., 14 fig., 8 in color, 24 tab., hard cover, 2012 CHF 159.00 / EUR 133.00 / USD 187.00 ISBN 978–3–8055–9986–3

S. Karger AGP.O. BoxCH–4009 Basel (Switzerland)Tel. +41 61 306 11 11 Fax +41 61 306 12 [email protected]

Jour

nals

Ophthalmologicawww.karger.com/oph

For further information and easy ordering please go to

www.karger.com/ophthalmology

www.karger.com/cop

Open access, online only, peer reviewed

www.karger.com/orewww.karger.com/oop

KI14

477

ESASO Course Series


Vol. 4

Optical CoherenceTomographyEditors

G. Coscas A. Loewenstein F. Bandello

ESASO Course Series


Vol. 5

Orbital SurgeryEditors

R. MedelL.M. Vásquez

5

ESASO Course Series, Vol. 4Optical Coherence TomographyEditors: Coscas, G. (Créteil/Paris); Loewenstein, A. (Tel Aviv); Bandello F. (Milan) XII + 134 p., 137 fig., 97 in color,9 tab., soft cover, 2014CHF 98.00 / EUR 82.00 / USD 115.00ISBN 978–3–318–02563–7

ESASO Course Series, Vol. 5 Orbital SurgeryEditors: Medel, R. (Barcelona); Vásquez, L.M. (Barcelona)VIII + 92 p., 75 fig., 70 in color, 3 tab., soft cover, 2014CHF 98.00 / EUR 82.00 / USD 115.00ISBN 978–3–318–02605–4

Just published


Editor: F. Bandello

Vol. 54

Microincision Vitrectomy SurgeryEmerging Techniques and Technology

Editors

H. OhY. Oshima


Editor: F. Bandello

Vol. 53

Cell-Based Therapy for Retinal Degenerative DiseaseEditors

R.P. Casaroli MaranoM.A. Zarbin

Developments in Ophthalmology, Vol. 53Cell-Based Therapy for Retinal Degenerative DiseaseEditors: Casaroli-Marano, R.P. (Barcelona); Zarbin M.A. (Newark, N.J.) XII + 206 p., 55 fig., 41 in color, 6 tab., hard cover, 2014CHF 198.00 / EUR 165.00 / USD 233.00ISBN 978–3–318–02584–2

Developments in Ophthalmology, Vol. 54Microincision Vitrectomy SurgeryEmerging Techniques and Technology

Editors: Oh, H. (Amagasaki); Oshima, Y. (Tokyo)XII + 268 p., 143 fig., 125 in color, 10 tab., hard cover, 2014CHF 224.00 / EUR 187.00 / USD 264.00ISBN 978–3–318–02660–3

Just published


115EUROTIMES SATELLITE EDUCATION PROGRAMME


MORNING SYMPOSIA

10.00 – 11.00Boulevard G (Level 1)

Ranibizumab: Compelling Evidence and Clear Guidance in Myopic CNV Management

Moderator: A. Tufail UK

Sponsored by


LUNCHTIME SYMPOSIA

13.00 – 14.00Boulevard C (Level 1)

Changing Perspectives in the Understanding of Diabetic Retinopathy / Macular Edema

Moderators: F. Bandello ITALY A. Loewenstein ISRAEL

Sponsored by

BOXED LUNCH INCLUDED

13.00 – 14.00Boulevard D (Level 1)

Ranibizumab: Optimizing Benefits and Risks in DME Management

Moderator: C. Pruente SWITZERLAND

Sponsored by



116

Friday 12 September

MORNING SYMPOSIA


Faster and Smaller in Retina Surgery: A Video Presentation of New Technologies and Techniques

Moderator: P. Dugel USA

Sponsored by


Aflibercept and the Evolution of CRVO Management

Moderator: A. Lotery UK

Sponsored by

10.00 – 11.00Boulevard H (Level 1)

Sucessful New Clinical Approaches with Diagnostics and Intra-operative OCT

Moderator: S. Binder AUSTRIA

Sponsored by

LUNCHTIME SYMPOSIA


DME: When Every Letter Counts

Moderator: J-F. Korobelnik FRANCE

Sponsored by



Ranibizumab: Expanding Horizons in RVO Management

Moderator: J. Monés SPAIN

Sponsored by


13.00 – 14.00Boulevard E (Level 1)

Stellaris® PC Next Generation – Latest Advances in Combined Surgery

Moderator: P. Lanzetta ITALY

Sponsored by

EUROTIMES SATELLITE EDUCATION PROGRAMME


117

Friday 12 September

LUNCHTIME SYMPOSIA


New Advances in Retinal Imaging: Rapidly Improving Diagnosis & Treatment Outcomes

Moderators: S. Sadda USA P. Stanga UK

Sponsored by



Changing Perspectives in DMO: Recognising & Understanding Chronic DMO

Moderators: U. Chakravarthy UK

Sponsored by


13.00 – 14.00Boulevard I (Level 1)

Swept Source: 3rd Generation OCT

Moderator: P. Patel UK

Sponsored by


Saturday 13 September

MORNING SYMPOSIA


Ocriplasmin: Beyond Clinical Trials into Real-World Experience

Moderator: P. Dugel USA

Sponsored by


Management of RVO - Lessons Learned from Long Term Clinical Experience

Moderators: B. Kuppermann USA A. Augustin GERMANY

Sponsored by


See the Impact of Oraya Therapy on Wet AMD Patients

Moderator: T.L. Jackson UK

Sponsored by



118


LUNCHTIME SYMPOSIA


Forging the Future in nAMD: The Role of anti-VEGF and Novel Therapeutic Targets

Moderator: R. Hamilton UK

Sponsored by



Is Now the Time to Challenge our Treatment Approach in Wet AMD? Lessons Learned from Patient and Clinical Experience

Moderator: P. Lanzetta ITALY

Sponsored by



Say No to Blindness with Second Sight’s Argus II Bionic Eye

Moderators: T. Wolfensberger SWITZERLAND L. da Cruz UK E. de Juan USA

Sponsored by



LUNCHTIME SYMPOSIA


Next Generation Vitrectomy – EVA and Other Surgical Innovations

Moderator: P. Stalmans BELGIUM

Sponsored by


13.00 – 14.00Boulevard I (Level 1)

Retina, Choroid and Vitreous: The Impact of Latest and Advanced Imaging on Clinical Practice

Moderator: E. Midena ITALY

Sponsored by




119

AAaberg, T. 19Abdala, C. 57Abdul Karim, M. 31, 84Abdullatif, A. 38Abouammoh, M. 90Abouhussein, M. 31, 64Abou-Ltaif, S. 71Abraham, A. 75, 76, 82Abreu, R. 76, 80, 84Abrishami, M. 63, 79, 84Absalijamov, M. 69Abulon, D. 90Abushaala, M. 84Acar, N. 14, 90Acer, S. 76Afonso, J. 76Agarwal, A. 47Agarwal, M. 69, 82, 94Agrawal, R. 22Agrawal, V. 14, 90, 94Ahmed, A. 57, 84Ainashar, H. 84Akca Bayar, S. 76Akhundova, L. 14Aki, S. 84Alabduljalil, T. 31Alahmadawy, Y. 64Alarcón Valero, I. 80, 82Ali, O. 90Ali, R. 26Almeida, R. 84Almuhtaseb, H. 53Al-Nashar, H. 14Alonistiotis, D. 13Alqahtani, A. 65Alshehri, K. 90Alvarez, I. 90Amantea, C. 91Ambresin, A. 64Ammous, I. 76Anastasilakis, K. 75, 94Androudi, S. 59Aramburu del Boz, A. 52Arevalo, F. 45Argaya Amigo, J. 94Arias, L. 49, 69Arifoglu, H. 76Aristodemou, P. 38Arndt, C. 80Arora, A. 31, 79Arroyo, R. 84Arsenevic, Y. 26Arsiero, M. 52Artunay, O. 84Arumí, J. García 54Asai, T. 84Ascaso, F. 76, 84Ascaso, J. 54Asteriades, S. 58Audo, I. 33Augustin, A. 16, 21, 27, 32, 34, 51, 59, 68, 117Aurora, A. 80Avitabile, T. 31

Avci, R. 91Averbukh, E. 28, 65Awadein, A. 39Aydin, E. 84Aydin, R. 91Aylward, B. 10, 11, 21, 44, 62Azrak, C. 76

BBabovic, S. 91Bacalhau, C. 79Bailey, C. 62Bainbridge, J. 26Bakbak, B. 84Balaggan, K. 58Balakrishnan, D. 75, 84Balasubramanian, R. 91Balatsoukas, D. 79, 84Balta, F. 19, 94Bamonte, G. 91Bandello, F. 13, 20, 23, 30, 32, 35, 44, 52, 65, 67, 115Banerjee, P. 12Banin, E. 26Barboni, P. 54Barman, M. 49, 80Barthelmes, D. 71Barton, K. 66Bastos, R. 76Batıoğlu, F. 76Batta Arora, S. 35, 68, 91Battaglia Parodi, M. 20, 57Bayborodov, Y. 93Beato, J. 76, 82Bechrakis, N. 16, 40, 55Beirão Cardoso Quadrado Gil, P. 79Bek, T. 70Belfort Jr, R. 82Belfort, R. 13Bellucci, R. 52Benjamin, L. 59Ben Yahia, S. 76Berger, L. 38Berg, K. 38Berker, N. 82Bertelmann, T. 80Bhatt, C. 94Bhende, M. 18, 91Bhushan, G. 94Bicer, T. 80Bikbova, G. 14Binder, S. 8, 45, 49, 57, 116Bleier, J. 84Bodis-Wallner, I. 54Boeker, T. 10, 11Bolz, M. 50Bompastor Ramos, P. 85Boon, C. 33, 40, 46, 63Boras, I. 85Borges, T. 85Bornfeld, N. 16, 17, 44Boscia, F. 19, 51, 67Bouchepillon, J. 12Brand, C. 71

INDEX

Branisteanu, D. 85Brazitikos, P. 59, 66Brent, A. 80Brito, R. 85Brosh, K. 91Buckle, M. 26, 71Budakoglu, O. 82Buitendijk, G. 63Burke, T. 31Burton, B. 13Busatto, P. 80Byon, I. 85

CCaballero Agudo, J. 82Cabugueira, A. 75, 85Cachulo, M. 27Calvão-Santos, G. 76Cano, R. 51, 57Caprani, S. 91Capuano, V. 53Caputo, G. 19Caramoy, A. 18Carbonell Puig, M. 80Cardoso, M. 91Cardoso, P. 63Carreño, E. 56Cascella, M. 91Casco Silva, B. 94Castro Navarro, V. 71Cebeci, Z. 85Ceklic, L. 52Celik, N. 85Cerovic, V. 91Cetin, E. 57, 76Chae, J. 91Chait Diaz, F. 76Chakraborty, D. 14, 57, 94Chakraborty, S. 94Chakravarthy, U. 13, 27, 33, 117Chanana, B. 64Chan, C. 17, 76Chan, E. 79Chandra, A. 12Chang, A. 45, 71Chao, H. 91Charbel Issa, P. 20Charteris, D. 44, 62Chatziralli, I. 85Chaudhary, V. 71Chawla, S. 85, 94Chee, C. 82Cheung, G. 45Chhablani, J. 76, 80, 94Chia, K. 71Ch’ng, S. 71Choi, S. 85Chong, V. 40, 49Cho, S. 91Chow, D. 36, 39Chowers, I. 28Cho, Y. 39Ciardella, A. 76Cilliers, H. 63, 85


120 INDEX

Claes, C. 19, 22, 44, 54Coelho, P. 79Cohen, S-Y. 28Colaço, M. 76, 81, 91Contreras, I. 81Coppola, M. 91Corcóstegui, B. 13, 51, 57, 65, 66, 67Corcostegui, I. 64Cordeiro, F. 54Cordes, A. 85Corvi, F. 76Coscas, G. 28, 31Cosendai, G. 52Coskun, E. 82Costa, J. 91Costin, D. 71Couceiro, R. 77, 85Coupland, S. 16Creuzot-Garcher, C. 22Crosby-Nwaobi, R. 85Cunha-Vaz, J. 20, 35, 65Cywinski, A. 71Czaplicka, E. 82

Dda Cruz, L. 15, 26, 58, 118Dalkara, D. 26Dameria, X. 82Danis, R. 33Darrad, K. 68, 85Das, S. 49, 82, 94de Boer, J. 37De Casas, A. 85de Giacinto, C. 14de Juan, E. 118de Massougnes, S. 27De Salvo, G. 77De Smet, M. 12Degli Esposti, S. 77Delori, F. 56Demircan, N. 85Demirel, S. 71Denniston, A. 15Desjardins, L. 16, 55Deutman, A. 57Devin, F. 59Diago, T. 81Di Antonio, L. 81, 85Dias-Santos, A. 68, 85Dirani, A. 71Dmitrii, A. 94Doefler Poulsen, C. 77Dogramaci, M. 12, 67Doi, N. 85Dolar-Szczasny, J. 46Dolz-Marco, R. 77, 82, 94Domínguez Fernández, R. 75Donati, S. 71Dong, Y. 39, 85Dooley, I. 45, 94Dorokhova, O. 57Dorta, P. 19Douvali, M. 85Downey, L. 36Dravitsa, L. 91

Drexler, W. 56Dsouza, S. 35, 77Dugel, P. 39, 116, 117, 71Dunaieva, M. 85Duncker, T. 31Dupas, B. 67Dysli, C. 77Dzinic, V. 31

EEckardt, C. 17, 36Efterpi, C. 75Eibenberger, K. 31El-Ashry, M. 45Elbaz, H. 26Eldem, B. 79Elgohary, M. 45, 91El Habbak, A. 18Elhousseini, Z. 22Elmalt, M. 35El Matri, L. 48El Rashedy, M. 22El-Sawy Habib, A. 22Eltanamly, R. 39Empeslidis, T. 71, 80Epstein, D. 85Erbagci, I. 85Erden, B. 77, 91Erzkuraj, S. 40Esen, E. 86

FFarmakakis, N. 80, 86Fayyad, F. 19, 30Fayzrakhmanov, R. 71, 91Felcida, V. 77, 91Feltgen, N. 39, 64, 70Fernandez Avellaneda, P. 77Fernandez-Perez, S. 86Fernandez Vega, A. 69Ferrara, V. 10, 11, 19Ferreira, C. 18, 79, 86Ferreira, N. 45Ferrero, A. 31Ferrone, P. 39Figueira, J. 14, 35Figueiredo, A. 91Figueroa, M. 69Figurska, M. 86Filloy Rius, A. 49Findl, O. 52, 91Fischer, D. 46Fleckenstein, M. 29, 46Fleck, O. 38Flores-Moreno, I. 77Foerster, M. 16Forlini, C. 19, 30Forlini, M. 30Fotis, K. 71Francesc, M. 94Franco, M. 86Funk, M. 37Fusi-Rubiano, W. 91

GGabela, G. 57Gaber, M. 91Gadhvi, K. 71Gajdošová, M. 82Gallego-Pinazo, R. 46, 77, 86Gama, I. 80Ganesan, S. 12, 79Gan, W. 22Garay-Aramburu, G. 94García Arumí, J. 14, 17, 21, 44, 66, 69Garcia Layana, A. 69García, M. 91Gardasevic Topcic, I. 86Garweg, J. 14Gaudric, A. 37, 38, 51, 59Geenen, C. 12Georgiou, T. 71Georgouli, T. 71Gerding, H. 27Ghasemi Falavarjani, K. 18, 35Ghassemi, F. 69, 86Gianni, A. 37Gil, F. 91Gillies, M. 13, 27Gil, M. 53, 71Gilmanshin, T. 91Giocanti, A. 71Gkika, M. 77Gkountelia, A. 71Gocho, K. 53Gogia, V. 81Goktas, A. 77, 81Goldstein, M. 28, 32, 67Gomaa, A. 12Gombos, D. 44Gomes, N. 35, 92Gomez Escobar, A. 75Gonçalves, R. 82, 86Gonglore, B. 86Gonul, S. 86Gonzales, C. 39Gonzalez, C. 69Gonzalez-Cortes, J. 75, 92Gonzalez Escobar, A. 82González-Gómez, A. 81Gonzalez-Lopez, J. 14Gopal, L. 22Gotzarides, S. 19Gouveia, P. 77, 82Gowda, P. 75Graue, F. 51, 57Gruener, A. 77Grzybowski, A. 53, 54, 65, 81, 92Guarnaccia, G. 65Gudsoorkar, S. 86Gulkilik, G. 86Gupta, A. 94Gupta, C. 45Gusson, E. 86Gutiérrez Benítez, L. 77Güven, D. 86Guzey, M. 68, 77, 86Guzman-Salas, P. 22


121INDEX

HHajjar, A. 80Hamam, R. 82Hamed, M. 69Hamilton, R. 58, 63, 118Hanumunthadu, D. 86Harding, S. 35, 38Hashmonay, R. 28Hassan, S. 52Hassan, T. 36, 39Hattenbach, L. 14Hatz, K. 68Healy, R. 86Hegazy, A. 22Heimann, H. 17, 21, 40, 54, 64Hejsek, L. 82Helbig, H. 17Henrich, P.B. 55Herbort, C.P. 15Heriot, W. 62Hernaez-Ortega, C. 86Herrera, L. 77Hidalgo Diaz, T. 77Hillenkamp, J. 47Hillier, R. 14Hoerster, R. 62Holder, G. 29, 48Holz, F. 29, 34, 35, 38, 56, 68Hood, M. 77Hosny, M. 49, 64Hoyng, C. 33Huang, H. 77Hua, R. 22, 53Hulpus, A. 86Hykin, P. 58, 62

IIakimov, A. 75Ibrahim, O. 71Idrees, M. 63, 86Iida, T. 45Ikeda, T. 86Ikuno, Y. 45Imamura, Y. 77Imshanetskaya, T. 30Imshenetskaya, T. 86Inan, U. 71Ingolotti, M. 86Insausti-García, A. 81Introini, U. 71Ivanescu, A. 72, 77, 82

JJackson, T.L. 27, 117Jager, M. 44Jain, P. 49Jaksic, V. 77Jay, C. 94Jelliti, B. 82Jha, S. 81Ji, Y. 94Johnson, M. 82

Johnston, R. 38, 72Jolly, J. 77Jonas, J. 10Jonasson, F. 72Jones, N. 15Jordan, S. 18Josifova, T. 86Joussen, A. 40, 50, 62Jo, Y. 92Jurgens, I. 69

KKadayifcilar, S. 81Kadifachi, M. 80Kadonosono, K. 54Kaga, T. 68Kahloun, R. 82Kaintatzis, A. 45Kaiser, P. 39, 49Kalliath, J. 79Kalogeropoulos, C. 83Kalouda, P. 86Kamalden, T. 75Kamal Salah, R. 77, 83Kambo, B. 72Kanchanaranya, N. 75, 87Kandonosono, K. 19Kannan, N. 35Kanonidou, E. 83Kanyukov, V. 81, 92Kaplan, H. 37Kapoor, B. 69Karagiannis, D. 87Karamitsos, A. 67Karastatiras, G. 92Karatay Arsan, A. 83Kar, D. 92Karliychuk, M. 72Karolczak-Kulesza, M. 87Karska-Basta, I. 72, 87Kaur, C. 87Kayabasi, U. 38Kaya, G. 72Kaya, M. 39Kayikcioglu, O. 92, 94Kaymak, H. 75, 87Kaynak, S. 19Kazaykin, V. 94Keane, P. 37Kelly, S. 72Kernt, M. 14Kestelyn, P. 15Keunen, J. 40Khafagy, A. 72Khairallah, M. 83Khalife, M. 92Khalil, H. 83Khanani, A. 72Khan, Y. 83Khatri, D. 75, 83Khattab, A. 68, 87, 92Khera, A. 92Khochtali, S. 77, 83Kida, T. 80

Kidess, A. 78Kim, H. 72, 80Kim, J. 72, 87Kim, M. 22Kirk, J. 31, 87Kir, N. 87Kiryttopoulos, P. 75, 87Kivelä, T. 44, 55Klaver, C. 27Klettner, A. 32Kocak Altintas, A. 87Kodjikian, L. 28Kogiantis, A. 72Kohn, D. 94Kojima, K. 36Kokame, G. 45Kolenko, O. 87, 92Kolli, H. 83Konstantinidis, L. 79, 94Kontou, E. 75Korobelnik, J-F. 13, 21, 52, 65, 116Korol, A. 14, 72Koshy, S. 78, 87Koshy, Z. 47, 81Kovacevic Pavicevic, D. 83Kozak, I. 13, 94Krebs, I. 8Kreissig, I. 10, 11, 30Krepler, K. 8, 68Kretz, F. 75, 81Krüger, E. 49Kubicka-Trząska, A. 72Kucukbay Yilmaz, S. 78Kucukerdonmez, C. 38, 81Kulyk, I. 35Kumar, I. 92Kumar, P. 78Kuppermann, B. 13, 51, 52, 67, 117Kusaka, S. 68Kuze, M. 81Kwak, H. 27Kychenthal, A. 19

LLa Cava, M. 83la Cour, M. 38, 52, 67LaFranco, F. 10, 11Lafuente, M. 87Laidlaw, A. 34, 36, 44, 59, 62, 66Laíns, I. 22Lai, T. 32, 45, 72Lalias, T. 78Lambrou, G. 63Lam, W. 12Lang, G. 64Lanzetta, P. 49, 70, 116, 118, 81Larsen, M. 27, 32, 62Leal, A. 72, 94Leal, I. 83Lee, D. 87Lee, E. 62, 92Lee, S. 78, 79LeHoang, P. 15, 18Leite, R. 13, 57


122 INDEX

Le Mer, Y. 44, 51, 52Lemos, J. 92Lemos, V. 83, 92Leong, T. 64, 92Leroy, B. 29, 33, 39Lesnik-Oberstein, S. 34Levytska, G. 80Leys, A. 49Leyvraz, S. 40Lezrek, M. 94Liaska, A. 72Lindner, M. 72Lin, J. 87Lipshitz, I. 47Little, B. 59Li, X. 45Lobo, C. 13Loewenstein, A. 26, 27, 28, 32, 39, 47, 51, 65, 67, 115Loganathan, D. 72Loh, B. 87Loo, V. 78López, J.C. 56Lopez Valverde, G. 83, 87Lorenz, K. 62Losada, M. 72Lotery, A. 41, 116Loukianou, E. 78Low, L. 78Lozano-Lopez, V. 81Lu, L. 81Lumi, X. 75Luo, Y. 12Luttrull, J. 40, 72Lyskin, P. 68, 81Lytvynchuk, L. 12, 27

MMaa, A. 57Machalińska, A. 52MacLaren, R. 17, 23, 26Madan, K. 68, 87Mahapatra, S. 22, 87, 94Mahdy, R. 26Mahmood, S. 63, 72, 83Mahuli, S. 83, 87Mainardi, P. 94Makled, H. 75Malhorta, S. 92, 94Malhotra, S. 39, 87Mangunkusumo, E. 87Mann, S. 36Manriquez, R. 92Mantel, I. 26Mantovani, A. 15Manurung, F. 31Marakis, T. 72March, F. 83Marin, J. 78Mariotti, C. 67Maris, D. 79Marques, J. 28, 87, 94Marques, N. 72, 87Martinez-Castillo, V. 62, 66

Martins, D. 95Martins de Almeida, I. 72, 88Martone, G. 88Mastropasqua, L. 26Mathai, A. 18Mathew, R. 64Matuskova, V. 73Mavija, M. 88Mazen, M. 64Mc Allister, I. 67McAtamney, S. 73Meillon, C. 73Menassa, N. 88Méndez, M. 88Mendonca, L. 73, 88, 95Menezes, C. 75, 79Mennel, S. 10, 11Menon, G. 63, 73Mentes, J. 78Mercanti, A. 92Merce, E. 18Mesquida, M. 64Mester, U. 10, 11Meyer, C.H. 31, 36, 55, 63, 88Michalska-Małecka, K. 88Michels, S. 81Midena, E. 13, 16, 32, 40, 50, 55Mikhail, M. 73Minaya, F. 92Mingorance Moya, E. 88Miranda, A. 52, 88Mishra, S. 69, 81Mitchell, P. 73Mitry, D. 38Mitsch, C. 38Moatez Billah, M. 88Mohamed, M. 36Mohi, A. 53Mohite, A. 73, 88Mokadam, S. 92Monaco, P. 57Mones, J. 26Monés, J. 69, 116Montero-Moreno, J. 68, 73, 81Moore, T. 58Morales, P. 79Morarji, J. 73Moraru, A. 92Morkhat, M. 73Mortada, H. 30Mourgela, A. 95Mousavi, K. 83Mrejen, S. 37, 46Mukherjee, S. 88Munier, F. 55Munk, M. 83Munoz Sanz, N. 83, 88Mura, M. 19, 34, 65Murray, P. 15Murthy, G. 83, 88

NNabawi, K. 14Nadal, J. 69Nagpall, M. 30Nagpal, M. 118Narayanan, R. 14, 31, 88Naser, M. 88Natarajan, S. 30, 62, 78, 95Nath, S. 78, 81Needham, A. 73Nehemy, M. 26, 51, 57Nemec, P. 73Neri, P. 15Neves, A. 73, 83Neves, P. 78, 92Ng, E. 68Nguyen, Q. 50Nicoara, S. 39Nikolakopoulos, A. 19, 30, 51Nobre-Cardoso, J. 14, 83Norrgren, G. 35Novolodsky, A. 75Nowilaty, S. 88Nuijts, R. 52Núñez, M. 75, 78

OOdrobina, D. 31, 92Ohji, M. 45Ohno, H. 92Ohta, K. 92Okamoto, F. 92Okamoto, Y. 78Okonkwo, O. 92Okur, V. 73Okuyama, K. 75Oliphant, H. 95Onen, M. 88, 92Oner, A. 73Oner, H. 88Örnek, K. 78, 81Oros, A. 57Oshima, Y. 36Otani, T. 88Ozdal, P. 83Özkan, B. 92Ozkaya, A. 73Özmert, E. 92Ozturk, F. 88Ozturk, T. 81, 83Ozyazgan, Y. 83

PPachkoria, K. 73Painhas, T. 50, 88Palanker, D. 34Panova, I. 18Papandreou, I. 88Papathomas, T. 31, 35Papayannis, A. 46Pappas, G. 80Pardianto, G. 50


123INDEX

Parikh, S. 49, 92, 95Park, J. 45Park, T. 53, 81Pastor-Idoate, S. 38, 56, 78Pastor, J.C. 27, 56, 62Pastor Vivas, A. 83, 93Pastukh, I. 88Patelli, F. 64Patel, N. 73Patel, P. 117Patwary, S. 38Pauleikhoff, D. 17, 20Pavesio, C. 15, 66Pearce, E. 73Pedanova, E. 73Pefkianaki, M. 78Pekel, G. 73, 88Pelayes, D.E. 16, 44, 51, 57, 63Penas, S. 88Pereira, C. 83, 88Perente, I. 78Perpétua, C. 88Pertille, G. 54Peto, T. 50, 70Pichi, F. 78Picoto Passarinho, M. 64Pierro, L. 13Pilkevich, T. 39Pinheiro-Costa, J. 22Pinto, C. 93Pircher, M. 41Pires, I. 53Plevachuk, O. 89Pleyer, U. 37Poli, A. 89Pollack, A. 73Pollreisz, A. 58Poposki, V. 81Porta, M. 20Portelinha, J. 89Pournaras, C. 32, 48, 67Pournaras, J. 12Prabhu, R. 77Prabhu, V. 89Prakash, P. 31, 89Prasartritha, W. 89Pras, E. 27Praveen, P. 33Prünte, C. 21, 115Pushpoth, S. 74Putienko, O. 93Putri, C. 89

QQuadrado Gil, J. 22Querques, G. 22, 28, 33, 46Quijano, C. 52Quintyn, J. 74Qureshi, N. 79

RRachwani, N. 78Radosavljevic, A. 84Rajendran, A. 53Ramezani, A. 35, 81, 89Rao, P. 79, 80, 84, 93Ratkovic, M. 75Razavi, S. 28Razi, F. 89Regenbogen, M. 28, 81Régnier, S. 89Rego, M. 84Rehak, M. 40, 46Rehman, A. 74Rekik, R. 93Relimpio Lopez, M. 95Rezaei, K. 54Rezar, S. 74Ribeiro, L. 35Richard, G. 10, 11, 34, 49, 52, 57Richardson, M. 78Riechardt, A. 40Riemann, C. 19, 63Rizvi, S. 93Rizzo, S. 12, 19, 34, 36, 39, 51, 54, 55, 59, 66Rodrigues, E.B. 55Rodrigues, F. 14, 80, 89Romano, M. 36, 46Romera Romero, P. 74, 84Romero-Aroca, P. 93Romina, I. 89Rosales Villalobos, F. 84, 89Rosenblatt, A. 26Rospond-Kubiak, I. 64Rossi, T. 36, 45, 49, 65, 68Rothwell, R. 18, 89Rozanova, Z. 89Rubio Caso, M. 78Rudolf, M. 27Ruiz-Medrano, J. 31, 78Ruiz-Moreno, J. 62, 69Ruiz-Moreno, O. 84, 89

SSaatci, A. 74Sabti, K. 30Sadda, S. 33, 53, 63, 117Sagoo, M. 58Saha, S. 89Sahel, J. 26Sakalar, Y. 89Sakhnov, S. 74, 93Sakurai, T. 93Sala, A. 56Salehi, A. 81Sallam, A. 63Sallo, F. 20Sandoval Codoni, J. 93Santiago, M. 80Sarmad, A. 74Satirtav, G. 18Sato, A. 74

Saw, S. 45Saxena, N. 57, 74, 89Scanlon, P. 70Scheerlinck, L. 35Schippling, S. 34Schlottmann, P. 57, 74Schmetterer, L. 48Schmidt-Erfurth, U. 17, 23, 32, 41, 52, 57Schmidt, J. 10, 11Schmitz-Valckenberg, S. 17, 29, 35, 53Scholda, C. 65Schrader, W. 30Schraermeyer, U. 31, 32, 57Schütze, C. 26Schwartz, S. 39Sebag, J. 16Seddon, J. 30Seibel, I. 40, 80Sekeroglu, M. 89Sengul, A. 78Seregard, S. 16, 44, 53, 65Seymenoglu, G. 78, 93Shafi, A. 63Shaimov, T. 74Shandurkov, I. 95Shapiro, M. 19Sharma, A. 14, 18, 22, 53, 78, 89Sharma, H. 26Sharma, M. 74Sheta, S. 45Shweikh, Y. 89Siddique, M. 89, 93, 95Siegel, R. 32Simader, C. 41Simo, R. 20Sinapis, C. 14Singh, M. 58Singh, R. 45, 78, 89, 95Sinha, T. 46, 69, 95Sin, P. 74Sinyavskiy, O. 93Sivaprasad, S. 20Sivkova, N. 10, 11Sizmaz, S. 39, 95Sımsek, H. 74Sobral, I. 89Soedarman, S. 18Soler-Garcia, A. 89Soliman, A. 93Sørensen, T.L. 38Soubrane, G. 33, 38Souied, E. 17, 28, 33Sousa, K. 31, 74Soylu, M. 84Spiteri Cornish, K. 31, 78Stahel, M. 89Stalmans, P. 12, 56, 118Stanford, M. 15Stanga, P. 10, 11, 67, 117Stanzel, B.V. 55Staurenghi, G. 20, 33, 37, 38, 41, 56Stavrakas, P. 45Stebnev, V. 93Steel, D. 21, 36, 47, 67Stefaniotou, M. 80


124 INDEX

Stefánsson, E. 16, 18, 20, 48, 65, 70Stemplewitz, B. 34Stoffelns, B. 11Stolba, U. 8Stopa, M. 75Strong, S. 89Suarez, P. 93Subramanyam, A. 68, 84Sudhalkar, A. 75, 95Sugiura, Y. 90Sujirakul, T. 31Sukavatcharin, S. 75Sullivan, P. 30, 66Sullu, Y. 81Sun, D. 63Susvar, P. 35, 75Szurman, P. 30, 44, 80

TTadayoni, R. 31, 44, 54, 55, 56Tan, A. 79Tan, L. 74Tan, S. 62Tavares-Ferreira, J. 74Tavassoli, S. 27, 95Tawansy, K. 19Taye, D. 79Taylor, S. 62Tee, J. 67Teixeira, C. 82Theelen, T. 29Theodoropoulou, S. 14Theodossiadis, P. 53Thompson, D. 29Tikhonovich, M. 18Tkachev, V. 76Toklu, Y. 90, 93Tomi, A. 84Torres-Peña, J. 79Totan, Y. 67, 79, 90, 93Toth, C. 17, 34, 41Tranos, P. 12, 58Traversi, C. 90Trese, M. 16, 19Trivedi, D. 90Troyanovsky, R. 14Tufail, A. 20, 28, 29, 35, 37, 58, 74, 115Tulasiram, L. 63Turan-Vural, E. 74Turkcuoglu, P. 93, 95Turner, G. 70

UUcgun, N. 90Udaondo, P. 74, 90Uhumwangho, O. 90Ulyanova, N. 79Umanets, N. 82Ünlü, C. 74, 82Unlu, N. 90Ünsal, E. 93

VVaclavik, V. 48Vale, C. 82, 93Valsero Franco, S. 93Vandekerckhove, K. 90van Meurs, J. 39, 44, 47, 54, 58, 62van Schooneveld, M. 49Van Zeeburg, E. 12Vatavuk, Z. 79Vaz-Pereira, S. 90Vazquez, E. 74Veckeneer, M. 62Vicente, A. 84Vieira, L. 79, 80Vilà, N. 49, 90Vinkovic, M. 90Volodin, P. 31Vossmerbaeumer, U. 11Vote, B. 74Vujosevic, S. 13, 50

WWaldstein, S. 74Walid, I. 90, 93Weinberger, D. 28Westborg, I. 27Westcott, M. 15Williamson, T. 21, 36Winder, S. 21Wolfensberger, T. 35, 44, 51, 118Wolf, S. 11, 13, 20, 23, 38, 48, 52, 56, 70Wong, C. 19Wong, D. 36Wong, I. 90Wong, R. 36Wong, S. 67Wong, T. 52

XXanthopoulou, P. 74Xirou, T. 90Xue, K. 14Xu, L. 90

YYadav, N. 22Yago, I. 84Yamaguchi, Y. 79Yamakawa, R. 93Yamamoto, S. 10, 11Yang, X. 68, 93Yang, Y. 75Yarmak, V. 31Yazar, Z. 90, 93Yazici, A. 75, 93

Yehoshua, Z. 17Yenerel, N. 76, 90Yepez, J. 95Yetik, H. 35, 93, 95Yeung, I. 79Yevsyukova, O. 93Yilmaz, G. 53Yilmaz, Y. 90Yip, P. 93Yong, S. 76Yorston, D. 21, 47Yu, S. 22, 28Yu Wai Man, P. 54

ZZachariah, S. 79Zaika, V. 93Zakri, R. 90Zanak, S. 18Zaouali, S. 90Zapata, M. 79Zarranz-Ventura, J. 75, 95Zbiba, W. 76Zborovska, O. 84Ziemssen, F. 62Zinicola, E. 65Zinkernagel, M. 38, 70Zografos, L. 16, 44, 48, 55Zrenner, E. 12

2013_066c_EE Publicité Euretina 210x297mm cor4.indd 1 10/07/14 15:01

TARGETING THE MEDIATORS OF INFLAMMATION1

Delivering efficacy in the clinical setting2-5

IL-6 IL-8 VEGF ICAM-1 MCP-1

These images are for illustrative purposes only and do not represent inflammatory mediator levels in the eye.

OZURDEX® (Dexamethasone 700 micrograms intravitreal implant in applicator)

Abbreviated Prescribing InformationPresentation: Intravitreal implant in applicator. One implant contains 700 micrograms of dexamethasone. Disposable injection device, containing a rod-shaped implant which is not visible. The implant is approximately 0.46 mm in diameter and 6 mm in length. Indications: Treatment of adult patients with macular oedema following either Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO). Treatment of adult patients with inflammation of the posterior segment of the eye presenting as non-infectious uveitis. Dosage and Administration: Please refer to the Summary of Product Characteristics before prescribing for full information. OZURDEX must be administered by a qualified ophthalmologist experienced in intravitreal injections. The recommended dose is one OZURDEX implant to be administered intravitreally to the affected eye. Administration to both eyes concurrently is not recommended. Repeat doses should be considered when a patient experiences a response to treatment followed subsequently by a loss in visual acuity and in the physician’s opinion may benefit from retreatment without being exposed to significant risk. Patients who experience and retain improved vision should not be retreated. Patients who experience a deterioration in vision, which is not slowed by OZURDEX, should not be retreated. There is only very limited information on repeat dosing intervals less than 6 months. There is currently no experience of repeat administrations in posterior segment non-infectious uveitis or beyond 2 implants in Retinal Vein Occlusion. Patients should be monitored following the injection to permit early treatment if an infection or increased intraocular pressure occurs. Single-use intravitreal implant in applicator for intravitreal use only. The intravitreal injection procedure should be carried out under controlled aseptic conditions which include the use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). The patient should be instructed to self-administer broad spectrum antimicrobial drops daily for 3 days before and after each injection. Before the injection, the periocular skin, eyelid and ocular surface should be disinfected and adequate local anaesthesia should be administered. Remove the foil pouch from the carton and examine for damage. In a sterile field, open the foil pouch and gently place the applicator on a sterile tray. Carefully remove the cap from the applicator. Once the foil pouch is opened the applicator should be used immediately. Hold the applicator in one hand and pull the safety tab straight off the applicator. Do not twist or flex the tab. With the bevel of the needle up away from the sclera, advance the needle about 1 mm into the sclera then redirect toward the centre of the eye into the vitreous cavity until the silicone sleeve is against the conjunctiva. Slowly press the actuator button until an audible click is noted. Before withdrawing the applicator from the eye, make sure that the actuator button

is fully pressed and has locked flush with the applicator surface. Remove the needle in the same direction as used to enter the vitreous. Immediately after injecting OZURDEX, use indirect ophthalmoscopy in the quadrant of injection to confirm successful implantation. Visualisation is possible in the large majority of cases. In cases in which the implant cannot be visualised, take a sterile cotton bud and lightly depress over the injection site to bring the implant into view. Following the intravitreal injection patients should continue to be treated with a broad spectrum antimicrobial. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Active or suspected ocular or periocular infection including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases. Advanced glaucoma which cannot be adequately controlled by medicinal products alone. Aphakic eyes with rupture of the posterior lens capsule. Eyes with Anterior Chamber Intraocular Lens (ACIOL) and rupture of the posterior lens capsule. Warnings/Precautions: Intravitreous injections, including OZURDEX can be associated with endophthalmitis, intraocular inflammation, increased intraocular pressure and retinal detachment. Proper aseptic injection techniques must always be used. Patients should be monitored following the injection to permit early treatment if an infection or increased intraocular pressure occurs. Monitoring may consist of a check for perfusion of the optic nerve head immediately after the injection, tonometry within 30 minutes following the injection, and biomicroscopy between two and seven days following the injection. Patients must be instructed to report any symptoms suggestive of endophthalmitis or any of the above mentioned events without delay. All patients with posterior capsule tear, e.g. those with a posterior lens, and/or those who have an iris defect (e.g. due to iridectomy) with or without a history of vitrectomy, are at risk of implant migration into the anterior chamber. Other than those patients contraindicated where OZURDEX should not be used, OZURDEX should be used with caution and only following a careful risk benefit assessment. These patients should be closely monitored for any signs of implant migration. Corticosteroids should be used cautiously in patients with a history of ocular herpes simplex and not be used in active ocular herpes simplex. The safety and efficacy of OZURDEX administered to both eyes concurrently have not been studied and is not recommended. OZURDEX is not recommended in patients with macular oedema secondary to RVO with significant retinal ischemia. OZURDEX should be used with caution in patients taking anti-coagulant or anti-platelet medicinal products. Interactions: No interaction studies have been performed. Systemic absorption is minimal and no interactions are anticipated. Pregnancy: There are no adequate data from the use of intravitreally administered dexamethasone in pregnant women. OZURDEX is not recommended during pregnancy unless the potential benefit justifies the potential risk to the foetus. Lactation: Dexamethasone is excreted

in breast milk. No effects on the child are anticipated due to the route of administration and the resulting systemic levels. However OZURDEX is not recommended during breast feeding unless clearly necessary. Driving/Use of Machines: Patients may experience temporarily reduced vision after receiving OZURDEX by intravitreal injection. They should not drive or use machines until this has resolved. Adverse Effects: RVO In clinical trials the most frequently reported adverse events were increased intraocular pressure (IOP) (24.0%) and conjunctival haemorrhage (14.7%). Increased IOP with OZURDEX peaked at day 60 and returned to baseline levels by day 180. Elevations of IOP either did not require treatment or were managed with the temporary use of topical IOP-lowering medicinal products. The following adverse events were reported: Very common (≥1/10): IOP increased, conjunctival haemorrhage* Common (≥1/100 to <1/10): Ocular hypertension, vitreous detachment, cataract, subcapsular cataract, vitreous haemorrhage*, visual disturbance, vitreous opacities* (including vitreous floaters), eye pain*, photopsia*, conjunctival oedema*, anterior chamber cell*, conjunctival hyperaemia*, headache Uncommon (≥1/1,000 to <1/100): Retinal tear*, anterior chamber flare* Headache. Uveitis In clinical trials the most frequently reported adverse events in the study eye were conjunctival haemorrhage (30.3%), increased IOP (25.0%) and cataract (11.8%). The following adverse events were reported: Very common: Increased IOP, cataract, conjunctival haemorrhage* Common: Retinal detachment, Myodesopsia, vitreous opacities, blepharitis, sclera hyperaemia*, visual impairment, abnormal sensation in the eye*, eyelid pruritis, migraine. (*Adverse reactions considered to be related to the intravitreous injection procedure rather than the dexamethasone implant). Please refer to Summary of Product Characteristics for full information on side effects. Basic NHS Price: £870 (ex VAT) per pack containing 1 implant. Marketing Authorisation number: EU/1/10/638/001 Marketing Authorisation Holder: Allergan Pharmaceuticals Ireland, Castlebar Road, Westport, Co. Mayo, Ireland. Legal Category: POM. Date of Preparation: May 2013.

References: 1. Nehme A & Edelman J. Invest Ophthalmol Vis Sci. 2008;49(5):2030-2038. 2. Capone Jr A, et al. Monotherapy vs Combination Therapy With Dexamethasone Intravitreal Implant (DEX Implant) in Retinal Vein Occlusion (SHASTA study). Presented at the American Academy of Ophthalmology 2013 Annual Meeting; November 16-19, 2013; New Orleans, LA, US. 3. Papathomas T, Kamal A et al. Presented at ARVO 2013, May 5-9; Seattle, USA. 4. Berthon L et al. Long-term use of OZURDEX® in macular oedema from retinal vein occlusions. CERK/RVO Study. Les Cahiers d’Ophthalmologie 2013; 15:25-27. 5.Tomkins-Netzer O, et al. Treatment with Repeat Dexamethasone Implants Results in Long-Term Disease Control in Eyes with Noninfectious Uveitis. Ophthalmology 2014 doi; 10.1016/j.ophtha.2014.02.003. [Epub ahead of print].

Date of Preparation: June 2014 UK/0430/2014c

Adverse events should be reported. Reporting forms and information can be found

at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Allergan Ltd. [email protected]

or 01628 494026.

Eurentina 2014 - London - Final programme

Documents

Transcript of Eurentina 2014 - London - Final programme